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ABSTRACT 
The dissertation describes an in-depth synthesis and optimisation of palladium(0) 
nanoparticles of three distinct size ranges, respective capping agents, and cellular uptake 
studies using a non-toxic concentration (10 µM), laying a foundation for the design of 
palladium-based folate receptor-targeted theranostic nanoradiopharmaceutical. 
In the preliminary selection to determine the optimal diamines for the study, 
ethylenediamine, hexamethylenediamine, 1,10-diaminodecane, 1,12-diaminododecane, 1,4-
diaminobenzene, 4,4’-ethylenedianiline, 1,2-diphenyl-1,2-diaminoethane, and 
tetraaminophthalocyanine were employed. The characterisation of the nanoparticles 
obtained from the in situ reduction of palladium(II) salt at room temperature by either 1,2,3-
trihydroxybenze (pyrogallol), citric acid, sodium metabisulphite, sodium borohydride, 
hydrazine hydrate, or formaldehyde was performed. Ethylenediamine and sodium 
borohydride were found to be the best diamine capping and reducing agent, respectively. 
Systematic investigations determined that the nanoparticle synthesis was dependent on 
various reaction parameters: such as reaction temperature, time, reductant reducing power, 
and capping agents. The parameters effects on the nanoparticle size, morphology, shape, 
stability, crystallinity, and surface charge were investigated. The optical properties, elemental 
composition, functional group, concentration and molecular weight for the synthesised 
nanoparticles or conjugates were determined. These properties were analysed using 
Ultraviolet–visible spectroscopy (UV-Vis), high resolution transmission electron microscopy 
(HRTEM) coupled with selective area electron diffraction (SAED) and energy dispersive X-ray 
spectroscopy (EDS), X-ray powder diffraction (XRD), zeta potential (ZP), dynamic light 
scattering (DLS), elemental analysis (EA), 1H and 13C-nuclear magnetic resonance (1H- and 13C-
NMR), Fourier-transform infrared spectroscopy (FTIR), inductively coupled plasma-optical 
emission spectroscopy (ICP-OES), and liquid chromatography-mass spectroscopy (LC-MS).  
The in vitro cytotoxicity, cell uptake, and internalisation studies of palladium nanoparticles 
(10 µM) ranging in size and different types of capping agent were performed using three 
breast cancer cell lines: MDA-MB-468 , MCF-7 and MDA-MB-231 , and a non-tumorigenic 
MCF-10A breast cell line. The cell uptake and internalisation were investigated using ICP-OES 
and TEM.  
A high dependence between reduction rate and concentration of palladium precursor was 
observed for the room temperature synthesis of palladium nanoparticles, and the employed 
synthesis procedure will be applied to the hot palladium isotope (109Pd). A facile, green, 
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aqueous synthesis route for palladium nanoparticles at room temperature was developed, 
and the synthesised nanoparticles indicated narrow size distributions. A concentration 
dependence between cytotoxicity and palladium nanoparticles was observed, with lower 
concentrations (10 µM) exhibiting minimal cytotoxicity relative to higher concentrations (100 
µM). The cellular uptake of palladium nanoparticles was found to be concentration, folate-
receptor, capping agent, and cell line proliferation-dependent. Well-defined, monodispersed, 
and negatively charged folate-ethylenediamine and folate-phthalocyanine capped palladium 
nanoparticles were taken up by cells, with higher nanoparticle internalisation in folate 
receptor positive tumorigenic cells relative to folate receptor negative non-tumorigenic cells. 
It can be concluded that palladium(0) nanoparticles can be synthesised from the reduction of 
palladium(II) by sodium borohydride at room temperature. The folate-conjugated palladium 
nanoparticles are non-cytotoxic at 10 µM and were successfully optimised and selectively 
delivered to folate receptor-positive breast cancer cells (MDA-MB-231 and MCF-7) relative to 
non-tumorigenic breast cells (MCF-10A) and folate receptor negative cancer cells (MDA-MB-
468). 
Keywords: Palladium nanoparticles, folate receptor, breast cell lines, cytotoxicity, 
transmission electron microscopy. 
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phthalocyanine capping agent, and (b) A plot of nanoparticle size (nm) 
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mM folic acid (FA), 13.2 mM methotrexate (MTX), 13.5 mM 
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in triplicate (N=3), and the significance was marked with asterisks *; for 
a p-value <0.05 (significant), ** for a p-value <0.01 (significant), and *** 
for a p-value <0.001 (highly significant) was determined using one-way 
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(FA), 1.32 mM methotrexate (MTX), 1.35 mM ethylenediamine (EDA), 
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a p-value <0.05 (significant), ** for a p-value <0.01 (significant), and *** 
for a  p-value <0.001 (highly significant) was determined using one-way 
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the significance was marked with asterisks *; for a p-value <0.05 
(significant), ** for a p-value <0.01 (significant), and *** for a  p-value 
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unstained MCF-10A cells after 24 h treatment with 10 µM (palladium 
content) small-sized folate-ethylenediamine capped palladium(0) 
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area where the following image was acquired. The nanoparticles were 
clearly visualised with no cell ultrastructure. .............................................. 115 
Figure 4.7:  The STEM-EDS spectrum of the nanoparticles on the unstained sample. 
Palladium presence was observed. The presence of carbon (C), nitrogen 
(N), and oxygen (O) can be attributed to the presence of folate-
phthalocyanine or cellular organelles. The presence of potassium (K) 
and chlorine (Cl) can be attributed to incomplete washing of PBSA with 
the cobalt (Co) and iron (Fe) attributed to system artefacts from the 
TEM chamber, while the presence of copper is attributed to the use of 
a copper TEM grid. ...................................................................................... 116 
Figure 4.8:  Bright-field TEM images of osmicated MCF-10A cells (from Figure 4.6) 
after 24 h treatment with small-sized folate-phthalocyanine capped 
palladium(0) nanoparticles (sz-FA-Pĉ-NPs); (a) TEM image showing a 
well- defined cell ultrastructure; intact cell membranes (CM), protruding 
cell membranes (encircled CM), mitochondrion (M), endoplasmic 
reticulum (ER), and possible metal stains, artefacts, or nanoparticles 
(encircled), (b) A magnified cellular area showing well-defined 
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artefacts (encircled), (c) Clear ultrastructure of magnified specimen area 
showing intact cell membranes (CM) and possible nanoparticles or 
metal stains or artefacts (encircled), (d) TEM image displaying the 
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(e) Inset showing a highly magnified section of the cells showing notable 
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Figure 4.9:  Bright-field TEM images of osmicated MDA‐MB‐231 cells after 24 h 
treatment with large‐sized folate‐ethylenediamine capped palladium(0) 
nanoparticles (lz‐FA‐EDÂ‐NPs); (a) Visible cell membrane (CM), 
endoplasmic reticulum (ER), nuclear membrane (NM), and nucleus (N) 
and possible metal nanoparticles or stains (encircled), (b) Visible cell 
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CHAPTER 1: INTRODUCTION 
1.1 CANCER 
With more than ten million new diagnoses annually, cancer remains a major fatal disease 
worldwide. In many countries, more than 25% of deaths are due to cancer. According to a 
published report by the World Health Organization (WHO) and International Agency for 
Research on Cancer (IARC), cancer mortality rates are expected to have an increase of 50% by 
2020. The high mortality rates highlight the challenges regarding cancer therapy and the need 
for ongoing work by researchers in drug delivery fields [1]. 
Cancer progression occurs when the normal mechanisms that regulate cell growth and 
proliferation are disturbed, for example, uncontrolled replication of deoxyribonucleic acid 
(DNA) [2]. A tumour develops from a single cell that undergoes a mutation that blocks its 
apoptotic signalling pathway resulting in uncontrollable proliferation [3]. A cancerous cell 
surrounded by healthy tissue will replicate at a faster rate than the other cells, thus placing a 
strain on the nutrient supply and elimination of metabolic waste products. Once a tumour 
mass has formed, the surrounding healthy tissues are unable to compete with the cancer cells 
for the nutrients supply from the bloodstream. This leads to the displacement of healthy cells 
until a tumour reaches a diffusion-limited maximal size [4, 5]. 
There are several types of cancers, most of them form solid tumours; however, some cancers 
like leukaemia (blood cancer) do not form tumours. Instead, leukaemia cells are present in 
the blood and blood-forming organs, circulating throughout the tissues. Not all tumours are 
cancerous; some tumours are benign (non-cancerous) and not life-threatening [6]. 
1.1.1 History and statistics of cancer  
The word cancer came from a Greek word karkinos to describe carcinoma tumours by a 
physician Hippocrates (460–370 Before Christ (B.C)). Some of the earliest evidence of human 
bone cancer was found in mummies in ancient Egypt and ancient manuscripts dating back to 
around 1600 B.C. The world’s oldest recorded case of breast cancer hails from ancient Egypt 
in 1500 B.C, and it was recorded that there was no treatment for cancer, only palliative 
treatment. According to inscriptions, surface tumours were surgically removed similarly to 
how they are removed today [6].  
In 2012, cancer was the second leading cause of death in the world after cardiovascular 
diseases. The WHO attributed 8.2 million deaths to cancer in 2012, constituting approximately 
13% of all recorded deaths. Within the next two decades, new global cancer incidences are 
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expected to increase from 14 million in 2012 to as many as 22 million by 2032. Half of the 
men and one-third of women in the world develop cancer during their lifetimes. In 2016, 1 
685 210 new cancer cases and 595 690 cancer deaths were recorded in the United States. 
This was the equivalent of more than 4 600 new cancer diagnoses per day and approximately 
1,600 deaths per day [7]. In 2018, 1 735 350 new cases and about 609 640 cancer deaths were 
projected to occur in the United States (Figure 1.1). This corresponds to approximately 1 700 
deaths per day [8]. This is approximately a 6% increase in deaths over two years.  
 
Figure 1.1: Ten leading cancer types for the estimated new cancer cases and deaths by sex, 
United States, 2018. Estimates are rounded to the nearest 10 and cases exclude basal cell and 
squamous cell skin cancers and in situ carcinoma except for urinary bladder. The ranking is 
based on modelled projections and may differ from the observed [8]. This image was 
reproduced from reference [8] with permission from Wiley Online (Copyright 2018). 
Worldwide, millions of cancer patients extend their life expectancy due to early identification 
and treatment. The most common causes of deaths are lung, bronchial, prostate, colorectum, 
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and breast cancer [7]. In African countries, the lifetime probability of being diagnosed with an 
invasive cancer is higher for men than women (Table 1.1), with Southern Africa having the 
highest number of both cancer incidences and mortality cases [9]. The high mortality can be 
attributed to our inability to administer therapeutic agents selectively to the targeted sites 
without adverse effects on healthy tissue [10] and expensive therapeutic methods.  
Table 1.1: Estimated age-standardised incidences and mortality rates per 100 000 in Africa 
and Eastern Asia by world area, 2012 and 2018 [11, 12]. 
 INCIDENCES MORTALITY  
 Male Female Male Female 
Year 2012 2018 2012 2018 2012 2018 2012 2018 
Eastern Africa 120.7 112.4 154.7 150.7 103.8 87.0 110.5 107.6 
Middle Africa 91.8 101.8 110.7 109.2 82.3 79.5 82.3 80.9 
Northern Africa 133.5 138.9 127.7 137.3 99.9 102.1 75.7 76.9 
Southern Africa 210.3 230.5 161.1 122.4 136.5 142.4 98.7 98.3 
Western Africa 78.7 95.6 112.4 122.0 68.5 72.1 75.7 83.6 
Eastern Asia 225.4 238.4 151.9 192.0 159.3 159.6 80.2 89.7 
Totals 860.4 917.6 818.5 833.6 650.3 642.7 523.1 537 
 
1.1.2 Cancer treatment methods 
Cancer cells have non-uniform microvasculature in tumour tissues. The tumour blood vessels 
are highly disorganised with a high proportion of proliferating cells, increased tortuosity and 
relatively thin-walled, leaky, and less supporting pericytes. The pore sizes are between 100 
and 780 nm, while normal cells have pore sizes less than 6 nm. The pore size difference can 
be exploited for selective cancer cell accumulation by nanoparticles [10]. In addition to that, 
there is a decreasing amount of oxygen available to peripheral tumour cells, this occurs due 
to the increased distance to the centralised blood vessels; thus, increasing the distance over 
which oxygen must diffuse to reach these cells. The oxygen availability is also decreased by 
the consumption of oxygen by tumour cells that have closer proximity to the blood vessels 
[10]. Tumours synthesise new blood vessels in a process known as angiogenesis; however, 
these vessels are abnormal and have an increased number of proliferating endothelial cells, 
increased vessel tortuosity, deficient pericytes, and abnormalities in the basement membrane 
with large gaps between adjacent endothelial cells ranging between 380 and 780 nm [13]. 
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The current therapeutic strategies for most cancers involve a combination of surgical 
resection, radiation therapy, and chemotherapy [14]. These therapies are associated with 
significant morbidity and mortality rates, primarily due to their non-specific detrimental 
effects on normal cells. The tumour microenvironment provides unique challenges for the 
delivery of chemotherapeutic agents in doses that are effective while ensuring minimal 
systemic toxicity and reduced costs [15]. 
1.1.3 Challenges/Limitations of current therapeutic methods 
Once the tumour mass initiates angiogenesis, blood vessels proliferate resulting in an 
unorganised and abnormal vasculature [2]. Tumours contain regions with extensive 
vasculature and rich blood supply and regions with poor vasculature and little blood supply. 
The leaky vasculature in tumours is highly permeable due to the increased size and quantity 
of fenestrations as well as incomplete or abnormal basement membranes [16]. The variance 
in the level of the vasculature, and the tendency of the vessels to have poor smooth muscle 
or nerve innervation results in significantly heterogeneous blood flow through a tumour [17]. 
Tumour blood vessels are also inherently less vascular due to abnormal basement 
membranes and incomplete endothelial linings caused by the inability of pericytes to 
completely line the rapidly proliferating cells forming the vessel walls [13]. Tumours also have 
a reduced ability to drain fluid and waste from the interstitial space. The reduced drainage is 
due to a poorly-defined lymphatic system caused by the demand of the rapidly proliferating 
tumour cells [18].  
Unlike healthy tissue which rapidly remove macromolecules and lipids from its interstitium, 
tumour cells accumulate these molecules. The highly permeable vasculature and poorly-
defined lymphatic system result in the enhanced permeability and retention effect (EPR) [19]. 
The EPR has been the focus of much research, due to its ability to target macromolecules 
including nanoparticles, passively [20, 21]. The EPR is a unique feature, which allows 
macromolecules or drug delivery nanoparticles (cut-off size of >400 nm) to accumulate and 
diffuse in tumour tissues preferentially [13]. Drug delivery nanoparticles can extravasate into 
tumour tissues, accumulate, and release the therapeutic drug locally in the extracellular area 
[22]. 
The drug delivery specificity and non-selectivity between healthy and tumourigenic tissues 
lead to various side effects. Another detriment to systemic drug delivery is that the drug 
encounters numerous extra-and intracellular barriers before reaching the tumour site [23]. 
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Moreover, the drug must retain its biological activity and reach the target site at high enough 
concentrations to have therapeutic efficacy. There is also a lack of drug accumulation in the 
centre of the tumour mass where the interstitial pressure is the highest [10]. In addition to 
that, the extracellular matrix possesses a physical barrier to chemotherapeutic drugs [24]. 
During cellular uptake of chemotherapeutic drugs via phagocytosis, the particles are shuttled 
from the early endosome to the late endosome and finally the lysosome for degradation. 
During which, the pH decreases from 7.4 to approximately 5.0, thus, the drug must maintain 
its activity through both decreased pH and rampant enzymatic activity [25].  
Despite rapid advances in diagnostic procedures and treatments, the overall survival rate 
from cancer has not improved substantially over the past 30 years [26]. This is because of the 
EPR and multi-drug resistance (MDR) challenges [27]. Approximately 99% of chemotherapy 
drugs do not reach the cancer cells and hence the need to develop pharmaceuticals that are 
target specific [28]. There may also be drug resistance at the cellular tumour level due to 
physiological barriers, and the distribution, biotransformation, and clearance of anticancer 
drugs in the body is equally a major concern [22, 29, 30]. 
To address the challenges and limitations mentioned above, it is necessary to create effective 
cancer therapeutics that overcome biological barriers, ensure specific targeting, prevent rapid 
clearance and causes tumour deaths [31]. The development of nanoradiopharmaceutical 
cancer therapies has the potential to overcome both systemic and tumour barriers and 
provide specific, targeted delivery [32, 33]. There is a need, therefore, to develop novel 
approaches for the accurate detection of the early stage of cancer and for targeted therapies 
based on the cancer-specific markers, which could lead to personalised medicine [34, 35]. 
1.2 RADIOPHARMACEUTICALS 
Radiopharmaceuticals portray physiological, biochemical, or pathological in the body without 
causing any detrimental effects [36]. They are referred to as radiotracers because they are 
given in sub-pharmacological doses that “trace” a physiological or pathological process in the 
body [37]. Most radiopharmaceuticals are a combination of a radioactive molecule that 
permits external detection and a biologically active molecule or drug that acts as a carrier and 
determines localisation and biodistribution [38].  
1.2.1 Diagnostic radiopharmaceuticals 
Radiopharmaceuticals are radiolabelled molecules designed for in vivo application. They 
consist of a molecular structure, which determines the fate of the radiopharmaceutical within 
C h a p t e r  1   P a g e  | 6 
 
Sendibitiyosi Gandidzanwa                           211175897                            Nelson Mandela University 
  
the organism (pharmacokinetics and pharmacodynamics) and a radionuclide being 
responsible for the signals detectability outside of the organism for subsequent visualisation 
with nuclear medical methods [39]. The half-life (t1/2) must be long enough to allow a 
radiochemist to carry out radiopharmaceutical synthesis (Table 1.2) and for nuclear medicine 
practitioners to collect useful images [26, 40]. 
Table 1.2: Commonly used diagnostic radionuclides [41].  
Radionuclide Half-life Gamma energy (keV) Decay mode Source 
64Cu 12.3 h 511(10%), 185 (24%) Electron capture Reactor 
67Ga 78.3 h 93(10%), 185 (24%) Electron capture Generator 
99mTc 6.02 h 141(89%) Isomeric transition  Generator 
111In 2.83 d 171(88%), 247(94%) Electron capture Cyclotron 
117mSn 14.0 d 159(87%) Isomeric transition  Cyclotron 
To allow for imaging (Table 1.3), the radionuclide should have γ energies in the range 100 - 
510 keV and its half-life should be long enough for the preparation of the radiopharmaceutical 
and yet short enough to limit radiation exposure [42]. 
Table 1.3: Diagnostic radionuclides used for imaging [43]. 
Radioisotope Half-life in hours Image uses 
99mTc 6,0 Bone, thyroid, brain, and kidneys 
201Tl 73,0 Heart 
123I 13,3 Thyroid 
67Ga 78,2 Various tumours 
18F 1,8 Brain 
1.2.2 Therapeutic radiopharmaceuticals 
Several β-emitting radionuclides (64Cu, 89Sr, 90Y, 109Pd, 153Sm, 165Dy, 166Ho, 169Er, 177Lu, 186Re, 
and 198Au) have been proposed for radionuclide therapy [44] for bone pain palliation, tumour 
therapy, and radiation synovectomy. Some single-photon radionuclides have been used in 
clinical medicine (Table 1.4), and so as positron-emitting radionuclides (Table 1.5). 
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Table 1.4: Physical characteristics of single-photon radionuclides used in clinical nuclear 
medicine [45]. 
Radionuclide Principal mode of 
decay 
Physical 
half-life 
Principal photon energy 
in keV (abundance %) 
Production 
method 
99Mo Beta minus 2.8 d 740 (12), 780 (4) Reactor 
99m Tc Isomeric transition 6 h 140 (89) Generator 99Mo 
131I Beta minus 8 d 364 (81) Reactor 
123I Electron capture 13.2 h 159 (83) Cyclotron 
67Ga Electron capture 78.3 h 93 (37), 185 (20), 300 
(17), 395 (5) 
Cyclotron 
201TI Electron capture 73.1 h 69-83 (Hg x-rays), 135 
(2.5), 167 (10) 
Cyclotron 
111In Electron capture 2.8 d 171 (90), 245 (94) Cyclotron 
127Xe Electron capture 36 d 172 (26), 203 (7), 375 
(17) 
Cyclotron 
133Xe Beta minus 5.2 d 81 (37) Reactor 
57Co Electron capture 272 d 122 (86) Cyclotron 
Table 1.5: Physical characteristics of positron-emitting radionuclide [46]. 
Radionuclide Physical half-
life (min) 
Positron energy 
(MeV) 
Range in soft 
tissues (mm) 
Production 
Method 
11C 20 0.96 4.1 Cyclotron 
13N 10 1.19 5.4 Cyclotron 
15O 2 1.73 7.3 Cyclotron 
18F 110 0.635 2.4 Cyclotron 
68Ga 68 1.9 8.1 Generator 68Ge 
82Rb 1.3 3.15 15.0 Generator 82Sr 
1.2.3 Design and development of theranostic radiopharmaceuticals 
Radiopharmaceuticals require unique properties that need to be considered, such as half-life, 
radiation energy, and tissue penetration that are associated with the onset of response, 
duration, and toxicity [47, 48].  
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Essential factors in developing therapeutic radiopharmaceuticals include the selection choice 
of the radionuclide, local production conditions, and carrier molecule biokinetics [17, 49]. For 
therapeutic purposes, the selection of a suitable radioisotope should consider not only the 
physical characteristics (type of energy, tissue penetration range, and half-life), however, 
specificity of localisation and pharmacokinetics [50, 51]. 
1.2.4 Radionuclides 
A radionuclide is an atom that has excess energy, that can be emitted from the nucleus as 
gamma radiation or as a “new” alpha or beta particle during a radioactive decay process [52]. 
The preferred isotopes are the γ-emitters for imaging as γ-radiation is less damaging to the 
body compared to α or β radiation [53]. Good therapeutical results would be obtained if the 
half-life of the radionuclide was not shorter than 12 h and not longer than 5 days for 
successful radiolabelling, and the period of the imaging procedure [54]. The emission energies 
should be significantly high enough to deliver a radiation dose [40]. In the case of 
radioimmunotherapy, where a limited number of binding sites are available, carrier-free 
radionuclides are ideal to achieve high binding affinities to the receptors [51]. Radionuclide 
decay should result in gamma emissions with sufficient energy for external detection. The 
radionuclide can contain particulate radiation (e.g., beta emissions), which increases patient 
radiation dose (Table 1.6). Beta emissions are also suitable for therapeutic 
radiopharmaceuticals [55]. The effective half-life should be long enough for only the intended 
application. Radionuclides that decay by β-particle emission are the most extensively used 
[41]. 
The radionuclide should be carrier-free, i.e. not contaminated by either stable radionuclides 
or other radionuclides of the same element [56]. Carrier material can negatively influence 
biodistribution and labelling efficiency. A carrier-free radionuclide has the highest specific 
activity [57, 58]. The pharmaceutical component should be free of any toxicity or physiological 
effects. The radiopharmaceutical should not disassociate in vitro or in vivo and should be 
readily available or easily compounded [54]. The radiopharmaceutical should rapidly and 
specifically localise according to the intended application, and a rapid background clearance 
is essential to ensure a good target-to-background ratio [26, 45]. Radiopharmaceutical should 
be inexpensive, relatively pure, can be produced in industrial quantities, appropriate physical 
properties, and be easily bound to a ligand [59]. The availability of the radionuclide, good 
physical characteristics of the radionuclide, radiochemical and radiopharmacological 
properties are of paramount importance for an excellent radionuclide [60]. The use of several 
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radionuclides has been documented; however, for this study, the radionuclide of interest was 
palladium. 
Table 1.6: The commonly used radionuclides. 
Radionuclide Decay mode Half-life E-maxα/β (MeV) Emax γ (keV) 
212Bi α 60.5 min 7.8 
 
213Bi α 
β 
45.6 min 5.8 
1.4 
 
212Pb α 10.64 h 0.28 (83%) 
0.57 (12%) 
 
99mTc γ 6 h 
 
141 
211At α 7.2 h 6.76  
186Re β 3.7 d 1.07 137 
188Re β 17 h 2.11 155 
166Ho β 1.1 d 1.6 81 
153Sm β 1.95 d 0.8 103 
109Pd β 13 h 1.10  
131I β 8 d 0.81 364 (81%) 
637 (7%) 
125I Low energy e- 60 d   
123I Low energy e- 13.3 h   
32P β 14.3 d 1.71  
47Sc β 3.4 d 0.6  
64Cu β 0.5 d 0.57  
67Cu β 2.6 d 0.57  
89Sr β 50.5 d 1.46  
90Y β 2.7 d 2.27  
105Rh β 1.5 d 0.57  
111Ag β 7.5 d 1.05  
117mSn β 13.6 d 0.13  
The table above was constructed from the data collected from multiple references [42, 44, 62]. 
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1.2.5 Palladium as a radiopharmaceutical 
Current major classes of metal-based anticancer drugs include platinum(II), platinum(IV), 
palladium(II), gold(I) and gold(III), ruthenium(II) and ruthenium(III), and tin(IV) complexes 
[61]. An attempt to use Pd(II) complexes as chemotherapeutic anti-cancer agents towards 
cisplatin-resistant cells has been discouraged by the high lability and fast hydrolysis reactions 
presented by the Pd(II) complexes compared to platinum(II) complexes [61]. Moreover, 
multidrug resistance (MDR), specificity, efficiency, biotransformation, and clearance of drugs 
in the body (Section 1.1.3) remain problematic for metal complexes anti-cancer agents [13, 
15, 61]. To circumvent these challenges, nanomedicine (Section 1.4) provide solutions; tissue 
and cell distribution profiles of anti-cancer drugs can be controlled while increasing anti-
tumour efficacy and reducing systemic side effects through use of nanoparticles (Section 1.3) 
[24, 59]. A gap exists in the biomedical applications of palladium(0) nanoparticles in targeted 
therapy and nanoradiopharmaceuticals, highlighting its prospects in the development of 
palladium-based nanoradiopharmaceuticals. 
1.2.5.1 Palladium’s key properties 
Palladium, (atomic number 46), was discovered in 1803 by William Wollaston during his 
studies on the refining of platinum. It was named after a newly discovered asteroid, Pallas, 
which bears the name of the Greek goddess of wisdom. Palladium (Pd) occurs in association 
with other platinum group metals (PGMs), and the extraction processes depend on the ore 
used. It is the second most abundant platinum group metal and its primary sources are in 
South Africa and Russia [63]. Palladium belongs to the periodic table’s group 10 and has the 
ground-state electronic configuration: [Kr] 4d10. Pd chemistry is dominated by the oxidation 
state +II (the most stable for the element) and exhibits rich organometallic chemistry [64]. 
Palladium exhibits similar chemistry to its 5d analogue, platinum (Pt); however, palladium is 
more reactive in comparison to platinum. It exhibits the oxidations states 0, +I, +II, and +IV. 
Many of the metal complexes in the 0 and I oxidation states form metal-metal bonded clusters 
[65] while the +II oxidation state forms a variety of monomeric complexes [66]. Palladium(0) 
has a face-centred cubic (fcc) lattice structure (Fm3m space group) with a lattice constant 
3.89 nm [67, 68]. Palladium nanoparticles may be amorphous [69–71] or crystalline [72–74]. 
When viewed in a transmission electron microscope at high resolution, the crystalline 
palladium nanoparticles may exhibit lattice fringes unique to palladium [75]. 
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Palladium is used in catalysis, electronics, technology, dentistry, jewellery, and photography 
[76]. Palladium is stable at room temperature, has low toxicity, is poorly absorbed by the 
human body when ingested and has limited toxicological effects [77–79], highlighting its 
possibility for use in pharmaceutical-related research. 
1.2.5.2 Palladium isotopes, radionuclides, and their properties 
Palladium has six naturally occurring isotopes have been found for palladium: 102Pd (1.02%), 
104Pd (11.14%), 105Pd (22.33%), 106Pd (27.33%), 108Pd (26.46%), and 110Pd (11.72%) [80], and 
ten common radioisotopes and stable isotopes (Table 1.7). The radioisotope of interest is 
109Pd, with a half-life of 13 hours which undergoes a β decay [81]. 
Table 1.7: Palladium isotopes and radionuclides.  
Isotope Abundance Half-life(t1/2) Decay mode Product 
100Pd Synthetic radionuclide 3.63 d ε 100Rh 
γ – 
102Pd 1.02% stable 
103Pd Synthetic radionuclide 16.991 d ε 103Rh 
104Pd 11.14% stable 
105Pd 22.33% stable 
106Pd 27.33% stable 
107Pd Trace radionuclide 6.5×106 y β− 107Ag 
108Pd 26.46% stable 
109Pd None 13 h β 109Ag 
110Pd 11.72% stable 
The above table was constructed from information from references [42, 81]. 
1.3 NANOPARTICLES 
Nanoparticles (NPs) are classified as particles with one dimension within the 1–100 nm size 
range and behave as a single unit with respect to transport and reactivity [82]. It has been 
demonstrated that NPs have a wide variety of unique applications, including cell targeting, 
intravenous nucleic acid delivery, environmental remediation, catalysis, bactericidal effects, 
etc. [83]. 
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The nanoparticle’s nanoscopic size facilitates intracellular uptake. NPs can encapsulate 
therapeutic drugs and release them in a controlled manner to specifically target diseased cells 
[84]. Additional advantages of NPs have brought widespread attention to the field of 
nanomedicine, including their large ratio of volume-to-surface area, modifiable external shell, 
biodegradability, and low cytotoxicity [30]. Metal nanomaterials have been found to have 
numerous applications such as in electronics, optics, magnetic devices as well as in catalysis. 
As the physical and chemical properties depend on the size and shape of the nanoparticles; 
their applications require non-agglomerated, uniform particles with a controlled mean size,  
narrow size distribution, and large surface-to-volume ratios [85]. 
The unique properties of nanoparticles allow the encapsulation of variety of drugs, whereas 
the tuneable surface chemistry is advantageous over their bulky counterparts [86]. 
Nanoparticles can be synthesised, assembled into desirable geometries and configurations, 
and coated with targeting agents and provide novel material properties for various 
applications in molecular and cellular labelling, tracking, detection, drug delivery, and medical 
imaging highlighting high levels of sensitivity and functionality [87]. To fully realise the 
promise they hold, nanoparticles must be capable of reaching their biological targets with 
high efficiency and specificity. In particular, delivery and targeting at the subcellular level have 
recently become increasingly important as we strive to decipher complex events that occur 
within living cells [88]. 
1.3.1 Synthesis of nanoparticles 
Physical, chemical, or electrochemical methods have been used to prepare uniform 
nanoparticles. Chemical methods include reduction of metal salts in solution-phase, 
microemulsion, or sol-gel process have been employed to obtain well-defined mono- and bi-
metallic particles [89–91]. 
Nanomaterials, including nanoparticles, can be constructed by the moulding or etching, top-
down approach, or by assembling structures atom by atom or molecule by molecule, bottom-
up approach [92]. 
1.3.1.1 Top-down and bottom-up approach  
Top-down technologies utilise mechanical forces to break down macroscopic particles to 
nanoscale size. Bottom-up technologies build-up nanoscale particles from molecular or 
atomic bond (Figure 1.2). 
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Figure 1.2: An illustration of top-down and bottom-up synthesis approaches [92]. 
1.3.2 Important nanoparticle properties in drug development  
The key parameters or characteristics include particle size, size dispersity, structure, surface 
characteristic, crystallinity, composition, and dissolution [93]. The nanoparticle ability to 
penetrate biological membranes, allowing accessibility to remote tissues and increased 
residence time in the body offers a more diverse portfolio of treatment options and improve 
the efficacy through both local and systemic targeting [9, 18, 94, 95]. 
1.3.2.1 Particle size and dispersity  
The size of nanoparticle governs its interactions with biological systems, including absorption, 
distribution, cellular internalisation, metabolism, and excretion [96]. Furthermore, 
nanoparticle size allows for interactions with various biomolecules on the cell membrane 
surfaces and within the cells, that do not necessarily alter the behaviour and biochemical 
properties of those molecules [93]. 
Nanoparticles with a diameter between 30 nm and 50 nm are more efficiently internalised by 
cells with greater efficiency than smaller (less than 30 nm) or larger (about 70 to 240 nm) 
particles. Nanoparticles with a diameter of 30 to 50 nm efficiently recruit and interact with 
membrane receptors and are subsequently taken up by receptor-mediated endocytosis [97]. 
The largest particle size of harnessing the EPR effect is 400 nm [98]. Particles with diameters 
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less than 200 nm will be cleared faster than particles with diameters over 200 nm. Varying 
particle sizes from 50 to 500 nm showed higher levels of agglomeration for the nanoparticles 
in the liver [22]. Therefore, to be an effective drug carrier, the nanoparticle should have a 
diameter between 10 and 150 nm [99, 100]. This size range will ensure longer circulation time 
and increased accumulation in the tumour interstitial [101, 102]. Cancer vascular pores range 
from 300-700 nm, therefore, the nanoparticles should be less than 250 nm for maximum 
efficacy [103]. Nanoparticles between 150 and 250 nm are also internalised by cells [99], 
[104].  
1.3.2.2 Surface charge  
The surface of a particle is the primary medium by which it interacts with its environment. 
The uptake and translocation of nanoparticles by organisms are affected by the nanoparticle 
surface charge [101]. For example, the nanoparticle surface charge has been documented to 
alter blood-brain barrier integrity and permeability [96]. Surface charge is responsible for a 
range of biological effects of NPs including cellular uptake, toxicity, and dissolution [105]. In 
one study, neutral and zwitterionic nanoparticles demonstrated longer circulation time via 
both intraperitoneal (IP) and intravenous (IV) administration, whereas negatively and 
positively charged nanoparticles possessed relatively short half-lives. Neutral and 
zwitterionic-charged nanoparticles are preferentially internalised via passive targeting [106]. 
Positively charged particles interact strongly with the slightly anionic plasma membrane 
[107]. They are taken up more readily or may disrupt plasma membrane integrity. Positively 
charged NPs are taken up via adsorptive mediated pinocytosis, whereas negatively charged 
NPs use alternative uptake routes, and are taken up via receptor-mediated or facilitated 
processes [108, 109]. Non-ionic particles tend not to interact with the cell membrane [97]. 
Positively charged nanoparticle surfaces enhance endocytosis [110]. pH affects net charge, 
and nanoparticles’ surface charge at cellular pH range is critical [111, 112]. 
The modification of the nanoparticles surface by the addition of hydrophilic polymers results 
in decreased clearance by the mononuclear phagocyte system (MPS) or reticuloendothelial 
system (RES). A hydrophilic polymer, poly(ethylene glycol) (PEG), imparts stealth 
characteristics by shielding the nanoparticles from opsonin adsorption and subsequent 
clearance by the MPS/RES once attached to nanoparticle surface [22].  
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1.3.2.3 Shape/morphology and organisation  
Elongated or filamentous nanoparticles have been shown to have distinct advantages over 
spherical particles regarding surface area-to-volume ratio, the rate of clearance from the 
body, and elimination mechanism [102, 113]. Cylindrical nanoparticles (NPs) have the highest 
percentage of cellular internalisation [22]. Spherical NPs (Figure 1.3) are efficiently taken up 
at a higher rate than rod-shaped NPs, presumably due to the longer membrane wrapping time 
required for the longer rod-shaped particles [97]. 
 
Figure 1.3: Some of the different arrangements of spherical nanoparticles; (a) random 
structure, (b) fractal structure, (c) structural alignment, (d) close-packed structure, (e) 
ordered structure (dispersion), and (f) ordered structure (dense). This image was reproduced 
from reference [114] with permission from Wiley Online (Copyright 2018). 
The effects of particle shape and curvature on cellular internalisation showed that 14 and 75 
nm spherical nanoparticles were up-taken by cells 3.75 to 5 times more than 14 by 74 nm rod-
shaped particles, leading to the hypothesis that the significant difference in uptake could be 
due to the difference in particle curvature, affecting the contact area with the cell membrane 
receptors as well as the distribution of targeting ligands on the particles [115–117]. 
1.3.2.4 Chemical composition/hydrophobicity 
Nanoparticles are usually taken up by the liver, spleen, and other parts of the 
reticuloendothelial system depending on the surface composition and hydrophobicity [101]. 
For instance, particles with more hydrophobic surfaces would preferentially be taken up by 
the liver, followed by the spleen, and lungs. Whereas, hydrophilic nanoparticles (35 nm 
diameter), such as those prepared from poly(vinylpyrrolidone) (PVP), showed less than 1% 
initial uptake by the spleen and liver and 8 h after injection showed 5 to 10% still circulating 
in the bloodstream [95]. 
Longer circulation time increases the nanoparticle ability to target deeper lying site of 
interests easily, and should be 100 nm or less in diameter and have a hydrophilic surface to 
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reduce clearance by macrophages [118]. Hydrophilic polymer coatings create particle 
surfaces that repel plasma proteins and adsorb surfactants thereby achieving easy targeting 
by avoiding RES [119]. 
The chain length of the PEG spacer between the ligand and the nanoparticle surface also 
requires consideration [120]. When the chain length of the PEG spacer is longer than the other 
PEG chains involved in the PEG-brush, the conjugated ligand can become buried within the 
brush layer. The extra units of a longer PEG spacer are subject to mushroom-like folding, 
which results in the limited exposure of the ligand [98]. 
1.3.2.5 Impurity and crystallinity  
The nanoparticles purity is vital for proper analysis, characterisation, and understanding of 
the outcome of the study. Purification of nanoparticles is performed during synthesis, mainly 
through centrifugation of the newly synthesised nanoparticles [121]. Preferred metal 
nanoparticles must be crystalline, and their crystallinity can be investigated using X-ray 
diffraction spectroscopy (XRD), or transmission electron microscope-selective-area electron 
diffraction spectroscopy (TEM-SAED analysis) [71]. 
1.3.2.6 Stability 
Their tuneable size, shape, and surface characteristics enable nanoparticles to have a higher 
stability, higher carrier capacity, the ability to incorporate both hydrophilic and hydrophobic 
substances and compatibility with different administration routes, thereby making them 
highly attractive in many aspects of oncology [27]. The nanoparticles stability during synthesis 
and in vitro or in vivo stability is key for proper drug development and must be reported for 
all studies [122]. Nanoparticles can be formulated to exhibit stability, in both shelf storage 
life, uptake rates, and specificity within the body, and response by the body to treatment 
[123, 124]. 
1.3.2.7 Toxicity 
Nanoparticles should not cause adverse health side effects [125]. Nanoparticles should be 
non-toxic to the cells, biodegradable, pure and non-immunogenic [126–128]. The 
nanotoxicology of NPs should be minimum for the successful design and development of 
radiopharmaceuticals [96]. 
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1.3.2.8 Stealth, specificity, and biodegradability 
The nanoparticle-drug complex must remain stable in the serum to allow the systemic 
delivery of the drug. The nanoparticle-drug complex must be delivered to tumour cells (either 
by receptor-mediated interactions or via the EPR effect), thereby reducing any unwanted 
complications from nontargeted delivery [22, 129]. The nanoparticle must be able to release 
the drug once at the site of the tumour. Nanoparticles that are used as carriers will either 
bind to the drug surface or entrap and encapsulate the drug to protect it from degradation or 
denaturation [130]. The residual nanoparticle carrier should ideally be made of a biological or 
biologically inert material with a limited lifespan to allow safe degradation [131, 132]. 
Alternatively, if a nonbiodegradable material is used, it must have proven to be safe at the 
doses needed or be easily cleared from the subject. 
1.3.2.9 Reproducibility  
Batch to batch reproducibility in nanoparticle synthesis is vital for the development of 
radiopharmaceuticals. The successful reproducibility of in vitro studies paves way for the in 
vivo studies, and subsequent preclinical trials upon the success of in vivo studies. This needs 
to be investigated and reported. 
1.3.3 Functionalisation of nanoparticles 
Functionalisation of nanoparticles to create a stealth surface from opsonisation is necessary 
to increase circulation times through removal avoidance by the reticuloendothelial systems 
(RES). Short circulation times, decrease the efficiency of the delivery of the nanoparticle to 
the tumour site [110]. Blood circulation residence, maximal tolerated dose (MTD), specificity, 
and selectivity are the principal factors for achieving a high therapeutical index and 
corresponding clinical success [22]. 
The surface functionalisation can be designed to provide either a controlled release or a 
triggered release of the therapeutic molecule. The nanoparticle surface can thus be 
functionalised by various methods. Tissue defects, stealth properties, targeting, and the size 
of the nanoparticles are major factors affecting the biodistribution and clearance of polymeric 
nanoparticles [22, 129]. Due to their unique size, and amenability to surface functionalisation 
to allow for the incorporation of the desired characteristics, nanoparticles are particularly well 
suited to overcoming most common drug delivery barriers [22]. Thus, over the past 20 years, 
numerous approaches to improving nanoparticle blood residence and accumulation in 
specific tissues for the treatment of disease have been developed [133, 134]. 
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1.3.3.1 Bioconjugate  
A limited number of chemical functionalities allow for the facile release of a covalently 
attached drug after targeted cell uptake. To facilitate this process, drugs must contain at least 
one of a limited number of functional groups (-SH, -COOH, -OH, or-NH2) that can be modified 
for cellular targeting or intracellular release [135]. An efficient drug release mechanism must 
be designed for the conjugate: i.e. the release mechanism needs to be inert during transit to 
the pathologic lesion but is rapidly activated after target cell binding and internalisation, 
enabling release of the therapeutic cargo only at the site of disease [94]. 
Prerequisites for an ideal bioconjugate include selectivity for tumour cells, chemical and 
physical stability, ensures maximum accumulation within the tumour tissues, optimal tissue 
penetration, have a small size, be easy to synthesise and modify, have good tumour 
penetration ability, excellent compatibility, and rapid clearance from the body [136]. The 
bioconjugates should enhance extended circulation, to allow maximum interaction with the 
target site to ensure sufficient delivery and dosing to target cells [97]. In addition, 
bioconjugates should be biocompatible/biodegradable, limiting immune response and 
facilitating degradation, and eventual removal from the body [137]. An excellent example of 
which is folic acid (Section 1.5). Folic acid is stable, inexpensive, and non-immunogenic [138], 
and is commonly linked to PEG [139] and has been considered for targeting [140]. However, 
in this study, we will explore the effects of palladium nanoparticles stabilised with diamine 
and phthalocyanine folate conjugates.  
1.4 NANOMEDICINE AND NANOTECHNOLOGY 
Nanotechnology is the creation, manipulation, and application of structures in the nanometre 
size range [141]. Nanomedicine is the application of nanotechnology to design and develop 
therapeutics and diagnostic tools [142]. It has drug delivery systems in the nanoscopic scale, 
and may include delivery vehicles and diagnostic agents [143], multivalent surface 
modifications with targeting ligands, efficient navigation of the complex in vivo environment, 
increased intracellular trafficking, and sustained release of the drug payload [30]. These 
nanoparticle advantages increase the potential of nanoparticles to be a superior treatment 
option to conventional cancer therapies [144, 145]. 
Nanotechnology allows for improved delivery of poorly water-soluble drugs, targeted delivery 
of drugs in a cell or tissue-specific manner, transcytosis of drugs across tight epithelial and 
endothelial barriers [146, 147]. Nanotechnology also entails the delivery of large 
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macromolecule drugs to intracellular sites of action, the co-delivery of two or more drugs or 
therapeutic modality for combination therapy [148], visualisation of sites of drug delivery by 
combining therapeutic agents with imaging modalities [29], and real-time read on the in vivo 
efficacy of a therapeutic agent [149]. 
1.4.1 Nanoparticle vehicle molecules 
In the modern era of medicine, cellular hitchhiking of circulatory cells offer an attractive 
option for therapies capable of performing functions which are often limited to applications 
of synthetic materials [150]. Red blood cells, macrophages, monocytes, T-cells, B-cells, and 
other circulatory cells are nature's own ‘delivery vehicles’ as they have evolved to perform 
delivery functions in vivo optimally [137]. The nanoparticle must be able to bind or contain 
the desired drug(s) [151]. 
Synthetic materials are significantly limited in their ability to circulate, target, and negotiate 
cellular barriers limiting clinical use [83]. Thus, it is essential to develop technologies to 
overcome these inherent limitations. Extensive research efforts are focusing on improving 
drug delivery through the use of nanoparticles to improve the biological outcome of 
therapeutic drugs [87, 152–157]. 
The biophysiochemical properties of the nanoparticle vehicle molecules, such as size, charge, 
surface hydrophilicity, nature and density of the ligands on their surface impacts the 
circulating half-life of the particles as well as their biodistribution [158]. The presence of 
targeting ligands on nanoparticle vehicle molecules can increase the interaction of the drug 
delivery system with increased cells specificity in the target tissue, enhancing cellular uptake 
by receptor-mediated endocytosis [159]. It is believed that targeting anchors drug delivery 
systems thereby decreasing the efficiency of diffusion and increasing uniform tissue 
distribution [160, 161].  
For optimal targeting ability, it is imperative for delivery vehicles to have controlled particle 
size, size distribution, shape, crystal structure and composition [162]. To achieve this, 
nanoparticles purity, aggregation, physical properties stabilisation, possible reactants, 
increased reproducibility, increased mass produce, and low production cost are essential 
factors to consider [114, 163]. The possibility of our designed nanoparticles acting as delivery 
vehicles will be advantageous to our study. 
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1.4.2 Nanoparticle based-targeting methods 
Nanoparticles have the advantage of targeting cancer by simply being accumulated and 
entrapped in tumours (passive targeting) [134]. The phenomenon is called the enhanced 
permeation and retention effect, caused by leaky angiogenetic vessels, poor lymphatic 
drainage and has been used to explain why macromolecules and nanoparticles are found in 
higher ratios in tumours, compared to normal tissues [59]; however, selective active targeting 
is preferred. The types of nanoparticles currently used in research for cancer therapeutic 
applications include dendrimers, liposomes, polymeric nanoparticles [164], micelles, protein 
nanoparticles, ceramic nanoparticles, viral nanoparticles, metallic nanoparticles, and carbon 
nanotubes [93]. 
The therapeutic index of the majority of drugs currently being used would be improved if 
delivery to their biological targets was nanotechnology-based and more efficient [165]. The 
efficacy can be increased, reducing the toxicity of a cancer drug to non-tumorigenic tissues, if 
a directed target system was employed at the target site for a sufficient amount of time [166]. 
Most common nanoparticles deliveries include injection, oral delivery, ocular delivery, 
delivery to the brain and gene delivery [167].  
Nanoparticles are capable of encapsulating drugs limiting degradation or deactivation before 
the drug reaches a target site in vivo, improving tissue-specific targeting ligands [168, 169]. 
Nanoparticles are subjected to rapid clearance from blood and majority of formulated 
nanoparticles drug systems do not reach clinical trials [137], highlighting the need for 
effective drug design.  
Nanoparticles offer significant improvements in therapeutics through site specificity, ability 
to escape from multi-drug resistance, and efficient delivery of drugs [147, 170]. This is 
achieved via passive or active targeting [152]. 
1.4.2.1 Passive targeting 
Passive targeting of nanoparticles takes advantage of the abnormal tumour physiology and 
structure that results in the EPR effect [171]. The permeability of the vasculature and 
retention by an insufficient lymphatic system can result in passive accumulation of 
macromolecules to increase their tumour concentration by 70-fold. This accumulation will 
only be observed if the macromolecules avoid clearance by mechanisms such as renal 
clearance and uptake by the MPS/RES [134].  
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Efficacy of nanoparticles as delivery vehicles is highly size- and shape-dependent. The size of 
the nanoparticles affects their movement in and out of the vasculature, whereas the 
margination of particles to the vessel wall is impacted by their shape [24]. Particles tend to 
passively extravasate through the leaky vasculature, which is characteristic of solid tumours 
and inflamed tissue, and preferentially accumulate through the EPR effect [172]. If this occurs, 
the drug may be released into the extracellular matrix and diffuse throughout the tissue for 
bioactivity [149, 171]. 
Passive targeting has been demonstrated for nanoparticles with sizes ranging from 10 to 500 
nm. It was found that particles (40–100 nm) accumulation depends on the blood residence 
half-life and is independent of nanoparticle size for the tested size range. In contrast, smaller 
particles (around 20 nm) accumulation depends on size and residence time [173, 174]. 
However, small particles have a relatively short residence time at the tumour site when 
compared with larger particles (> 40 nm). The blood residence time is a crucial parameter for 
therapeutic efficiency, as the nanoparticles are initially transported by the blood, followed by 
passive diffusion from the blood vessel into the tumour [175, 176]. 
Passive targeting has disadvantages similar to traditional chemotherapy, i.e. inability to 
actively and effectively distinguish between healthy tissue from tumour tissues [177]. Passive 
targeting also involves the use of other innate characteristics of the nanoparticle highlighting 
the need for active targeting [139]. 
1.4.2.2 Active targeting  
Once nanoparticles have extravasated in the target tissue, the presence of ligands on the 
particle surface can result in the active targeting of particles to receptors present on the target 
cell or tissue, resulting in enhanced accumulation and cell uptake through receptor-mediated 
endocytosis [145], enhancing the therapeutic efficacy of drugs, that not readily permeate the 
cell membrane and require an intracellular site of action for bioactivity [178]. 
Active targeting involves the use of peripherally conjugated targeting moieties for the 
enhanced delivery of nanoparticle systems [179]. The four major advantages of targeting 
tumour vasculature in comparison to conventional therapies include; by-passing the 
physiological barrier that prohibits the dissemination of nanoparticles through a tumour 
vasculature, destroying the vasculature to decreases the growth and metastatic capabilities 
of a tumour, the phenotypic changes in neovascular endothelial cells are inhibited diminishing 
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the possibilities of acquired drug resistance, which is conventional cancer therapies, and the 
tumour vasculature is not specific for the type of cancer [110, 180]. 
Active targeting takes advantage of ligand-receptor, antigen-antibody and other forms of 
molecular recognition, to deliver a nanoparticle or drug to a specific location. For cancer 
therapy, active targeting of cancer-specific receptors is beneficial because it reduces or 
eliminates the delivery of potentially toxic drugs to healthy tissue [98]. 
Active targeting takes advantage of the overexpression of receptors, such as folate and 
transferrin, on the tumour cell surface [110]. These targeted nanodelivery systems have 
performed significantly better than their non-targeted counterparts resulting in increased 
cytotoxicity to tumour cells and reduction of side effects [181]. 
1.4.3 Uptake mechanism 
Both targeted and non-targeted nanoparticles arrive at the tumour vicinity via the EPR effect. 
Tumour cell internalisation is enhanced by the presence of surface ligands [139]. Faster 
clearance from circulation generally corresponds to increased accumulation in the liver and 
spleen via the RES [98]. The internalisation of nanoparticles is vital for effective delivery of 
some anticancer drugs, especially in gene delivery therapies, gene silencing, and other 
biotherapeutics [110, 182]. 
The targeting moieties are essential to the mechanism of cellular uptake. Long circulation 
times allows for effective transport of the nanoparticles to the tumour site via the EPR effect, 
where the targeting molecule can induce the endocytosis of nanoparticles [159]. The 
internalisation of nanoparticle drug delivery systems has shown an increased therapeutic 
effect [183]. The nanoparticle attaches to vascular endothelial cells via a non-internalising 
epitope, high local concentrations of the drug will be available on the outer surface of the 
target cell [184].  
It is widely accepted that nanoparticles are suitable to crossing biological barriers through 
tissue diffusion, extravasation, and escape from hepatic filtration [185]. Historically, the 
administration of therapeutic agents has been limited by multiple factors, primarily low 
solubility, stability, and rapid clearance, resulting in a short circulation half-life and low 
efficacy, thus, requiring the frequent administration of the drug [186]. The uptake and 
internalisation of nanoparticles are affected by a few factors. 
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1.4.4 Factors affecting nanoparticle cellular uptake 
The most important properties of effective nanocarriers are the carriers’ increased blood 
residence time, ability to target specific tissues selectively, and to overcome biological 
barriers (Figure 1.4); depending on a particle’s shape, size, and surface characteristics [186]. 
Particle size is a crucial factor in the biodistribution of circulating nanoparticles and achieving 
therapeutic efficacy [103]. Nanoparticles carrying a positively charged surface have a high 
nonspecific internalisation rate with a short blood circulation half-life. Whereas, 
nanoparticles with a negative surface charge showed a marked reduction in the rate of non-
receptor mediated cellular uptake [22]. The surface functionality is another critical parameter 
in controlling the development of long-circulating nanoparticles [187]. Nanoparticle’s uniform 
size distribution, ease of detection, purity (lack contamination), and commercial availability 
are essential for improved cellular uptake [188, 189].  
 
 
Figure 1.4: A summary of the key properties of nanoparticles in drug delivery systems and 
targeted therapy that affect nanoparticle’ cellular uptake, clearance, toxicity, etc. [190]. This 
image was reproduced from reference [190] with permission from Springer (Copyright 2018). 
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The effectiveness of the prediscussed factors is cell specific. In normal tissues and organs, FR-
expression is restricted to only a few sites where it is confined to the luminal surface of 
polarised epithelia and is overexpressed on tumour cells [181]. Thus, using folate receptor-
based nanoparticle systems to selectively and effectively deliver drugs to tumour cells has 
been explored for the last two decades [191], and folate receptor-targeted radionuclide 
therapy has great prospects [146, 192]. 
1.5 FOLATE-BASED DRUG DEVELOPMENT 
Folate receptors are overexpressed in numerous cancers to meet the demand of folate by the 
rapidly dividing cells. This folate dependency of tumours has been therapeutically and 
diagnostically exploited in cancer folate-receptor mediated tumour targeting [164, 193]. 
1.5.1 Structure of folic acid 
Folic acid is also known as pteroylglutamic acid (Scheme 1.1). It has the chemical formula 
C19H19N7O6 (MW = 441.4 Da). Folic acid is a well-known water-soluble vitamin in the vitamin 
B-complex group. Folate, the folic acid salt, or pteroylglutamate, is water-soluble [194], 
stable, inexpensive, and non-immunogenic chemical, with a high affinity as a cell surface 
receptor [195]. 
 
Scheme 1.1: The structure of folate showing the pteridine ring (red), 4-aminobenzoate (blue), 
and the glutamate (black) [196]. 
1.5.2 Importance and functions of folic acid  
Folic acid is an essential vitamin required for DNA nucleotide synthesis (synthesis of purines 
and pyrimidines) and cell division [197]. Folic acid (or folate), binds explicitly with a folate 
receptor existing on the surface of tumoral cells. Tumour cells require more folate than 
healthy cells [198]. The deficiency of folate is linked to anaemia, foetal neural tube defects, 
cardiovascular diseases, and cancer [199]. 
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1.5.3 Folate antagonists  
Antifolates are folate analogues that inhibit vitamin B9 (folic acid) cellular uptake, primarily 
via widely expressed facilitative membrane transporters [200]. Human folate receptors (FRs) 
transport folate via endocytosis with high affinity, are proposed targets for the specific 
delivery of new classes of antifolates or folate conjugates to tumours or sites of inflammation 
[201]. 
Three antifolates (Figure 1.5); pemetrexed, aminopterin, and methotrexate are commonly 
used due to structural similarity to folate [193, 202]. 
 
Figure 1.5: (A) The structure of folic acid and methotrexate, (B) the crystal structure of the 
folate receptor bound to folic acid, and (C) methotrexate binding to folate receptor [203]. This 
image was reproduced from reference [203] with permission from PubMed (Copyright 2018). 
1.5.4 The folate receptors 
Nearly all cells express the folate receptor; for normal DNA replication and cell division, 
however, cancerous cells express a much higher amount of folate receptors (500+ times more 
than healthy cells) [204]. Cancer cells overexpress the folate receptor due to of their increased 
folate requirements [205, 206]. As a result, the high affinity of folic acid and folate presents a 
unique opportunity to use these molecules as targeting ligands to deliver nanoparticles to 
cancer cells [207]. 
1.5.4.1 Structure and composition of the folate receptor 
FRs, also known as folate-binding proteins (FBP), are N-glycosylated proteins with high 
binding affinity to folate. FRs include at least four isoforms, α, β, γ / γ ′, and δ [208]. The α, β, 
and δ isoforms are glycosylphosphatidylinositol (GPI) anchored membrane proteins, whereas 
γ/γ′-FR- is constitutively secreted by lymphoid cells [209]. The affinities of folic acid for the 
FRs are α-FR, Kd ∼ 0.1 nM; β-FR, Kd ∼ 1 nM; and γ-FR, Kd ∼ 0.4 nM. α-FR and β-FR share high 
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amino acid sequence identity (∼70%) and are distinguishable by differential affinities for folic 
acid and stereoisomers of reduced folates [193, 199, 210]. 
The α-FR, a 38 kDa glycosyl-phosphatidylinositol-anchored glycoprotein, has restricted 
expression in the kidney, lung, choroid plexus, placenta, and normal cells [211]. In these sites, 
the α-FR is confined to the luminal surface of polarised epithelia and is not in contact with 
circulating folates or intravenously administered folic acid conjugates. The α-FR is over-
expressed in a variety of tumours such as ovarian carcinomas, choricarcinomas, meningiomas, 
uterine sarcomas, osteosarcomas, and non-Hodgkin’s lymphomas [212]. The β-FR expression 
is restricted mainly to the placenta, white blood cells of myeloid lineage, and activated 
macrophages [209, 213]. The presence of the folate receptors on a cell surface is regulated 
by the cell function [164].  
The crystal structure of the folate receptor was reported to be 2.8 Angstroms. The α-folate 
receptor has a globular structure, stabilised by eight disulphide bonds. It contains a deep and 
open folate-binding pocket comprised of residues that are conserved in all folate receptors 
[201]. The folate pteroyl moiety is buried inside the receptor, whereas its glutamate moiety 
is exposed and protrudes from the pocket entrance (Figure 1.6), allowing it to be conjugated 
to drugs without affecting the α-FR binding [193]. 
 
Figure 1.6: The crystal structure of the α-FR showing surface distribution of α-FR with a close-
up view of the ligand binding pocket entrance. Folic acid carbon atoms are coloured grey, 
nitrogen atoms blue, and oxygen atoms red [199]. This image was reproduced from reference 
[199] with permission from PubMed (Copyright 2018). 
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Folic acid is oriented with its basic pteroate moiety docked deep inside of the negatively 
charged pocket and the two negatively charged carboxyl groups of its glutamate moiety 
extruding from the positively charged entrance of the ligand-binding pocket [193]. The folate 
receptor constitutes a useful target for tumour-specific drug delivery.  
1.5.4.2 Active targeting of folate receptors  
As previously mentioned, targeted delivery via selective cellular markers can potentially 
increase the efficacy and reduce the toxicity of therapeutic agents. Conjugates of folic acid 
and anti-FR molecules can be taken up by cancer cells via receptor-mediated endocytosis, 
thus providing a mechanism for targeted delivery to FR+ cells [210]. 
The FR-targeted radionuclides have several advantages, including relatively easy and cost-
effective synthesis, potential broad applications for the treatment of several tumours, and 
favourable tumour-to-background ratios [214]. However, current radiotracer-based imaging 
techniques are limited in anatomic resolution, which necessitates additional imaging 
modalities and other techniques to localise the detected tumour [123].  
FR density appears to increase as the cancer worsens. However, in some tissues, FR access is 
limited due to the FR location on the apical (externally-facing) membrane of polarised 
epithelia [215]. Nonetheless, FR active targeting is achievable when folate is conjugated to a 
drug-containing molecule or compound [212]. 
1.5.5 Folate conjugation  
FRs mediate cellular internalisation of folate conjugates via receptor-mediated endocytosis, 
thus constitutes a method for targeted intracellular delivery of therapeutic agents to FR+ cells 
[210, 216]. 
Folate conjugation presents an alternative method of targeting the folate receptor. Folate 
receptor-specific delivery of protein toxins, anti-T-cell receptor antibodies, interleukin-2, 
chemotherapy agents, γ-emitting radiopharmaceuticals, magnetic resonance imaging 
contrast agents, liposomal drug carriers, and gene transfer vectors [212]. The small size, 
convenient availability, simple conjugation chemistry, and lack of immunogenicity of folic acid 
make it an ideal ligand for folate conjugation and targeted delivery to tumours [212]. 
Folate conjugation has been successfully used for the delivery of small molecules, 
macromolecules, and nanocarriers in numerous preclinical studies [147]. For nanocarriers, 
which include liposomes, polymeric nanoparticles, and several types of nucleic acid vectors, 
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a drug carrier is typically conjugated to folate, through a PEG linker to overcome steric 
hindrance surrounding the FR on the cell surface [217]. Among macromolecules, folate has 
been conjugated to protein toxins, antibodies, polymeric drug carriers, and prodrug 
converting enzyme [215]. Folate conjugates can target both α-FR- and β-FR. This potentially 
enables the targeting of tumours that are low in α-FR but high in β-FR (e.g., tumours that are 
highly infiltrated by β+-FR tumour associated macrophages, and chronic inflammatory 
diseases like rheumatoid arthritis [218]). However, this reduces the selectivity for the tumour 
cells, but may expand the range of disease targets and subsequently patient population that 
are responsive to FR-targeted therapy [219]. 
A low molecular weight (MW) folate conjugate is rapidly distributed into tumour tissues and 
is rapidly cleared from systemic circulation, reducing the concentration in the plasma and 
non-target tissues. This typically leads to a higher tumour-to-normal tissue ratio. The low MW 
conjugates are typically not immunogenic and are not subject to denaturation and the 
associated loss of biological activity and can be produced by total synthesis as a single pure 
chemical entity, which is not always feasible for macromolecular conjugates [215]. In addition 
to low toxicity, biodegradability, and biocompatibility of these folate conjugates [220], the 
small size, convenient availability, simple conjugation chemistry, and lack of immunogenicity 
of folic acid makes it an ideal biomolecule for targeted drug delivery to tumours [212] with 
effective cellular uptake. 
1.5.6 Folate uptake 
Folic acid and its reduced derivatives, including 5-methyltetrahydrofolate and 10-
formyltetrahydrofolate, are transported via the widely expressed folate receptors, and the 
two facilitative transporters, namely; reduced folate carrier (RFC) and proton-coupled folate 
transporter (PCFT) [221].  
1.5.6.1 Folate receptor-mediated endocytosis 
A universal anion channel with a low folate-binding affinity (Km 5-10mM) is responsible for the 
uptake of folate in adult tissues. The folate food supplement had a high binding affinity of Kd, 
1nM and the physiologically prevalent folate N5-methyltetrahydrofolate (5-mTHF), requires 
the function of three subtypes of folate receptor (α-FR, β-FR, and γ-FR), which are cysteine-
rich glycoproteins that mediate folate uptake through endocytosis, in which the α-FR is the 
mostly expressed [222]. Inside the cell, the acidic environment of the endosome promotes 
the release of folate from receptors [223]. In normal tissues, the exception for folate 
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receptors overexpression and increased folate uptake is essential and restricted to embryonic 
development (for example, placenta and neural tubes) and folate resorption (kidney) [199]. 
Most eukaryotic cells are unable to produce folate [224] and folates cannot directly penetrate 
the cell membrane because of their hydrophilic anionic nature; cellular uptake also occurs via 
endocytosis through folate receptors (FRs) [162]. Substantial targeting efficacy has been 
found both in vitro and in vivo [210], although the precise mechanism of FR transport of folic 
acid into cells remains unresolved, folate conjugates are primary taken up non-destructively 
(Figure 1.7) by mammalian cells via folate receptor-mediated endocytosis [225]. 
 
Figure 1.7: Folate receptor-mediated folate uptake [226]. Folate linked to intracellular or 
extracellular active agents bind to the folate receptor; the folate linked to intracellular drug 
is internalised, develops into endosomes, and is released into the cytoplasm while the 
endosome gets recycled. On the contrary, folate linked extracellular active agents activate 
cytotoxic function(s) outside the cell. This image was reproduced from reference [226] with 
permission from Elsevier (Copyright 2018). 
1.5.6.2 Reduced folate carrier  
The reduced folate carrier (RFC) is a ubiquitously expressed anion transporter primarily 
responsible for the transmembrane transport of reduced folates, with Kt values in the μM 
range. RFC is the primary pathway for reduced folate uptake into various tissues under 
physiological pH. Reduced folates and antifolates, such as methotrexate, pralatrexate, and 
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pemetrexed, are transported into cells through the RFC and are subsequently retained in the 
cytoplasm through polyglutamylation by the polylpoly(g-glutamate) synthetase [221, 227]. 
RFC, however, has a relatively low affinity for folic acid relative to the FRs and is not expected 
to transport folate derivatives across the cellular membrane. In contrast, α-FR binds folate 
derivatives with high affinity and mediates their internalisation by endocytosis via a pathway 
that is associated with caveolae and receptor recycling [210]. 
1.5.6.3 Proton-coupled folate transporter  
Folate uptake via the proton-coupled folate transporter (PCFT), which is responsible for 
intestinal folate absorption at the acidic pH of the upper small [228]. The key role of PCFT in 
obligatory intestinal folate absorption has been established in studies with hereditary folate 
malabsorption, a congenital disorder in which loss-of-function mutations in PCFT, results in 
low folate levels in the blood and cerebrospinal fluid [202]. PCFT is a proton-driven folate 
cotransporter whose activity can be upregulated by the folate receptor to satisfy heightened 
needs [229]. PCFT regulates folate homeostasis and is known for internalising antifolates 
[230] and not folate conjugates [210]. 
1.5.7 Antifolates uptake 
Antifolates are also taken up by the mechanisms mentioned above for folate uptake (Figure 
1.8). For over 60 years, antifolates have been developed to treat a variety of cancer types and 
inflammatory diseases[231]. More recently, the emphasis in folate-mediated drug therapy 
has shifted to obtain a better understanding of transport mechanisms of antifolates because 
dose-limiting toxicities arise from their transport via RFC, and possibly PCFT, into normal cells 
[232].  
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Figure 1.8: Antifolates mechanism of action [211]. The folate conjugates bind to the folate 
receptor, internalised via endocytosis, and the drug is cleaved and released exerting activity 
on cell while folate receptor is recycled back to the cell surface. This image was reproduced 
from reference [211] with permission from Elsevier (Copyright 2018). 
To date, antifolates approved for clinical use are transported primarily via RFC, although one 
of the most recently developed antifolates, pemetrexed (PMX), may also transit through PCFT 
[210]. Despite the published successes, folate-targeted therapy has limitations and 
challenges.  
1.5.8 Challenges/Limitations of nanoparticle folate-targeted therapy 
One of the potential limitations of FR-targeted nanomedicines could be their high renal 
uptake. Significant amounts of FA-conjugated nanoparticles have been observed in the liver 
and kidneys [233]. Nanoparticles may accumulate in the liver, spleen, and lungs based on their 
size distribution, i.e., nanoparticles of 50–100 nm tend to accumulate in the liver due to non-
continuous endothelia with vascular fenestrations; nanoparticles of 200–500 nm tend to 
accumulate in the spleen due to inter-endothelial cell slits; and microparticles of 2–5 μm tend 
to accumulate in the capillaries of the lungs [59]. 
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Only nanoparticles of 5 nm or smaller can be filtered out by the kidneys. Physiologically, folate 
binding proteins (FBP) including α-FR, β-FR, and RFC are highly expressed in the kidneys. FBP 
is in the brush board membrane of the proximal tubule cells and participates in folate 
reabsorption from the convoluted proximal tubules. Hence, these proximal tubular cells are 
not directly exposed to the circulating FA-conjugated nanoparticles unless they are filtered 
from glomeruli. Filtration initially occurs at the interface of glomerulus and Bowman's capsule 
[234]. Filtered molecules or nanoparticles need to pass through three filtration layers: the 
endothelium, glomerular basement membrane (GBM), and foot processes of the podocytes. 
The endothelium serves as an initial physical barrier with a pore size of 80–100 nm in 
diameter. The GBM with a high concentration of heparin sulphate in the middle layer provides 
a negative charge to repel negatively charged molecules electrostatically but attract positively 
charged molecules or nanoparticles, e.g., dendrimers, from the blood. The foot processes of 
podocytes with a pore size of 15–20 nm in diameter represent the last filtration barrier [234]. 
Another potential disadvantage of the strategy of using folate conjugates includes 
interference of FR targeting by circulating folate, which may be influenced by a patient’s diet. 
Conversely, it is worth noting that dietary folate has not been a significant issue in clinical 
studies. Folic acid has been given to the patient in clinical trials to reduce normal tissue uptake 
of etarfolatide in a clinical trial, suggesting that low concentrations of circulating folate may 
be helpful for targeting tumour cells in vivo [235]. 
The high-level accumulation of folate-based radiopharmaceutical suggests that kidney uptake 
of low MW folate conjugates is extremely high since both types of agents similarly bind the 
FR. The accumulation of these conjugates in the kidneys has been found to be persistent 
rather than transient, reducing the prospective applications of low MW folate conjugate-
based radiopharmaceuticals for targeted therapy [215]. The lack of FR subtype specificity of 
folate conjugates is also viewed as a disadvantage [236]. 
Another limitation is that folate-linked macromolecules do not appear to target normal 
tissues. This is primarily limited by the poor penetration of macromolecular conjugates into 
solid tumours. This problem may be addressed by inducing a two-stage targeting strategy, in 
a similar manner to the folate–hapten therapy. A reduction in the size of the targeted complex 
to facilitate better tumour penetration and application of strategies to increase the 
permeability of solid tumours. Alternatively, the use of more potent therapeutic agents that 
are effective at the lower doses that penetrate the tumour masses [237]. 
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Folate targeting shows considerable promise for the development of tumour-specific 
therapeutic agents, but obstacles must still be overcome before it can reach its full potential. 
[226]. The above-mentioned challenges have solutions [145], and the experimental design 
factored in the published limitations. 
1.6 FOLATE RECEPTOR EXPRESSION  
Different cells express different amounts of folate receptors on their surfaces (Figure 1.9).  
 
Figure 1.9: Folate receptor expression among a wide variety of human tumours [211]. Ovarian 
and non-small cell lung cancer (NSCLC) have the highest tumour folate receptor expression 
and breast tumours have positive folate receptor expression in most tumours. This image was 
reproduced from reference [211] with permission from Elsevier (Copyright 2018). 
Among normal tissues, the α-FR expression is mostly limited to the apical plasma membrane 
of the polarised kidney and specific epithelial cells and other areas as previously elaborated 
[216]. In this study, four breast cell lines were selected based on their α-folate receptor 
expression levels [238], namely; MDA-MB-468, MCF-7, MDA-MB-231, and MCF-10A (Table 
1.8). 
 
 
 
 
 
C h a p t e r  1   P a g e  | 34 
 
Sendibitiyosi Gandidzanwa                           211175897                            Nelson Mandela University 
  
Table 1.8: The four breast cell lines employed for the cytotoxicity and cell uptake studies.  
Cell line MDA-MB-468 MCF-7 MDA-MB-231 MCF-10A 
α-folate receptor 
expression levels 
- + ++ +* 
Oestrogen 
receptor 
- + - + 
Progesterone 
receptor  
+ + - + 
HER2 receptor - - - + 
Epidermal growth 
factor (EGF) 
receptor 
+ - - + 
Endogenous A2B 
receptor 
- - + - 
Tumorigenicity yes yes yes no 
Tissue source M(PE) M(PE) M(PE) M(PE) 
Tumour 
identification 
basal A luminal basal B 
(invasive) 
basal B (non-
invasive) 
Cell morphology grape-like mass stellate round 
Proliferative index 82.4 56.7 9.42 49.5 
The above table was constructed from multiple references [238–245]. For the alpha folate receptor levels; - denotes negative 
receptor expression, + denotes low levels of receptor overexpression, ++ denotes high levels of receptor overexpression, and 
+* denotes normal. For the other receptors, the levels of expression are unreported; - denotes negative receptors, + denotes 
positive receptors, M = metastasis, and PE = pleural effusion. 
1.6.1 MDA-MB-468 
The MDA-MB-468 breast cancer cell line was first derived from a pleural effusion of a 51-year-
old breast cancer patient in 1977 [245]. It does not have any folate receptor on its surface and 
has disorganised nuclei with poor cell-cell adhesion [244]. 
1.6.2 MCF-7 
The Michigan Cancer Foundation-7 (MCF-7) is an adherent breast cancer cell line isolated in 
1970 from a 69-year-old Caucasian woman [246]. The MCF cell line has a low folate receptor 
expression [244] with disorganised nuclei and robust cell-cell adhesion. 
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1.6.3 MDA-MB-231  
It is an epithelial human breast cancer cell line with high folate receptor expression [247], 
disorganised nuclei and elongated cell body with invasive processes [244]. 
1.6.4 MCF-10A 
The Michigan Cancer Foundation-10 (MCF-10A) is a non-tumorigenic human epithelial human 
breast mammary gland cell [248] with normal cell folate receptor expression, organised nuclei 
and robust cell-cell adhesion [249].  
1.7 RATIONALE AND MOTIVATION 
Folate-conjugate based radiopharmaceuticals are hypothesised to have favourable 
pharmacokinetic properties than other radiolabelled agents [181], but with no folate-
targeting drugs that are past clinical trials [250], only six folate-targeted drugs, four folate-
targeted imaging agents, and an α-FR specific monoclonal body are in clinical trials [164, 249, 
251]. Therefore, there is a gap in folate receptor-targeted therapy. 
South Africa has the world’s second largest reserves of palladium [63], and palladium-109 has 
the key properties required for a nanoradiopharmaceutical (Section 1.2.5). Palladium has 
been reported to be a prospective key element in the nanomedical field [252]. To the best of 
our knowledge, palladium use as a biofunctionalised radionuclide for cancer-specific 
receptor-mediated targeted endocytosis has not been previously reported, highlighting 
prospects for the development of palladium-based nanoradiopharmaceuticals. 
1.8 AIMS OF THE STUDY  
The study primarily aims to design new nanoradiopharmaceuticals based on the 109Pd nuclide. 
A cold 108Pd was used for the development stage in this study, and the palladium was in the 
form of palladium(II) which was reduced to palladium(0) nanoparticles. 
The key objectives are summarised as follows: 
(i) The in situ synthesis of palladium(II) complexes with capping agents followed by 
their in situ reduction to Pd(0) nanoparticles. 
(ii) Preliminary synthesis, characterisation, and optimised synthesis (at room 
temperature) of palladium(0) nanoparticles capped with 
tetraaminophthalocyanine, diamines, and folate conjugates as biomolecules for 
cancer cell localisation.  
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(iii) The in vitro cell cytotoxic studies were carried out to determine the required non-
cytotoxic concentration of palladium nanoparticles for active targeting. 
(iv) The cell uptake and localisation studies were investigated using transmission 
electron microscopy (TEM) and inductively coupled plasma-optical emission 
spectroscopy (ICP-OES). The size- and capping agent-dependency with respect to 
cancer cell accumulation via folate receptor-mediated endocytosis was explored. 
The preliminary development of a unique class of folate-conjugated palladium-based 
nanoradiopharmaceuticals providing theranostic (therapy and diagnosis) abilities, designed 
to reach their specific target (cancerous cells) selectively and efficiently ensuring tissue 
bioavailability was conducted. 
1.9 SCOPE OF THE DISSERTATION  
The dissertation is composed of five themed chapters and list of references. 
Chapter 1: As described in detail in the preceding pages, Chapter 1 delivers an in-depth and 
thorough introduction of a variety of concepts that are fundamental to this study. 
Chapter 2: This chapter provides a comprehensive list, summary, and descriptions of the 
materials used, preparative and synthetic methods, and instrumentation used. 
Chapter 3: A detailed synthesis, optimisation, and characterisation of conjugates and 
nanoparticles is presented in this chapter. Stepwise elimination of reducing agents, capping 
agents, and preferred synthetic conditions and methods are explained. 
Chapter 4: The in vitro cytotoxic effects of the palladium nanoparticles are reported in this 
chapter. It further presents the qualitative and quantitative cell uptake of the palladium 
nanoparticles by the four breast cell lines. 
Chapter 5: The last chapter provides summarised conclusions and suggested future work for 
this study. 
List of references: This section lists all the bibliography. 
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CHAPTER TWO: MATERIALS, TECHNIQUES, AND EXPERIMENTAL 
METHODS 
2.1 MATERIALS: REAGENTS USED 
All the glassware and magnetic bars were soaked with aqua-regia for a few days, then rinsed 
with distilled water, and dried in an oven before use. A list of the chemicals used is provided 
(Table 2.1). 
Table 2.1: List of chemicals or materials used and their suppliers  
Chemical name Percentage purity  Supplier  
1,10-diaminodecane 97.0 Sigma-Aldrich 
1,2,3–trihydroxybenzene  98.0 Sigma-Aldrich 
1,2-diphenyl-1,2-diaminoethane 98.0 Sigma-Aldrich 
1,4-diaminobenzene 99.0 Sigma-Aldrich 
1,8-diazabicyclo [5.4.0] undec-7-ene 98.0 Sigma-Aldrich 
1.5 mL Eppendorf tubes sterile Sigma-Aldrich 
15 mL falcon tubes sterile Sigma-Aldrich 
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
99.9 Sigma-Aldrich 
4,4’-ethylenedianiline 95.0 Sigma-Aldrich 
4-Nitrophthalonitrile 99.9 Sigma-Aldrich 
Acetic acid Glacial Sigma-Aldrich 
Acetone 98.0 Merck-Chemicals 
Agar 100 resin - Agar Scientific 
Cacodylate buffer 99.0 Agar Scientific 
Camptothecin 99.9 Sigma-Aldrich 
Citric acid 99.5 Sigma-Aldrich 
Corning® cell scrapersblade L 1.8 cm, 
handle L 25 cm 
sterile Sigma-Aldrich 
Dichloromethane (DCM) 99.0 Merck- Chemicals 
Diethyl ether 98.0 Sigma- Aldrich 
Dimethyl sulfoxide (DMSO) 99.5 ACE Chemicals 
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Table 2.1: Continued. 
Disodium hydrogen phosphate 98.0 Sigma-Aldrich 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
sterile Biowest 
Ethanol 99.0 Merck-Chemicals 
Ethyl acetate Analytical grade Merck-Chemicals 
Ethylenediamine  98.0 Sigma-Aldrich 
Foetal bovine serum (FBS) 99.9 Thermofisher & Biowest 
Folic acid (FA) 98.8 Sigma-Aldrich 
Formaldehyde 38.0 (w/v) Sigma-Aldrich 
Glass Pasteur pipettes sterile Sigma-Aldrich  
Glutaraldehyde 50.0 (w/v) Agar Scientific 
HAMS F12 sterile Biowest 
Hexamethylenediamine 98.0 Sigma-Aldrich 
Hexane 97.0 Sigma-Aldrich 
Hydrazine hydrate 98.0 Sigma-Aldrich 
Hydrochloric acid 97.0 Merck-Chemicals 
Hydrocortisone 99.9 Sigma-Aldrich 
Insulin 99.9 Gibco 
Lead citrate  98.0 Sigma Aldrich  
Leibovitz’s L-15 Medium sterile Gibco 
Methotrexate 99.9 Sigma-Aldrich 
Molecular grade ethanol  99.0 Sigma-Aldrich 
N,N’-Dicyclohexylcarbodiimide (DCC) 98.0 Sigma-Aldrich 
N,N’-Dimethyl formamide (DMF) 99.0 Fluka 
N-Boc-Ethylene diamine Analytical grade Sigma-Aldrich 
N-Hydroxysuccinimide (NHS) 98.0 Sigma-Aldrich  
n-Octanol 99.9 FluoroChem 
Osmium tetroxide 98.0 Sigma-Aldrich  
Parafilm - Sigma-Aldrich  
Paraformaldehyde 98.0 Agar Scientific 
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Table 2.1: Continued. 
Potassium chloride 99.0 Sigma-Aldrich 
Potassium dihydrogen phosphate  99.5 Sigma-Aldrich 
Potassium tetrachloropalladate  99.0 Sigma-Aldrich  
Propylene oxide 98.0 Sigma-Aldrich  
Pyridine 99.0 Sigma-Aldrich 
Pyridine-HCl 90.0 Merck-Chemicals 
Sodium borohydride 99.0 ACE Chemicals 
Sodium chloride 99.5 Sigma-Aldrich 
Sodium metabisulphite 98.0 Sigma-Aldrich 
Sodium sulphide hydrate 60.0 Sigma-Aldrich 
Triethylamine 99.0 Merck- Chemicals 
Trifluoroacetic acid 99.0 Sigma-Aldrich 
Trypan blue 99.5 ACE chemicals 
Trypsin  sterile Sigma-Aldrich 
Uranyl acetate  99.9 Lonza Chemical 
Zinc(III) chloride 98.0 Sigma-Aldrich 
2.2 INSTRUMENTATION  
Various instruments were employed for analytical and spectroscopy analysis.  
2.2.1 1H-and 13C-Nuclear magnetic resonance (NMR)  
The 1H-Nuclear Magnetic Resonance (NMR) and 13C-NMR measurements were acquired on a 
Bruker NMR (400 MHz) spectrometer in deuterated DMSO (DMSO-d6) solution and reported 
relative to tetramethylsilane (δ 0.00). The NMR spectra were used to confirm the chemical 
structures. 
2.2.2 UV-Vis absorption spectroscopy (UV-Vis) 
UV-Vis absorption spectra of the synthesised nanoparticles (NPs) and compounds were 
recorded on a Thermo Scientific spectrophotometer on a wavelength interval between 200 
nm and 800 nm. Quarts square spectrophotometer cuvettes with a path length of 10 mm 
were used. Water and DMSO were used as the solvents.  
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2.2.3 Fourier-transform infrared spectroscopy (FTIR) 
The infrared spectra were recorded on a Bruker Tensor 27 Platinum ATR-FTIR 
spectrophotometer in the range 4000−400 cm−1. 
2.2.4 X-ray diffraction spectroscopy (XRD) 
The crystallinity of the nanoparticles was confirmed using powder XRD data obtained using a 
Bruker Kappa Apex II diffractometer with a monochromated Cu Kα radiation (λ = 0.71073 Å). 
(The use of XRD was limited to only large-sized nanoparticles that were precipitated, 
collected, dried, powdered, and analysed). 
2.2.5 Liquid chromatography-mass spectroscopy (LC-MS) 
LC-MS spectra were acquired from a Water Synapt G2 liquid chromatography-mass 
spectroscopy using methanol as a solvent at 15 V. 
2.2.6 Elemental analysis 
Elemental analysis was conducted using a Vario Elementary ELIII Microcube CHNS elemental 
analyser. Calibration of the instrument was done with the use of the following standards in a 
linear curve adjustment within the total working range.  
Standard 1: Sulfanamide: C - 41.81; H - 4.65; N - 16.25; S - 18.62%  
Standard 2; Acetanilide: C - 71.09; H - 0.67; N - 10.36% 
2.2.7 Zeta potential (ZP) and dynamic light scattering (DLS) 
The surface charge (zeta potential) and hydrodynamic sizes of nanoparticles were determined 
by analysing sonicated particle suspensions using a Malvern Zetasizer Nano ZS particle size 
analyser (Malvern Instruments GmbH, Herrenberg, Germany). The mean value and standard 
deviation of three readings were reported. 
2.2.8 Transmission electron microscopy (TEM) 
Transmission electron microscope (TEM) images of the palladium nanoparticles and culture 
cells were acquired using a Zeiss Libra 120 and JEOL JEM2100 LaB6 transmission electron 
microscope operated at 120 and 200 kV, respectively. Nanoparticle solutions in ethanol were 
ultrasonicated for 30 s and the carbon-coated copper grids or 300-mesh carbon coated grids 
purchased from Electron Microscopy Sciences and SPI carbon coated grids, respectively, were 
used to collect the nanoparticles from the homogenous solution. The grids were completely 
dried in vacuum for at least 60 min and the images were acquired using a Mega-view III digital 
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camera’s embedded self-imaging system. The diameter of the smallest circle of best fit was 
measured using ImageJ™ software for 30 to 50 nanoparticles and the nanoparticle size 
distribution constructed. For the agglomerated large-sized nanoparticles, the sizes were 
obtained from the measurable nanoparticles.  
Selective area electron diffraction (SAED) patterns and energy dispersive X-ray (EDS) spectra 
were acquired from the JEOL JEM2100 LaB6 TEM, with the latter acquired in scanning 
transmission electron microscope (STEM) mode.  
2.2.9 Inductively coupled plasma-optical emission spectroscopy (ICP-OES). 
The nanoparticle analysis was carried out with an Avio 200 ICP-OES (Table 2.2). The metal 
standards, dissolved in 0.5 M HNO3, were used to prepare standard solutions for the 
construction of calibration curves using distilled, deionised, Milli-Q water with a resistivity of 
18.2 MΩcm-1 for dilution [253]. The solutions were analysed at 248.89 nm for minimal 
interferences [254]. The instrument was calibrated by using 0.01, 0.1, 1, 10, 50, and 100 ppm 
standard solutions for the palladium(II) ions. 
Table 2.2: Inductively coupled plasma-optical emission spectrometer parameters. 
Applied radio frequency (RF) power  1500 W  
Plasma gas flow rate  10 L/min  
Auxiliary gas flow rate  0.2 L/min  
Nebulizer gas flow rate  0.55 L/min  
Sampling depth  8.5 mm  
Sample pump rate  50 rpm  
Sample flow rate 1 mL/min 
Sample flush time 10 s 
Time scan acquisition  50 ms/point  
Cooled spraying chamber temperature  4°C  
The camera temperature  46.63°C  
Generator temperature  24°C  
Optics temperature  36.9°C  
Total integration time  30 s per analyte  
Autosampler wash rate 2.5 mL/min 
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Table 2.2: Continued. 
Autosampler wash normal time 20 s 
Autosampler source equilibration delay 1 s 
Plasma view axial 
Number of replicates  6 
Number of points per peak 7 
Purge gas flow normal 
Delay time 25 s 
Palladium wavelength  248.89 nm  
Potential interferences 92Zr16O+, 92Mo16O+, 68Zn40Ar+ 
2.2.10 Powerwave spectrophotometer (BioTek) 
The Powerwave Epoch|2 microplate reader Biotek spectrophotometer was used to measure 
absorbance in 96-well microplate after cell counting using haemocytometer. 
2.2.11 Centrifuge 
Labofuse 200 Heraeus sepatech centrifuge was used for centrifugation.  
2.2.12 Ultrasonicator 
Ultrasonication of nanoparticles was done by a Bransonic 1800 Lasec 150W ultrasonic water 
bath. 
2.2.13 Incubator 
Thermo Electron Corporation Forma Direct Heat CO2 Incubator 311 was used to grow and 
culture the different cell lines. It maintained optimal temperature (37 ͦC), Carbon dioxide (% 
CO2 = 5%), and humidity (95%) needed for cell growth.  
2.2.14 Other instrumentation 
A 691-pH meter (Metrohm Herisau, Switzerland), micro weighing balance (A&D Company 
Limited, Japan), temperature-controlled heating stove (Lasec, South Africa), millipore water 
dispenser (Simplicity 185, France), gyrotory G16 water bath shaker (model G76 New 
Brunswick Scientific, USA), and an inverted light microscope (Zeiss Primo Star, Axiovert 40 C, 
100-240 V), CSV 90 Auto Vortex Mixer (Crown Scientific, 100 W, 220-240 V), PowerTome XL 
ultra-microtome (Labtech, UK), and a special diamond knife for microtome were also used.  
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2.3 PREPARATIVE ASPECTS 
Several methods were used to prepare the different compounds. A summary of the 
preparative aspects is presented. 
2.3.1 Synthesis of N‐Boc-ethylenediamine‐folate 
According to the literature [258], tert-Butyloxycarbonyl (Boc) protecting group can be used to 
protect one side of the diamine and allow the conjugation of folate. The method was modified 
as reported by Lee et al., (2007) [259]. 
 
Scheme 2.1: The protection and deprotection steps for the synthesis of folate-
ethylenediamine.  
In a round-bottomed flask 640 mg of folic acid (1.34 mmol, 1 eq. dehydrated powder) was 
dissolved in 25 mL of dimethylsulfoxide (DMSO). After the dissolution was complete (about 
30 minutes with mild heating), 308 mg (2 eq.) of N-hydroxysuccinimide (NHS), and 552 mg of 
N,N'-Dicyclohexylcarbodiimide (DCC) were added successively (Scheme 2.1). The reaction 
mixture was gently stirred for 16 h at room temperature, after which the urea was filtered 
off. The solution was added to 0.376 mL (2 eq.) of triethylamine followed by 429 mg (2 eq) of 
N-Boc-ethylene diamine dissolved in 5 mL of DMSO, and the mixture was stirred overnight 
followed by addition of a mixture of 20% acetone in diethyl ether. A yellow precipitate was 
carefully centrifuged and washed four times with acetone and two times with diethyl ether 
and dried under vacuum [258]. 
2.3.2 Synthesis of folate-ethylenediamine 
The folate-ethylenediamine was prepared (Scheme 2.1) as per published literature [258]. N-
Boc-ethylenediamine-folate conjugate (205 mg) was dissolved in 2 mL of trifluoroacetic acid 
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(TFA) and stirred for 2 hours. The solvent was removed under pressure with the aid of 
dichloromethane (DCM), and the red residue was dissolved with a minimal amount of dry 
dimethylformamide (DMF). The addition of triethylamine (TEA) resulted in the precipitation 
of a yellow powder which was washed and centrifuged four times, and twice with diethyl 
ether (80% yield, 136 mg). Further purification was done [138].  
2.3.3 Synthesis of tetraaminophthalocyanine (TAPc) 
The synthesis of TAPc (Scheme 2.2) was conducted as reported in literature [260]. 4-
Nitrophthalonitrile (5.14 g, 29.7 mmol) and zinc chloride (1.23 g, 7.42 mmol) were added to 
n-octanol (8 mL), and catalytic amounts of 1,8-diazabicyclo-[5.4.0]-undec-7-ene (DBU) was 
added to the reaction mixture. The reaction was allowed to proceed at 180°C for 4 h. After 
that, the reaction mixture was cooled and diluted with toluene (80 mL), and the precipitate 
that resulted was collected by centrifugation at 6400 rpm for 30 min. The solid was filtered 
and washed with toluene, water, MeOH/ether (1:9), and lastly EtOAc/hexane (2:1). The dark 
green solid (TNZnPc) that resulted was dried and weighed. 
 
Scheme 2.2: The synthesis of metal-free tetraaminophthalocyanine from 4-nitropthalonitrile. 
TAZnPc was synthesised under a nitrogen atmosphere at 65°C by dissolving 4.08 g (5.35 
mmol) of TNZnPc in 80 mL DMF, followed by addition of 15.88 g (66.1 mmol) of sodium sulfide 
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nonahydrate. The reaction mixture was allowed to continue overnight and then cooled to 
room temperature (Scheme 2.2). It was then diluted with cold water (200 mL), and the 
resulting precipitate was collected by centrifugation at 6400 rpm for 30 min. The precipitate 
was repeatedly washed with MeOH/ether (1:9), EtOAc, and dried to afford a dark green solid. 
TAZnPc was demetalated to form TAPc by dissolving 0.75 g in a solution of pyridine (4 mL), 
and pyridine HCl (2 g) while being stirred, under nitrogen, at 110 °C for 17 h. The reaction was 
stopped, and 20 mL of H2O was used to cool the mixture. Centrifugation was used to collect 
the dark green precipitate at 6400 rpm for 30 min, followed by filtration and repeated 
washing with H2O, MeOH, and EtOAc [260]. 
2.3.4 Synthesis of folate conjugated TAPc/EDA 
Firstly, folic acid was activated (Scheme 2.3) using a published method [226]. 
 
Scheme 2.3: The activation of folate for phthalocyanine or diamine conjugation [261]. 
A solution of TAPc (313 mg) in DMSO was then added to activated folate, and the solution 
was further stirred at room temperature for 48 h. The solid product was acquired through 
centrifugation of the resulting solution at 7000 rpm for 10 min (Scheme 2.4), and was weighed 
as described in the literature [258, 262]. Diamines were conjugated to folate (Scheme 2.5) as 
per published literature [223]. 
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Scheme 2.4: Conjugation of activated folate with TAPC [263]. 
 
Scheme 2.5: Activation of folate and its conjugation to diamines. 
After the first step, excess acetonitrile is added for removal of DCC and NHS. Unreacted DCC 
and NHS precipitate out, and the solution is filtered [263]. A ratio of 1:2:1 (FA:DCC:NHS) gives 
a yield of 99% activation at the α position and 90% selectivity. These are the stoichiometric 
ratios used for all direct conjugation reactions [258]. The conjugation reactions result in both 
the α and γ isomers. These isomers were not separated and with the structures of the α-
conjugates presented in-text, the structures of the γ-conjugates are presented (Scheme 2.6). 
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Scheme 2.6: The γ-isomers of the folate conjugates; (a) N-Hydroxysuccinimide (NHS) 
activated folic acid (NHS-FA), (b) tert-Butyloxycarbonyl-ethylenediamine protected folic acid 
(FA-EDA-Boc), (c) folate-ethylenediamine (FA-EDA), and (d) folate-phthalocyanine (FA-Pc). 
2.3.5 Synthesis of palladium nanoparticles 
The method used was a modification of the previously published methods [264–266]. The 
adopted synthesis was designed to meet the conditions inherent from the production of the 
hot isotope [267]. A small amount of PdCl2 was dissolved in acidified (10% HCl) millipore water 
to obtain H2PdCl4 of known concentration. Gentle continuous stirring was done at room 
temperature to ensure homogeneity of the mixture. Freshly prepared sodium borohydride 
solution of known concentration was added dropwise to the brownish palladium chloride 
solution. The solution was further stirred, and aliquots analysed using UV-Vis to confirm the 
complete reduction of palladium(II) to palladium(0). Visually, this was noted by the colour 
change from the brownish solution to a blackish colour. The solution was then transferred to 
polyethylene tubes and the nanoparticles were subjected to purification by centrifugation at 
15 000 rpm for 10 minutes. The obtained precipitate (large nanoparticle sizes) was washed 
with ethanol and collected by filtration for further analysis. For smaller nanoparticles in 
solution, the supernatant was carefully removed by using a pasteur pipette or precipitated 
out using acetone. The nanoparticles were prepared for TEM analysis by ultrasonication in 
ethanol solution for 30 seconds and collected on the TEM grids.  
The above was also repeated for the nanoparticles synthesised from potassium 
tetrachloropalladate (K2PdCl4). The method was the same except for the addition of 10 % HCl. 
The pH of the nanoparticle’s solution was maintained at 7.4. 
(a) (b)
(c) (d)
C h a p t e r  2   P a g e  | 48 
 
Sendibitiyosi Gandidzanwa                           211175897                            Nelson Mandela University 
  
During preliminary stages, different reducing agents and capping agents were investigated, 
and the concentrations were optimised with the best conditions retained for future 
experimentation. The stoichiometric concentration variations employed during optimisation 
are presented (Table 2.3) and the optimal concentrations reported (Table 3.4). 
Table 2.3: An illustration of the varied concentrations of reducing and capping agents used 
during the concentration ratios optimisation. For each experiment, two parameters were kept 
constant and one concentration varied until the desired nanoparticle sizes were achieved. X 
denotes a known concentration.  
Sample  Moles of metal salt Moles of reducing agent Moles of capping agent 
P1 X 0.5X 0.5X 
P2 2X 0.5X 0.5X 
P3 X X X 
P4 X X 5X 
P5 X 5X X 
P6 X 5X 10X 
P7 X 10X 20X 
P8 X 20X 50X 
The reducing agent used after optimisation was sodium borohydride and the reaction scheme 
is presented (Scheme 2.7). 
 
Scheme 2.7: The reaction scheme of the formation of Pd(0) nanoparticles; (a) the reduction 
of palladium(II) chloride with sodium borohydride, and (b) the reduction of potassium 
tetrachloropalladate(II) with sodium borohydride. 
2.3.6 Synthesis of capped palladium nanoparticles 
The accurately weighed palladium(II) salt was dissolved in 10% HCl water. The capping agents 
(known concentration) were mixed with the palladium solution and stirred for at least 10 min 
before the dropwise addition of the reducing agent. Continuous stirring was done at room 
temperature (rt) to obtain the capped palladium nanoparticles. 
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The differently capped palladium nanoparticles; borohydride capped (Bĥ), 
tetraaminophthalocyanine-capped (TAPĉ), ethylenediamine-capped (EDÂ), folate-
ethylenediamine capped (FA-EDÂ), and folate-tetraaminophthalocyanine-capped (FA-TAPĉ), 
were reported (Scheme 2.8). The nanoparticles were categorised into small-, medium-, and 
large-sized nanoparticles (Table 2.4). 
Table 2.4: The size ranges of the synthesised palladium nanoparticles. 
Sample description (abbreviation) Size range  
Small-sized (sz) Less than 10 nm 
Medium sized (mz) Between 10 and 80 nm 
Large-sized (lz) Between 80 and 300 nm 
 
 
Scheme 2.8: The amine-stabilised palladium nanoparticles; (a) borohydride-capped (Bĥ), (b) 
tetraaminophthalocyanine-capped (TAPĉ), (c) ethylenediamine-capped (EDÂ), (c) folate-
ethylenediamine capped (FA-EDÂ), and (d) folate-phthalocyanine capped (FA-TAPĉ) 
palladium(0) nanoparticles, where n is unknown. 
 
 
(a)
(d)
(b)
(e)
(c)
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2.4 CELL LINES AND CULTURE CONDITIONS 
The following cell lines were used in this study; MDA-MB-468, MCF-7, MCF-10A, and MDA-
MB-231. The cell lines (MCF-7 and MCF-10A) were cultured at 37 ֯C with 5% carbon dioxide. 
The MDA-MB-468 cell line were cultured at 37 ֯C, in a 100% air (CO2 free atmosphere). The 
MDA-MB-231 and MDA-MB-468 cell lines were cultured in Leibovitz’s (L-15) media 
supplemented with 10% (v/v) FBS. The MCF-7 cell line was cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10 % (v/v) foetal bovine serum (FBS). The MCF-
10A cell line was cultured in Hams F 12 media supplemented with 5% (v/v) donor horse serum, 
20 ng/mL epidermal growth factor (EGF), 10 g/mL insulin, and 0.5 g/mL hydrocortisone. 
Upon reaching 70-80% confluence, the cells were subcultured from a ratio of 1:4 to a ratio of 
1:8 depending on the growth rate of the cell line. Subculturing was performed as follows: the 
cells were washed thrice with phosphate-buffered saline (PBSA) supplemented with 
ethylenediaminetetraacetic acid (EDTA) (137 mM NaCl, 2.68 mM KCl, 10 mM Na2HPO4.12H2O, 
1.47 mM KH2PO4, and 0.68 mM of EDTA), with pH 7.4. The cells were trypsinised with a 0.25% 
(w/v) trypsin PBSA solution for 5 to 15 minutes at 37 ֯C, the cell detachment was confirmed 
using a microscope. Cryopreservation was done where necessary by using 10% DMSO (v/v) 
with the appropriate media and stored in nitrogen vapor. Cell subculturing and or medium 
change was done every 2 to 3 days, depending on the degree of confluence. The cells were 
resuspended in the respective media and subcultured in 10 cm2 tissue culture treated petri-
dishes. 
2.5 CELL VIABILITY ASSAY 
The trypan blue exclusion assay and the methythiazol tetrazolium (MTT) assay were routinely 
used to assess the cell morphology, cell viability, and determine seeding densities during 
experiments. 
The cells were seeded at 50 000 cells per ml in 96-well plate and allowed to attach for 24 h. 
Initially, the MDA-MB-468 was treated with 100 µM nanoparticle concentrations, however, 
this concentration was cytotoxic. All cell lines (MDA-MB-238, MCF-7, MDA-MB-231, and MCF-
10A) were subsequently treated with 10 µM nanoparticle concentrations (Table 2.5). 
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Table 2.5: The treatments used to investigate the cytotoxicity of the compounds used. The 
reported concentration for the palladium nanoparticles is 10 μM palladium(II) content.  
Treatment Abbreviation  Concentration 
Untreated  UT - 
Folic acid FA 1.36 mM 
Methotrexate MTX 1.32 mM 
Ethylenediamine EDA 1.35 mM 
Phthalocyanine Pc 1.36 mM 
Folate-ethylenediamine FA-EDA 1.25 mM 
Folate-phthalocyanine FA-Pc 1.29 mM 
Small-sized borohydride capped nanoparticles sz-Bĥ-NPs 
10 µM 
Medium-sized borohydride capped nanoparticles mz-Bĥ-NPs 
Large-sized borohydride capped nanoparticles lz-Bĥ-NPs 
Small-sized ethylenediamine capped nanoparticles sz-EDÂ-NPs 
Medium-sized ethylenediamine capped nanoparticles mz-EDÂ-NPs 
Large-sized ethylenediamine capped nanoparticles lz-EDÂ-NPs 
Small-sized phthalocyanine capped nanoparticles sz-Pĉ-NPs 
Medium-sized phthalocyanine capped nanoparticles mz-Pĉ-NPs 
Large-sized phthalocyanine capped nanoparticles lz-Pĉ-NPs- 
Small-sized folate-ethylenediamine capped nanoparticles sz-FA-EDÂ-NPs 
Medium-sized folate-ethylenediamine capped nanoparticles mz-FA-EDÂ-NPs 
Large-sized folate-ethylenediamine capped nanoparticles lz-FA-EDÂ-NPs 
Small-sized folate-phthalocyanine capped nanoparticles sz-FA-Pĉ-NPs 
Medium-sized folate-phthalocyanine capped nanoparticles mz-FA-Pĉ-NPs 
Large-sized folate-phthalocyanine capped nanoparticles lz-FA-Pĉ-NPs 
 
2.5.1 Trypan Blue Exclusion Assay  
A 20 µL aliquot of 0.4% trypan blue solution was mixed with 20 µL of cell suspension and 
vortexed. The cells (10µL) were counted using a  haemocytometer and a Zeiss Primo Star light 
microscope. Trypan blue penetrates dead cells staining their cytoplasm blue while live cells 
remain clear. Unstained (viable) and stained (nonviable) cells were counted in the 16 squares 
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in the corner of the grid. The cells were diluted to the appropriate cell densities (equation 1), 
seeded as per the assay requirements, and cell viability determined (equation 2). 
Cell density (number of cell per mL) = number of cells (mm-2) x 2 (dilution factor) x 104 (1) 
Cell viability (%) =  
Number of viable cells (stained cells)
Total number of cells (stained and unstained cells)
 X 100             (2) 
2.5.2 Methylthiazol tetrazolium (MTT) assay  
To determine cell viability, the MTT assay was performed. After 24 hours of treatments 
exposure, the medium was aspirated and replaced with 200 L of fresh media containing 0.5 
mg/mL MTT and incubated for 2 hours for the MDA-MB-468, MDA-MB-231, and MCF-7 cell 
line, and 3 hours for the MCF-10A cell line. Subsequently, the excess MTT was removed and 
the formazan crystals were solubilised using DMSO. The absorbance was read at 540 nm and 
recorded on an Epoch 2 Powerwave spectrophotometer (BioTek) The formation of purple 
formazan from the reduction of yellow (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide by mitochondrial reductase enzymes only occurs in live cells. 
A standard curve of 0–100 000 cells was used to determine cell number and  allow for 
normalisation. The cells were allowed to attach for 4-8 h, and MTT assay was performed. All 
treatments were conducted in triplicate (N=3). 
2.6 CELL UPTAKE STUDIES: TRANSMISSION ELECTRON MICROSCOPY (TEM) 
The cells were split and grown in 10 cm2 petri dishes until ± 80% confluence. The cells were 
treated for 24 hours with the following palladium nanoparticles; small-sized and medium-
sized borohydride, folate-phthalocyanine, and folate-ethylenediamine capped nanoparticles 
(Untreated cell lines were used as control). After the 24-hour treatment exposure, the cells 
were washed thrice with PBS at 37 ֯C. The cells were fixed using a prewarmed (37 ֯C) 2.5% 
glutaraldehyde and 2% paraformaldehyde in media in a 0.1 M cacodylate buffer at a 
controlled pH of 7.4 at room temperature. After an hour, the cells were gently scraped off the 
plate using a scrapper, aliquoted into test tubes, pelleted loosely and fixed for 3 hours. The 
cell pellet was washed thrice with cacodylate buffer at 5 min intervals and spun between the 
washes. 
The cells were stained with 1% osmium tetroxide in cacodylate buffer for 1.5 hours at 4 ֯C. The 
cells were washed several times with cacodylate buffer, dehydrated in 10% and 70% ethanol 
for 10 minutes and further dehydrated in 100% ethanol for 15 minutes, and. in propylene 
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oxide twice for 15 minutes. The pellet was infiltrated with epoxy resin/propylene oxide 1:1 
ratio mixture for at least 1.5 hours on a rotary. An overnight infiltration with 100% epoxy resin 
was done at room temperature. The cells pellet was embedded on the epoxy resin in dried 
plastic and polymerise at 60-70 ֯C for 18–24 hours. Ultrathin sections of 70–100 nm were cut 
using glass microtome a diamond knife, collected on carbon-coated copper grids, and stained 
with uranyl acetate and lead citrate [268]. Specimens were analysed using TEM.  
Some specimens were viewed unstained (without the osmium tetroxide, uranyl acetate and 
lead citrate contrasting steps), some with only osmium tetroxide staining, and others with 
only uranyl acetate and lead citrate providing the contrast (Section 4.4.1). 
2.7 CELL UPTAKE STUDIES: INDUCTIVELY COUPLED PLASMA-OPTICAL EMMISSION 
SPECTROSCOPY (ICP-OES) 
Cells were cultured and grown as previously described (Section 2.4). After 24 hour exposure 
to treatments (10 µM palladium content small-sized and medium-sized borohydride, folate-
phthalocyanine, and folate-ethylenediamine capped nanoparticles and untreated cell line 
was used as control), cells were carefully washed thrice with 3 mL PBS solution. Each cell well 
was treated with 0.5 mL of 0.5 M HNO3 for 1-1.5 h at room temperature. The cell well contents 
were transferred and stored in eppendorfs. Milli-Q water was used to fill 15 mL tubes and the 
metal ions concentration determined using ICP-OES [269, 270]. 
2.8 STATISTICS 
For the cytotoxic effects of the nanoparticles, the presented data are a mean ± standard 
deviation from the three measurements (N=3) and were analysed using descriptive statistics 
and single factor analysis of variance.  
The significance of the results in comparison to the control was determined using Microsoft 
Excel 2016 by one way analysis of variance (ANOVA) function. The significance was marked 
with asterisks * for p-value <0.05 (statistically significant), ** for p-value <0.01 (statistically 
significant), and *** for p-value <0.001 (statistically highly significant). 
C h a p t e r  3   P a g e  | 54 
 
Sendibitiyosi Gandidzanwa                           211175897                            Nelson Mandela University 
  
CHAPTER THREE: SYNTHESIS, OPTIMISATION, AND 
CHARACTERISATION OF CONJUGATES AND NANOPARTICLES 
3.1 GENERAL INTRODUCTION   
Several novel nanotechnology methods are currently under investigation and development 
for cancer therapy, with nanotechnology offering the opportunity to produce specific 
nanoparticles holding capabilities [49, 271]. Over the past few years, the synthesis of 
nanoparticles with optimal catalytic or bio-friendly properties has been the focus of extensive 
research [272–274]. The synthesis and use of nanoparticles constitute a major research area 
that attracts both academic and industrial interest [275]. As intensively discussed (Section 
1.3), the synthesis and optimisation of nanoparticles is critical in ensuring cellular uptake and 
internalisation. A great deal of previous research has focused on the synthesis of 
nanoparticles and cellular uptake, delivery, and cell membrane interactions are key 
considerations in the nanoradiopharmaceutical design [276–278]. The size, shape or 
morphology, surface charge, stability, and other physical and chemical properties were 
carefully monitored, and the experimental reproducibility investigated. The unique physical 
and chemical characteristics of nanoparticles results in the differences in chemical and 
biological activities, highlighting the importance of constant synthesis parameters [279].  
The investigation of the following nanoparticle synthetic parameters was conducted; 
temperature, time, pH and importantly the concentrations of precursor salt, capping and 
reducing agents used. With limited synthesis procedures available in the literature, different 
stoichiometric ratios, and reducing agents were used to synthesise different sizes of the 
nanoparticles [264, 280–282]. 
Generally, a fast, simple, reliable, and eco-friendly process for the synthesis of 
nanoradiopharmaceutical is critical [283, 284]. In this study, of foremost importance was the 
need to employ a green chemistry synthesis procedure while controlling physical and 
chemical parameters, lowering immunogenicity, and minimising the cost of production for 
future clinical use. The preferred capping agent or conjugate should uniquely target cells and 
be characterised by optimal binding affinity and minimal immunogenicity [161]. 
More recent attention has focused on the synthesis of nanoparticles using greener synthetic 
routes [285, 286]. Green chemistry is all about reducing and eliminating the use of substances 
hazardous to human health and the environment [125, 287]. Strategies of addressing the 
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mounting environmental concerns with the current approach include the use of benign 
solvents, biodegradable polymers, and non-toxic chemicals [284]. The use of simple diamines, 
tetraaminophthalocyanines, and their folate conjugates as capping agents was considered 
and explored. 
3.2 SYNTHESIS AND CHARACTERISATION OF CAPPING AGENTS 
The amine groups-containing diamines and tetraaminophthalocyanine were used as capping 
agents. Ethylenediamine was subsequently chosen as the best diamine, by elimination. The 
folate conjugation of ethylenediamine and tetraaminophthalocyanine is outlined (Section 
3.2.1 - 3.2.3). 
3.2.1 Synthesis of tetraaminophthalocyanine (TAPc) 
Phthalocyanines are planar molecules with 18-π electron systems which are known for their 
intense dark green colour [288]. They are thermodynamically and chemically stable and have 
medical applications [289–291]. The obtained UV-Vis spectroscopy characterisation of the 
intermediates synthesised during the synthesis of tetraaminophthalocyanine (TAPcs) 
(Scheme 2.2) were presented (Figure 3.1).  
 
Figure 3.1: The UV-Vis spectra of the different phthalocyanine compounds; zinc 
tetranitrophthalocyanine (TNZnPc), tetraaminophthalocyanine (TAPc), and zinc 
tetranitrophthalocyanine (TAZnPc). 
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The lack of sharpness of bands for TNZnPc is possibly due to possible aggregation. It is evident 
(for TNZnPc) that nitro (-NO) group causes slight splitting of the Q-band. The amino (-NH2) 
group on the TAPc shows a bathochromic shift that occurred due to the negative inductive 
effect of NH2 (Figure 3.1). Splitting of the Q-band indicates the presence of both monomeric 
and dimeric forms of the complexes in formation. The shoulder or splitting of the observed 
peak can also be due to the fine vibronic structure in addition to dimeric species in solution 
[292]. 
Phthalocyanines have a strong absorption band in the far red in the visible region of the 
spectrum, near 670 nm, known as a Q-band, usually accompanied by a vibronic shoulder 
which is caused by their intense green colour. A less intense band is usually observed near 
340 nm and is known as the B-band [293]. An unmetalated Pc exhibits a split Q-band due to 
a non-degenerate LUMO, giving rise to 2 allowed electronic transitions of different energies. 
Gourtaman’s four orbital theory suggests that these bands arise due to the electronic 
transitions between the HOMO (a1u and a2u) to the LUMO (doubly degenerate eg) [294]. Q-
band is a result of the transition from a2u of HOMO to degenerate eg of LUMO. B-band is a 
result of the superimposition of B1 and Bc that arises from transitions between a2u and b2u of 
HOMO to the e2g of LUMO [294, 295]. The reproducibility of the synthesis of 
tetraaminophthalocyanine was confirmed and the corroborated with published literature  
[262, 296–298]. The products were further characterised with FTIR (Figure 3.2). 
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Figure 3.2: Overlaid FTIR spectra of the different phthalocyanine compounds; zinc 
tetranitrophthalocyanine (TNZnPc), tetraaminophthalocyanine (TAPc), and 
tetranitrophthalocyanine (TAZnPc). 
The spectrum of TNZnPc (Figure 3.2) displayed a ν(N-O) peak at 1538 cm-1. An aromatic ν(C-
N) bond peak at 1332 cm-1 and the ν(C-H) stretch peak around 3100 cm-1 are significant and 
consistent for all the phthalocyanine compounds. The amine ν(N-H) peaks were notable 
around 3362 cm -1 for both the amino group-containing phthalocyanines.  
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The notable disappearance of the nitro (-NO) group and the successful formation of the amino 
(-NH2) group (Figure 3.2) confirmed the success of the reaction (Scheme 2.2). A comparison 
of the TAZnPc and TAPc spectra does not explicitly show the difference between the two 
compounds. This might due to the limitation of the FTIR technique and the incomplete 
demetallation of TAZnPc. However, there is a difference in the NH bending region the visual 
difference (intensity of the green colour) and the UV-Vis confirmation concurred with the 
published literature on the two compounds [262, 296–298]. 
With little to no reported 13C-NMR spectrum for tetraminophthalocyanines. The obtained 
spectrum (Figure 3.3) showed more than 80% similarity to the expected spectrum as 
estimated by ChemDraw [299]. This further confirmed the success of the synthesis. For the 
rest of this thesis, tetraaminophthalocyanine (TAPc) is referred to as phthalocyanine (Pc). 
 
 
Figure 3.3: The 13C-NMR spectrum of the synthesised tetraaminophthalocyanine. 
3.2.2 Synthesis of folate-phthalocyanine  
The folate-phthalocyanine was synthesised (Scheme 2.4) and the obtained final product was 
characterised using UV-Vis (Figure 3.4), LC-MS (Figure 3.5), and FTIR (Figure 3.6). 
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Figure 3.4: The UV-Vis spectra of folate (FA), folate-ethylenediamine (FA-EDA), folate-
phthalocyanine (FA-Pc), and phthalocyanine (Pc). 
Folate (FA) showed two peaks, around 290 and 360 nm. The formation of the additional amide 
bond between the folic acid carboxylic group and the amine group of the ethylenediamine or 
phthalocyanine resulted in spectral shifts. The presence of the peaks at 670 and 730 nm for 
the folate-phthalocyanine (FA-Pc) confirmed the presence of phthalocyanine π-bond systems 
in the FA-Pc compound, absent in folate-ethylenediamine (FA-EDA) and folate spectra [300]. 
A notable folate bathochromic shift from 350 nm to 380 nm (B-band) confirmed the folate-
phthalocyanine conjugation, together with the phthalocyanine hypsochromic shift 735 nm to 
715 nm (Figure 3.4). These shifts can be attributed to the phthalocyanine-folate auxochrome-
chromophore effect. Folate-phthalocyanine had different molecular spectra from either 
folate or phthalocyanine. The prominent peak at 715 nm (Q-band) confirmed the success of 
the FA-Pc conjugation. 
γ-conjugates are intrinsically obtained as the primary product (between 55 to 90% selectivity 
using carbodiimide chemistry), and both conjugates have reported medicinal relevance [258]. 
The γ-carboxyl conjugate also maintains a high affinity to the folate receptor, and the 
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mechanism of cellular uptake is as effective as that of folic acid [301, 302]. With this in mind, 
the separation of the two isomers was not conducted. The reported characterisation and 
analysis are for the unseparated isomers. However, the structures of the γ-isomers were 
presented (Scheme 2.6). The liquid chromatography-mass spectrometry (LC-MS) data of the 
folate-phthalocyanine (Figure 3.5) was analysed.  
 
Figure 3.5: The LC-MS of the folate-phthalocyanine.  
The successful formation of folate-phthalocyanine (C55H55N19O5) is evidenced by the m/z of 
1061.81. The prominent peaks at 1062.81 and 1063.81 are undoubtedly allocated to M+1 and 
M+2, respectively. The other unexpected and unwanted peaks are due to fragmentation, 
dimerisation, and impurity of the obtained compound. The peak at 1147.38 is due to the 
formation of activated folate-phthalocyanine (M+1) which is an impurity of the final product. 
Phthalocyanines are known to fragment. The used (commercial) folate was found to contain 
some impurities (Table 3.1) and also contributed to the presence of many peaks. FTIR spectra 
of the precursor compounds and conjugates were analysed and compared (Figure 3.6). 
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Figure 3.6: The FTIR spectra of folate (FA), folate-phthalocyanine (FA-Pc), and phthalocyanine 
(Pc). 
The spectrum for folic acid (FA) shows a peak corresponding to the carbonyl ν(C=O) stretch 
around 1675 cm-1. Furthermore, the in-ring carbon to carbon ν(C=C) stretch at 1591 cm-1 is 
common for folate and also appeared in folate-phthalocyanine (FA-Pc). FA-Pc shows an amine 
ν(N-H) sharp stretch at 3308 cm-1. Notable ν(C-H) stretches at 2928 cm-1 and 2836 cm-1, and 
the prominent medium intensity ν(C=O) stretch at 1645 cm-1 specific for FA-Pc are observed. 
An ν(N-H) bend for primary amines around 1620 cm-1 is shared across the three compounds. 
Pc exhibits a unique peak for ν(C=C) aromatic stretch at 1525 cm-1. FA-Pc FTIR corresponds to 
FA-Pc
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reported literature. The obtained UV-Vis and FTIR for Pc-conjugation are in agreement with 
recently published literature [303, 304]. 
3.2.3 Synthesis of folate-ethylenediamine  
The folate-ethylenediamine was analysed and the characterisation of the N-Boc protected 
folate-ethylenediamine’s 1H-NMR reported (Figure 3.7).  
 
 
Figure 3.7: The 1H-NMR of the N-Boc-ethylenediamine-folate conjugate. 
The obtained 1H-NMR is consistent with the one available in the literature [258]. 1H-NMR (400 
MHz, D6MSO) (δ): 8.64 (s, 1H, pterin), 8.04 - 7.86 (m, 2H), 7.68 - 7.62 (m, 2H, aromatic), 7.10 
- 6.82 (m, 3H), 6.65 - 6.53 (d, 2H, aromatic), 4.48 (bs, 2H, aromatic), 4.27 (m, 1H, αH), 3.43 (bs, 
water), 3.06 – 2.88 (m, 4H, ethylenediamine), 2.28 - 1.85 (m, 4H, glutamic moiety), 1.35 (s, 
9H, Boc). After the deprotection step of N-Boc, ethylenediamine-folate 1H-NMR was reported 
(Figure 3.8). 
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Figure 3.8: The 1H-NMR of the folate-ethylenediamine 
1H-NMR measurement obtained from a 400 MHz using D6MSO as a solvent exhibited the 
following peaks (δ): 8.64 (s, 1H, pterin), 8.19 - 7.96 (m, 1H), 7.66 - 7.58 (m,2H, aromatic), 7.18 
- 6.91 (m, 3H), 6.66 - 6.53 (m, 2H, aromatic), 4.47 (bs, 2H, benzylic), 4.31 - 4.07 (m, 1H), 3.52 
(water), 2.92 - 2.60 (m, 2H, ethylenediamine), and 2.24 – 1.93 (m, 4H, glutamic moiety). The 
obtained 1H-NMR was as expected [258].  
The LC-MS of the synthesised folate-ethylenediamine (C21H25N9O5) (Figure 3.9) was analysed. 
The formation of the expected product is irrefutably confirmed with the prominent m/z peaks 
at 484.20 and 485.20 which correspond to M+1 and M+2, respectively, for folate-
ethylenediamine (Figure 3.9). The possible presence of folate at 442.14 (M+1) and the 
presence of some activated folate (NHS-folate) can also be suggested as the unlabelled peaks 
at 523.16 and 524.17 for M+1, and M+2, respectively, are significant. It is further noted that 
there is a possibility of some unreacted N-Boc-ethylenediamine-folate due to the presence of 
the unlabelled 584.25 and 585.26 peaks which can be assigned to M+1 and M+2 of N-Boc-
EDA-FA. The peaks at 569.36, 570.36, and 557.38 are attributed to possible folate-
ethylenediamine with Boc fragments attached to it. 
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Figure 3.9: The LC-MS of the folate-ethylenediamine.  
Due to possible dimerisation, fragmentation and incomplete purifications, few unexpected 
peaks are seen (Figure 3.9). However, the toxicity of all the reactants and all the formed 
products were investigated (Chapter 4), and their possible presence were not significant to 
our study. For further characterisation, FTIR analysis was performed (Figure 3.10). 
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Figure 3.10: The FTIR spectra of folate (FA), folate-ethylenediamine (FA-EDA), and N-Boc-
ethylenediamine-folate conjugate (FA-EDA-Boc).  
Folate (FA) showed an amine ν(N-H) peak at 3318 cm-1, alkane ν(C-H) peak at 3109 cm-1, and 
a carbonyl ν(C=O) peak at 1693 cm-1 (Figure 3.10). FA-EDA exhibited a peak for the amide ν(N-
H) group at 3311 cm-1 and the amine ν(N-H) group’s peak at 1590 cm-1. Carbon to carbon 
ν(C=C) in ring peak at 1499 cm-1 is significant and clearly seen for FA-EDA. FA-EDA-BOC 
showed a broad amide N-H bend at 3299 cm-1, a carbonyl ν(C=O) at 1692 cm-1, and an alkane 
ν(C-H) at 3005 cm-1. 
Elemental analysis of folate (FA), folate-ethylenediamine (FA-EDA), and folate-
phthalocyanine (FA-Pc) was determined (Table 3.1). 
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Table 3.1: The obtained elemental compositions (%) for the purchased folate and synthesised 
conjugates; folate-ethylenediamine (FA-EDA) and folate-phthalocyanine (FA-Pc). 
 Folate (C19H19N7O6) FA-EDA (C21H25N9O5) FA-Pc (C55H55N19O5) 
Element Expected  Obtained Expected Obtained Expected Obtained 
C 51.70 49.48 52.17 46.37 62.19 44.1 
H 4.34 6.81 5.21 5.81 5.22 0.54 
N 22.21 20.24 26.07 22.82 25.06 19.01 
 
The elemental analysis of the commercially purchased folate was done as an instrumentation 
control. From its values, a ± 2% variation was obtained for the reported data. However, the 
obtained results for folate-ethylenediamine and folate-phthalocyanines did not correlate 
with the expected values. The deviation agrees with the LC-MS spectra (Figure 3.5 and Figure 
3.9), and this is attributed to impurities. These results should be accepted given that the 
commercial folate used was not free of impurities. After the successful synthesis of 
phthalocyanines, folate-ethylenediamine and folate-phthalocyanine, the synthesis of 
nanoparticles was conducted. 
3.3 PRELIMINARY OPTIMISATION OF SYNTHESIS PARAMETERS 
With size and morphology being primarily dependent on capping agent used, employing a 
reducing agent, reaction time, the ratio of the precursor to the other reagents, and ionic 
strength of solvent used is key [305]. To optimise the essential size and desired morphology, 
the effects of using different reducing and capping agents were investigated. The cost-
effectiveness, time-efficiency, ease of synthesis, and reproducibility of the results were vital. 
Taking into account all the principal factors previously discussed (Section 1.3.2), the selection 
of the reducing and capping agents was conducted. 
The use of a greener solvent, water, was preferred to organic solvents. Water is non-
flammable, non-toxic, and non-tumorigenic. Dispersity of the nanoparticles in water without 
loss of physical and chemical properties over extended periods of time was studied. The 
water-based synthesis of nanoparticles is fraught with the problem as a result of ionic 
interactions, which were overcome by using low concentrations of the precursor molecule 
(about 5 x 10-4 M) [275]. Literature exists that support the need for the development of an 
environmentally friendly medium in place of the commonly used volatile, toxic organic, ionic 
solvents, and polyionic liquids synthesis [306, 307]. 
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The reducing power of the reducing agent is reported to be pH dependent [308]. As a result, 
a neutral pH was carefully monitored and controlled. Strong reducing agents rapidly increase 
nucleation [309] and makes it difficult to obtain nanoparticles with a uniform size. Weaker 
reductants are usually preferred at higher temperatures and stronger reductants preferred 
at low temperatures [305, 309]. Pd(II) is reported to be reduced by alcohols, sodium 
borohydride, ascorbic acid, hydrazine, poly(ethylene glycol) (PEG), dimethylamine borane in 
supercritical carbon dioxide, thermal induced reduction and sonochemical reduction under 
different reaction conditions [310–318]. Commonly used capping agents include long chain 
hydrocarbons, polymers, dendrimers, block copolymers, small molecules, polysaccharides 
etc. [319]. The size, shape, and morphology of the palladium nanoparticles can be controlled 
in a narrow range by changing the concentration of the starting materials as previously 
reported [320]. Taking into account the above, the selection of reducing and capping agents 
was conducted as detailed below. 
3.3.1 Reducing and capping agents 
One of the primary aims of this study was to develop a greener synthesis method of palladium 
nanoparticles at room temperature in water with minimum time. Unlike most of the organic 
solvents, water is non-flammable, non-toxic, and non-tumorigenic. With the reducing and 
capping agent being key determinants on most of the nanoparticle’s properties, the different 
reducing agents (Scheme 3.1) and commercially available capping agents (Scheme 3.2) were 
used. 
 
Scheme 3.1: The different reducing agents investigated in the optimisation of the required 
nanoparticle sizes. 
Firstly, the reducing abilities of the reducing agents were investigated without any capping 
agents used. Some reducing agents can reduce and cap or stabilise the formed nanoparticles. 
However, the primary focus was on the reducing agent strength to reduce Pd(II) to crystalline 
Pd(0) at room temperature in an aqueous medium.  
The strength of a reducing agent is important in the formation of dispersed crystalline 
nanoparticles of good morphology [114]. Varying concentrations were used to reduce 
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palladium chloride (PdCl2) to palladium(0) with no capping agent. UV-Vis was used as the 
primary characterisation technique to confirm the reduction of palladium(II). The 
disappearance of the palladium chloride peak and the notable colour change of the solution 
was evident for the possible formation of Pd(0) nanoparticles [287, 311, 321]. At this stage, 
the crystallinity was confirmed by X-ray powder diffraction. The optical properties for the 
nanoparticles formed from the different reducing agents were investigated (Figure 3.11).  
 
Figure 3.11: UV-Vis spectra of the different reducing agents investigated in the reduction of 
palladium(II) salt at room temperature, synthesised from the reaction of 100 µM palladium(II) 
with 500 µM reducing agent at room temperature. 
Aqueous Pd2+ absorb at 465 nm while palladium nanoparticles do not. The disappearance of 
this prominent Pd2+ peak and a single strong absorption maxima appearing at 324 nm  are an 
indication of the formation of palladium nanoparticles (PdNPs) [322, 323]. All the spectra 
showed the disappearance of the Pd2+ absorption peak, confirming the reduction. However, 
due to instrumentation limitations, only a few of spectra clearly showed the 324 nm peak 
(Figure 3.18a). The sharpness of the peak indicates the size distribution of the particles. The 
expected blue shift confirms the formation of NPs with the π-π* transitions [324] . The lower 
intensity is attributed to the lower concentration of Pd(0). Further characterisation 
techniques such as XRD were used to confirm this conclusion. 
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One of the most important things is the greener synthesis of the nanoparticles. Despite citric 
acid and sodium borohydride being labelled as corrosive (hazard code), formaldehyde and 
hydrazine being toxic, these were preferred due to their reducing strength (Figure 3.11). 
Other reducing agents like ethanol, carbon monoxide, olelylamine, ethylene glycol, and 1-
octadecene are known to have low reducing power at room temperature [125]. As a result, 
these were not used in this study.  
Hydrazine has been used to reduce palladium(II) to palladium(0) with ammonium derivatised 
isocyanides as stabilising agents at high temperatures [325]. Hydrazine and borohydride 
produced similar NPs. These nanoparticles were well defined and circular. This agrees with 
the available literature [310]. Despite being a conventional method, the citrate method did 
not work for the reduction and capping of palladium nanoparticles at room temperature, and 
pyrogallol and sodium metabisulfite. The obtained products were characterised using XRD 
(Figure 3.12).  
 
Figure 3.12: The X-ray diffraction (XRD) spectra of the amorphous particles obtained from the 
reduction of 100 μM palladium(II) salt with 50 mM of; (a) citrate, (b) sodium metabisulfite, (c) 
pyrogallol, and (d) hydrazine at room temperature. 
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It was concluded that sodium borohydride and formaldehyde were the best-reducing agents 
(Figure 3.11). A comparison of the UV-Vis spectra of the two reducing agents (Figure 3.12), 
showed that sodium borohydride achieved complete reduction, therefore, it was preferred 
to formaldehyde. Sodium borohydride and formaldehyde can reduce palladium(II) to 
palladium(0) at low concentrations at room temperature. The obtained UV-Vis spectra of the 
palladium(0) nanoparticles obtained from their reduction (Figure 3.13).  
 
Figure 3.13: The stability studies (UV-Vis spectra) of ethylenediamine-capped nanoparticles 
synthesised from the reduction of palladium(II) by; (a) 1 mM sodium borohydride, and (b) 5 
mM formaldehyde, obtained from the reduction of 10 µM and 50 µM palladium(II) salt, 
respectively.  
Varying concentrations of the reducing agents was carried out to investigate the best capping 
agents. Palladium nanoparticles primary nuclei are known to have extremely high surface 
energy [308]. Owing to this, they tend to aggregate a lot as seen for uncapped nanoparticles, 
hence the need for the nitrogen-containing capping agents. It has been confirmed that amine-
group containing compounds can stabilise palladium nanoparticles [326]. Diamines and 
amine containing phthalocyanines were used in this study with preference given to the less 
toxic diamines that are highly biocompatible. Selected commercially available aliphatic, 
aromatic, short, and lengthy diamines were used in the preliminary studies (Scheme 3.2). 
 
Scheme 3.2: The commercially available symmetrical diamines employed in the optimisation 
of nanoparticle sizes. 
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The primary aim of the preliminary studies was to determine a diamine that meets all the 
requirements previously discussed (Section 1.3). The chosen diamine (ethylenediamine) was 
then conjugated to folate, and its capping agent abilities and that of its conjugate explored. 
The effects of the chosen diamine on nanoparticles properties were later compared to the 
effects of synthesised phthalocyanines and the folate conjugates. Amine-containing 
molecules have been used in radiopharmaceutical conjugation [327]. 
The use of hexamethylenediamine as a capping agent has been reported [305, 328]. However, 
the aspect of solubility and the need for heating caused its elimination from the list. 
Palladium(II) amine complexes are very sensitive to preparative conditions, and several forms 
are often stabilised in the powders produced (polymorphism) such that single crystals are not 
easily obtained [329]. Amine molecules provide hydrophilicity in aqueous solution [323]. The 
diamines that produced amorphous precipitates are reported (Figure 3.14), and were 
expected to stabilise crystalline palladium(0) nanoparticles similarly to how they  stabilise 
palladium(II) complexes. 
The determination of the crystallinity of the synthesised nanoparticles was conducted. 
Amorphous nanoparticles have been considered for use in pharmaceutical industry [330–
333]. Some amorphous nanoparticles have better prospects to crystalline nanoparticles [334, 
335], however, water solubility and size determination remain challenges [336, 337]. On the 
other hand, crystalline nanoparticles are easier to characterise and more stable compared to 
amorphous nanoparticles [72, 73, 331, 338–340], despite their tendency to agglomerate at 
larger sizes [341]. With special focus on improved solubility, controlled size, well-defined 
morphology, and easy characterisation; capping agents that produced amorphous palladium 
nanoparticles were eliminated (Figure 3.14). 
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Figure 3.14: Bright-field TEM images of amorphous precipitates obtained from the reduction 
of 100 μM palladium(II) with 100 μM sodium borohydride in the presence of 100 μM of; (a) 
1,6-hexamethylenediamine, (b) 4,4’ -ethylenedianiline, (c) 1,2-diphenyl-1,2-diaminoethane, 
and (d) 1,4-diaminobenzene as capping agents. The inset shows a SAED for a non-crystalline 
precipitate, similar to the SAED patterns for the other three images.  
Palladium nanoparticles exist in amorphous or crystalline form [69–71, 74, 342]. 
Ethylenediamine, 1,10-diaminodecane, and 1,12-diaminodocane produced crystalline 
nanoparticles (Figure 3.15). 
 
Figure 3.15: Bright-field TEM images of crystalline nanoparticles obtained from the reduction 
of 10 μM palladium(II) with 2mM sodium borohydride capped with 800 μM; (a) 
ethylenediamine, (b) 1,10-diaminodecane, and (c) 1,12-diaminododecane. 
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The UV-Vis spectra were similar; independent of the capping agent (diamine) used, and this 
agreed with the published work [324]. Longer diamines were expected to result in more stable 
NPs [314], however, the obtained results showed more dispersed and non-aggregated 
nanoparticles for ethylenediamine. Further investigation was conducted to confirm 
crystallinity and the absence of PdO using X-ray diffraction spectroscopy (XRD) (Figure 3.16), 
scanning transmission electron microscopy-energy dispersive X-ray spectroscopy (STEM-EDS) 
(Figure 3.17), and selective area electron diffraction (SAED) (Figure 3.18).  
 
Figure 3.16: An XRD spectrum of the ethylenediamine-capped palladium nanoparticles 
synthesised from the reduction of 100 μM palladium(II) with 10 mM sodium borohydride in 
the presence of 100 μM ethylenediamine. 
The above X-ray diffraction profile of the synthesised PdNPs, with the indices (1 1 1), (2 0 0), 
and (2 2 0), corresponds to the palladium XRD crystal structure open database [68] and the 
particle size calculated using Scherrer’s equation [343]. The three fringe patterns with plane 
distances of 0.225, 0.195, and 0.138 nm were consistent with the indices (1 1 1), (2 0 0), and 
(2 2 0) of pure face-centred cubic (fcc) palladium as confirmed by SAED estimation (Figure 
3.18) [344, 345].  
There was no obvious diffraction peak of Pd(II) species. In addition, no peaks were found on 
the XRD pattern which could be attributed to PdO [68, 346], confirming the absence of PdO. 
Different capping agents gave PdNPs which exhibited similar XRD spectra (Figure 3.19) and 
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complementary SAED (Figure 3.20), highlighting the reproducibility of crystalline PdNPs 
synthesis irrespective of optimised capping agent used.  
Despite XRD being primarily used to confirm crystallinity (Figure 3.16), the crystal particle size 
was calculated using Scherrer equation [343]; 
D =  
ĸ𝜆
𝛽Cosθ
                                (3) 
Where D is particle size, ĸ is Scherrer constant (0.94), λ is wavelength of the X-ray source 
(0.15406 nm), β is the full width half maximum (FWHM), θ is peak position (2θ/2), and βcosθ 
is in radians. At (1 1 1); d = 110.63 nm, at (2 0 0); d = 90.48 nm, at (2 2 0); d = 83.73 nm, and 
Daverage = 92.79 nm. The obtained size was within the large-sized nanoparticles range (Table 
2.4) as expected.  
 
Figure 3.17: The scanning transmission electron microscope-energy dispersive X-ray 
spectroscopy (STEM-EDS) spectrum of the ethylenediamine-capped palladium(0) 
nanoparticles formed from the reduction of 100 μM palladium(II) with 10 mM sodium 
borohydride in the presence of 100 μM ethylenediamine. The inset shows the analysed region 
of the agglomerated ethylenediamine-capped palladium nanoparticles.  
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The STEM-EDS spectrum confirmed the presence of palladium. The detection of copper can 
be attributed to the copper grid used and the presence of iron and cobalt (Figure 3.17) can 
be attibuted to system artefacts as the TEM chamber is made of iron and cobalt. The carbon 
can be attributed to the ethylenediamine carbon atoms. SAED was employed (Figure 3.18) to 
further affirm the findings from XRD and STEM-EDS. The obtained SAED spectra were 
compared with the simulated Java Electron Microscopy Software (JEMS) and it corresponded 
[345], affirming the crystallinity and elemental composition of the palladium nanoparticles 
(Figure 3.16 and Figure 3.19).  
 
Figure 3.18: The SAED patterns for; (a) folate-phthalocyanine capped crystalline palladium 
nanoparticles, (b) JEMS simulated SAED for palladium crystal, and (c) annotated JEMS 
simulated SAED for palladium showing the (1 1 1), (2 0 0), (2 2 0), (3 1 1), and (2 2 2) rings. 
The XRD spectra (Figure 3.19) did not show the (3 1 1), (2 2 2), and other peaks due to 
instrumentation settings (maximum 2θ value was 70°), while the (3 1 1) and (2 2 2) peaks 
occur at 2θ = 82 and 86°, respectively. New runs with maximum 2θ = 90° will be conducted. 
The XRD spectra were used to confirm crystallinity and absence of PdO for the differently 
capped large-sized palladium nanoparticles. The particle sizes of the large-sized nanoparticles 
(Figure 3.19) was confirmed using Scherrer’s equation (Table 3.2). The findings confirmed 
that the differently capped palladium nanoparticle had a relatively similar average particle 
size. XRD could not be employed for all nanoparticles as small- and medium-sized 
nanoparticles could be not be precipitated and collected in solid form for XRD analysis. Due 
to this limitation, XRD use in this study was limited to confirming crystallinity and the absence 
of PdO, and not for particle size analysis, resulting in XRD particle sizes not being compared 
to other particle size analysis techniques used. 
(a) (b)
10   1/nm
(c)
10   1/nm
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Figure 3.19: The XRD spectra showing the reproducibility of large-sized palladium 
nanoparticles capped with; (a) phthalocyanine (Pc), (b) borohydride (Bh), (c) folate-
phthalocyanine (FA-Pc), and (d) folate-ethylenediamine (FA-EDA) synthesised from the 
reduction of 100 µM palladium(II) salt with 1 mM sodium borohydride.  
Table 3.2: Summary of the particle diameters calculated using Scherrer’s method for XRD 
spectra presented (Figure 3.19). The FWHM (β) values were determined using SigmaPlot™.  
Capping 
agent 
Parameter For (1 1 1) peak For (2 0 0) peak For (2 2 0) peak D average (nm) 
Pc 
2θ (°) 40.8 47.1 68.5 
96.19 β(cm) 0.08 0.1 0.115 
D (nm) 110.70 90.55 87.33 
Bh 
2θ (°) 40.8 47.1 68.5 
96.19 β (cm) 0.08 0.1 0.115 
D (nm) 110.70 90.55 87.33 
FA-Pc 
2θ (°) 40.3 47.0 68.6 
96.14 β (cm) 0.08 0.1 0.115 
D (nm) 110.53 90.52 87.39 
FA-EDA 
2θ (°) 40.5 47.2 68.5 
96.17 β (cm) 0.08 0.1 0.115 
D (nm) 110.60 90.59 87.33 
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The obtained average particle diameters (Table 3.2) are within the large-sized nanoparticle 
size range or category (Table 2.4). With the small and medium-sized nanoparticles difficult to 
precipitate out, collect and analyse using powder XRD; selective area electron diffraction 
(SAED) was used (Figure 3.20) to primarily confirm crystallinity for the small- and medium-
sized palladium nanoparticles.  
 
Figure 3.20: The selected area electron diffraction (SAED) patterns of the synthesised and 
characterised nanoparticles; (a) small-sized ethylenediamine capped (sz-EDÂ), (b) medium-
sized phthalocyanine capped (mz-Pĉ), (c) medium-sized folate-ethylenediamine capped (mz-
FA-EDÂ), and (d) small-sized folate-phthalocyanine capped (sz-FA-Pĉ) nanoparticles 
synthesised from the reduction of 10 µM palladium(II) salt with sodium borohydride.  
The SAED patterns were as expected [345]. With this success, special focus was shifted to the 
shape and morphology of the nanoparticles. However, it was difficult to obtain uniform sizes 
when using strong reducing agents, because they increase rate of nucleation and result in 
agglomeration. Changing the temperature, time, and pH also play a vital role in the synthesis 
[347]. The shape and morphology of the nanoparticles were investigated using TEM (Figure 
3.21). Palladium nanoparticles exist in different shapes ranging from triangular, rhomboidal 
or square, pentagonal, symmetrical, round NPs, irregular shaped, or elongated, cuboidal, 
(a) (b)
(c) (d)
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cuboctahedron, octahedron, tetrahedron, decahedron, icosahedron, spherical, polyhedral 
shaped nanoparticles, 4-sided rhombohedral, hexagonal, pentagonal, sponge-like structures, 
and nanoflowers [264, 266, 305, 342, 348]. A few of the shapes were observed (Figure 3.21). 
 
Figure 3.21: Bright-field TEM images showing the different shapes obtained from the 
synthesis of the nanoparticles; (a) circular shaped, (b) tetrahedral and semi-regular shaped, 
(c) circular flower-like shaped, (d) square shaped nanoparticles, (e) elongate shaped 
nanoparticles, (f) regular square shaped nanoparticles, and (g) flower-like undefined 
nanoparticles. 
The proportion of the different morphologies can be varied by changing synthesis conditions 
including the molar ratios of precursor salt: reducing agent and stabilising agent [347]. 
Monodispersity, shape, size, and the surface charge of the particles are dependent on the 
precursor, nature of ligands, and nature of solvent [305, 349]. The success of the reduction of 
the palladium(II) salt were primarily confirmed using UV-Vis (Figure 3.11). The success of the 
reduction was confirmed visually. The colour change of palladium solution (Figure 3.22), from 
brown to the black-greyish colourless solution further confirmed the successful reduction of 
palladium(II) to palladium(0). When in solution, palladium nanoparticles are black-greyish. 
However, when agglomerated and out of solution, the shiny silver-greyish colour was 
observed. Visually, the success of the synthesis could be observed (Figure 3.22). The 
temperature and time effects on palladium nanoparticles were investigated. 
 
(a)
(f)
(g)
(d)
(e)(c)
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C h a p t e r  3   P a g e  | 79 
 
Sendibitiyosi Gandidzanwa                           211175897                            Nelson Mandela University 
  
 
Figure 3.22: The visual presentation of the palladium solutions; a) 100 μM palladium(II) 
solution, (b) ethylenediamine-capped palladium(0), (c) borohydride-capped palladium(0), (d) 
phthalocyanine-capped palladium(0), (e) folate-ethylenediamine capped palladium(0), and (f) 
folate-phthalocyanine capped palladium (0) nanoparticles. (b) to (e) were synthesised from 
the reduction of 100 µM Pd(II) solution by 20 mM sodium borohydride. 
3.3.2 Temperature and time 
The synthesis temperature is known to affect the shape of nanoparticles. In this study, higher 
temperatures triggered coagulation and formation of crumps or agglomerates were noted, 
and preference was given to room temperature. The effects of synthesis time were 
investigated (Figure 3.23). 
 
Figure 3.23: The UV-Vis spectra of palladium nanoparticles after different synthetic times; (a) 
3, 10, and 30 min), and (b) 1 hour, 1 day, and 1 week. 
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There is no significant UV-Vis absorption difference between after 3 and 10 minutes reduction 
time (Figure 3.23a). Three minutes was reported in literature as the time taken to completely 
reduce palladium(II)  to palladium(0) under optimal conditions  and concentration [314]. At 
100 µM the palladium(II) salt exhibited higher absorbance values compared to the 
palladium(0) systems and this will be investigated further in future studies. With no reported 
significant UV-Vis absorption increase after three minutes to 8 hours from synthesis [314], 
and the obtained UV-Vis spectra being repeatedly obtained, the effects of temperature were 
investigated (Figure 3.24).  
 
Figure 3.24: The UV-Vis spectra of palladium(0) nanoparticles depicting the effects of 
temperature on the synthesis at different temperatures a) UV-Vis spectra for nanoparticles 
synthesised at room temperature, 40 °C, 50 °C, and 60 °C (b) 70 °C, 80 °C, and 90 °C. 
As expected, higher temperatures accelerated reduction by introducing more reaction energy 
into the reaction system (Figure 3.24), hence promoting nucleation [308]. The atoms nucleate 
under thermodynamically controlled processes to achieve the formation of nucleating 
centres and capping agents stabilising the nucleating centres to achieve controlled growth 
[314]. The presence of a broad continuous absorption throughout the visible region is a 
characteristic feature of palladium nanoparticles (Figure 3.24). Kinetic nucleation is 
accelerated at 70 ֯C [350], and hence the unusual high absorbance.  
Since the concentration of palladium atoms in the reaction system would quickly drop below 
the minimum supersaturation level after the formation of copious primary nuclei, generation 
of new nuclei would be inhibited, eventually leading to the smaller nanoparticles with narrow 
distribution aggregating [350]. At higher temperatures, agglomerates were observed upon 
the addition of a few drops of the reducing agent. As observed (Figure 3.24), the UV-Vis 
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spectra at room temperature is as published in literature [65, 351]. It was concluded that the 
synthesis of palladium nanoparticles at room temperature could be safely employed in this 
study, and the stability of the nanoparticles investigated. NPs dispersed in solution can 
agglomerate because of thermodynamic effects and can also leach molecular species 
promoted by solvent, ligands or other reaction parameters [349]. 
3.3.3 Stability  
With the concentration of precursor reported to significantly affect or directly influence the 
size of obtained nanoparticles [352], the experiments were conducted at low concentrations. 
pH is known to affect protonation and thereby changing the reduction rate, resulting in 
nanoparticles of different sizes and morphologies [307]. Palladium nanoparticles capped with 
N-containing stabiliser are reported to aggregate more at lower pH. This is due to the 
protonation of the N-groups and unavailability for bonding to the nanoparticle surface, 
subsequently becoming deprotected causing aggregation [275]. To prevent any pH-related 
variation, pH was kept constant. The zeta potential (surface charge) of the nanoparticles in 
different media at a pH of 7.4 (Figure 3.25) was presented.  
 
Figure 3.25: An illustration of the zeta potential distribution of the palladium nanoparticles 
capped with: phthalocyanine (green), borohydride (red), and ethylenediamine (blue) 
synthesised from 100 µM palladium(II), 2 mM reducing and capping agents’ concentrations.  
The borohydride-, phthalocyanine-, and ethylenediamine-capped nanoparticles possessed 
surface charge that is within the preferred -30 mV to +30 mV zeta potential range as published 
in literature [96, 353]. Characterisation of the nanoparticles used in cellular uptake was 
inevitable. The summary of the surface charge of the nanoparticles used for the cell studies 
was presented (Table 3.3). 
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Table 3.3: The zeta potential (surface charge) of the differently capped optimised palladium 
nanoparticles in DMEM cell media at 25 °C and pH 7.4.  
Sample Name ZP (mV) Mob (µmcm/Vs) Cond (mS/cm) 
sz-Bĥ-NPs -2.86 ± 0.64 ‐0.2241 216 
lz-Bĥ-NPs -10.9 ± 2.10 ‐0.8572 214 
sz-EDÂ-NPs -0.66 ± 0.07 ‐0.0520 30.1 
lz-EDÂ-NPs +1.34 ± 0.18 ‐0.087 90.2 
sz-Pĉ-NPs +0,063 ± 0.02 ‐0,0049 189 
lz-Pĉ-NPs +2.81.± 0.78 ‐0.1109 249 
sz‐FA‐EDÂ‐NPs -0,051 ± 0.09 ‐0,0040 193 
lz‐FA‐EDÂ‐NPs -0,101 ± 0.14 ‐0,0079 258 
sz‐FA‐Pĉ‐NPs -3,96 ± 0.24 ‐0,3106 521 
lz‐FA‐Pĉ‐NPs -4,70 ± 0.57 ‐0,3684 519 
sz=small sized, mz=medium-sized, lz=large-sized, EDÂ=ethylenediamine capped, Bĥ=borohydride, NPs=nanoparticles, 
Pĉ=phthalocyanine capped, FA-EDÂ=folate-ethylenediamine capped, FA-Pĉ=folate-phthalocyanine capped, 
Mob=electrophoretic mobility, Cond=conductivity. 
Most of the nanoparticles had a preferred negative charge (Table 3.3). Negatively charged 
nanoparticles are not easily taken up via endocytosis [354, 355], however, they are taken up 
via receptor mediated endocytosis. In this case, negatively charged nanoparticles could be 
taken up via folate receptor mediated endocytosis despite their sizes. With the positive 
charged nanoparticles being ethylenediamine-capped and phthalocyanine capped, these 
were not employed for cell studies (Section 4.4). The trend of the small negative charges 
within the -30 to +30 mV was noted for all the characterised nanoparticles (Table 3.4). Folate-
conjugates capped nanoparticles exhibited negative charges that synergises their uptake via 
folate receptor-mediated uptake and not passive diffusion, or any other endocytosis 
mechanisms. It can be noted that borohydride-capped nanoparticles also exhibited negative 
charges in both the preliminary and optimised characterisation (Table 3.3 and Table 3.4). The 
low electrophoretic mobility values (Table 3.3) also confirm the stability of the nanoparticles 
in cell media. The cell lines were exposed to the palladium nanoparticles for 24 hours, and 
the stability of palladium nanoparticles in cell culture media was performed and the findings 
reported (Figure 3.26). 
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Figure 3.26: The UV-Vis stability analysis of ethylenediamine capped nanoparticles formed 
from the reduction of palladium(II) salt by sodium borohydride after 3 minutes, 1 hour, 12 
hours, and 24 hours in Leibovitz-L15 cell media. 
The stability of the nanoparticles in cell media was key to the success of this study. Over 24 
hours, the nanoparticles were stable in Leibovitz-L15 media (and exhibited similar UV-Vis 
spectra for DMEM and Hams F-12 media) (Figure 3.26). The spectra’s trend was the same for 
DMEM and Hams F12. The UV-Vis stability studies confirmed that the palladium nanoparticles 
were stable in both aqueous (Figure 3.13), and in vitro (Figure 3.26) and it can be suggested 
that the nanoparticles could be stable in vivo.  
Hydrodynamic size investigation (Figure 3.27) showed that the nanoparticles can have broad 
size distributions with a possibility of bi or multimodality (Figure 3.27 (b), (d), and (f)). 
However, for this study the synthesis was optimised to obtain nanoparticles of narrow 
distributions and non-overlapping sizes (Table 2.4). Broader size distributions were noted in 
some of the optimised nanoparticles, more prominent in the large-sized nanoparticles (Table 
3.4). However, the size range non-overlap allowed the nanoparticles to be employed for 
applications in in vitro studies. The nanoparticle solutions were stable after 5 min, 10 min, 
and 15 min with no significant size change (Figure 3.27).  
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Figure 3.27: The hydrodynamic size distributions of differently capped palladium 
nanoparticles were measured using dynamic light scattering (DLS) in DMEM cell media for; 
(a) small-sized ethylenediamine-capped palladium nanoparticles (sz-EDÂ-NPs) synthesised 
from the reduction of 10.15 μM palladium(II) salt with 2 mM sodium borohydride solution in 
the presence of 1 mM ethylenediamine, (b) medium-sized phthalocyanine capped palladium 
nanoparticles (mz-Pĉ-NPs) synthesised from the reduction of 10.11 μM palladium(II) salt with 
800 μM sodium borohydride solution in the presence of 100 μM phthalocyanine, (c) medium-
sized folate-ethylenediamine capped palladium nanoparticles synthesised from the reduction 
of 10.15 μM palladium(II) salt with 800 μM sodium borohydride solution in the presence of 
200 μM folate-ethylenediamine, (d) medium-sized folate-phthalocyanine capped palladium 
nanoparticles (mz-FA-Pĉ-NPs) synthesised from the reduction of 10.49 μM palladium(II) salt 
with 800 μM sodium borohydride solution in the presence of 200 μM folate-phthalocyanine, 
(e) large-sized folate-phthalocyanine capped palladium nanoparticles (lz-EDÂ-NPs) 
synthesised from the reduction of 10.38 μM palladium(II) salt with 800 μM sodium 
borohydride in the presence of 1.7 mM folate-phthalocyanine. The DLS runs were done after 
5 min (red), 10 min (green), and 15 min (blue) for (b), (d), and (f), and after 5 min only for (a), 
(c), and (e). 
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3.4 GENERAL DISCUSSION: PRELIMINARY OPTIMISATION OF NANOPARTICLES SYNTHESES 
Palladium nanoparticles were successfully synthesised at room temperature. The dropwise 
addition of reducing agent allowed nucleation under thermodynamically controlled processes 
achieving the formation of nucleating centres. In aqueous solution, the capping agents 
stabilised the nucleating centres resulting in achieved controlled growth with monodispersed 
nanoparticles being obtained. It was difficult to obtain uniform sizes when using strong 
reducing agents at higher temperatures. Strong reducing agents made the nucleation process 
faster and triggered agglomeration as published in literature [314]. Sodium borohydride 
produced well defined and various shaped palladium nanoparticles. Controlled reactant 
concentration variations produced nanoparticles of different sizes as expected [356]. 
The investigated capping agents showed strong ability to attach to the surface of 
nanoparticles and consistent results were obtained. Being essential for biological applications 
[310], the stability of the nanoparticles and favourable surface charges provided remarkable 
results. Phthalocyanines and phthalocyanine conjugates were able to stabilise the palladium 
nucleating centres as expected [304]. Ethylenediamine also proved to successfully conjugate 
to folate on one end, with the free end being available to attach to the solid surface of the 
nanoparticles. 
The generalisability of much-published research on this topic is problematic. The nanoparticle 
synthesis findings at room temperature do not correlate to those obtained at higher 
temperatures. The stability of the bioconjugates, their precursors, and the nanoparticles in 
aqueous and cell media conditions was a great advantage for the intended in vivo use of the 
palladium nanoparticles as reported in literature [122, 357, 358]. 
3.5 CHARACTERISATION OF THE NANOPARTICLES FROM THE OPTIMISED METHOD 
Recently, particle size, shape, and morphology have been emphasised as key physical 
parameters which have exerted a tremendous impact on cellular uptake and biodistribution 
[99, 102, 117, 359]. Prior to in vitro studies of the nanoparticles, three varied sizes (Table 2.5) 
of nanoparticles were synthesised from the reduction of palladium(II) to palladium(0) 
nanoparticles by sodium borohydride. Considering the important properties of nanoparticles 
in drug development (Section 1.3.2), the optimised nanoparticles were synthesised (Table 
3.4).  
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Table 3.4: Summary of the TEM sizes and surface charges (in DMEM media) of the optimised 
palladium nanoparticles. 
Capping 
agent 
Figure Nanoparticle 
size ± standard 
deviation (nm) 
Surface charge 
± standard 
deviation (mV) 
[Pd(II)] 
μM 
[NaBH4] [Capping 
agent] 
Bh 
3.28 2.1 ± 0.5 -12.2 ± 0.8 10.65 2 mM 2 mM 
3.29 1.6 ± 0.4 -10.8 ± 0.6 10.04 800 μM 800 μM 
3.30 30 ± 10 -12.8 ± 1.7 10.65 500 μM 500 μM 
3.31 
371 ± 72 -12.6 ± 1.8 10.65 100 μM 100 μM 
308 ± 61 -13.35 ± 1.1 10.04 100 μM 100 μM 
EDA 
3.32 2.5 ± 0.4 +3.2 ± 0.3 10.38 2 mM 800 μM 
3.33 1.4 ± 0.2 +4.4 ± 0.8 10.15 2 mM 1 mM 
3.34 22 ± 6 +3.9 ± 0.5 10.38 800 μM 200 μM 
3.35 37 ± 6 +2.3 ± 0.3 10.15 800 μM 200 μM 
3.36 
95 ± 16 +4.8 ± 0.9 10.38 800 μM 1.7 mM 
122 ± 48 +5.9 ± 0.7 10.15 800 μM 1 mM 
Pc 
3.37 2.8 ± 0.4 +12.1 ± 0.4 10.32 2 mM 1 mM 
3.38 3 ± 0.5  +13.6 ± 1.3 10.11 2 mM 1 mM 
3.39 16 ± 2 +8.9 ± 0.8 10.11 800 μM 100 μM 
3.40 27 ± 5 +10.9 ± 0.3 10.32 800 μM 200 μM 
3.41 
134 ± 30 +11.2 ± 0.9 10.32 800 μM 1 mM 
252 ± 36 +10.7 ± 1.1 10.11 800 μM 500 μM 
FA-EDA 
3.42 2.1 ± 0.3 -3.4 ± 0.1 10.83 2 mM 1 mM 
3.43 4.9 ± 0.8 -2.6 ± 0.4 10.41 2 mM 500 μM 
3.44 28 ± 6 -1.8 ± 0.6 10.83 800 μM 200 μM 
3.45 21 ± 3 -1.1 ± 0.7 10.41 800 μM 200 μM 
3.46 650 ± 164 -3.9 ± 0.5 10.41 800 μM 20 μM 
3.47 150 ± 30 -2.7 ± 0.4 10.83 800 μM 50 μM 
FA-Pc 
3.48 3.5 ± 0.9 -3.7 ± 0.9 10.99 2 mM 1 mM 
3.49 1.2 ± 0.2 -1.6 ± 0.3 10.49 2 mM 800 mM 
3.50 16 ± 0.63 -3.2 ± 0.7 10.49 800 μM 200 μM 
3.51 23 ± 5 -2.5 ± 0.7 10.99 800 μM 200 μM 
3.52 168 ± 28 -2.8 ± 0.3 10.99 800 μM 1 mM 
3.53 190 ± 29 -2.4 ± 0.1 10.99 800 μM 1 mM 
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The reproducibility of the synthesis with acceptable variation was conducted, and the size 
and surface charge presented (Figure 3.28 - Figure 3.53; Table 3.4). The nanoparticle 
distribution range was considered narrow (if less than 10 nm) and broad (if more than 10 nm). 
3.5.1 Borohydride capped nanoparticles 
With the capping of nanoparticles by borohydride ions having been previously reported [360, 
361], the reduction of palladium(II) ions with sodium borohydride was reported (Figure 3.28-
Figure 3.31). 
 
Figure 3.28: (a) Bright-field TEM image of monodispersed small-sized borohydride-capped 
palladium nanoparticles with an average diameter of 2.1 ± 0.5 nm, synthesised from the 
reduction of 10.65 µM palladium(II) salt with 2 mM sodium borohydride solution, (b) A plot 
of nanoparticle size (nm) against frequency (y-axis), highlighting a narrow size distribution. 
The inset presents a magnified (5X) view of small-sized borohydride-capped palladium 
nanoparticles.  
 
Figure 3.29: (a) Bright-field TEM image of monodispersed small-sized borohydride-capped 
palladium nanoparticles with an average diameter of 1.6 ± 0.4 nm, synthesised from the 
reduction of 10.04 µM palladium(II) salt with 800 µM sodium borohydride solution , and (b) 
A plot of nanoparticle size (nm) against frequency (y-axis), highlighting a narrow size 
distribution. 
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Figure 3.30: (a) Bright-field TEM image of medium-sized borohydride-capped palladium 
nanoparticles with an average diameter of 30 ± 10 nm, synthesised from the reduction of 
10.65 µM palladium(II) salt with 500 µM sodium borohydride solution, and (b) A plot of 
nanoparticle size (nm) against frequency (y-axis), highlighting a broad size distribution. The 
inset presents borohydride-capped palladium nanoparticles at magnified view (10X) of (a). 
 
Figure 3.31: Bright-field TEM images of agglomerated large-sized borohydride-capped 
palladium nanoparticles synthesised from; (a) the reduction of 10.65 µM palladium(II) salt 
with 100 µM sodium borohydride solution, (b) the reduction of 10.04 µM palladium(II) with 
100 µM sodium borohydride solution. The inset presents a magnified (2X) agglomerate of (a). 
From the measurable nanoparticles, the size ranges were found to be 371 ± 72 nm and 308 ± 
61 nm for (a) and (b), respectively. 
The synthesis of borohydride-capped palladium nanoparticles provided remarkable results. 
The nanoparticles (Figure 3.28 – Figure 3.31) has a relatively similar negative surface charge 
(Table 3.4) attributed to the negatively charged borohydride ions. Borohydride ions are small 
and were unable to fully stabilise the nucleating centres resulting in formation of 
agglomerates (Figure 3.30).  
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3.5.2 Ethylenediamine capped nanoparticles 
Diamines can stabilise metal nanoparticles and ethylenediamine was employed in the 
optimised synthesis and the obtained results reported (Figure 3.32 – Figure 3.36). 
 
Figure 3.32: (a) Bright-field TEM image of monodispersed small-sized ethylenediamine-
capped palladium nanoparticles with an average diameter of 2.5 ± 0.4 nm, synthesised from 
the reduction of 10.38 µM palladium(II) salt with 2 mM sodium borohydride solution in the 
presence of 800 µM ethylenediamine capping agent, and (b) A plot of nanoparticle size (nm) 
against frequency (y-axis), highlighting a narrow size distribution. The inset presents 
ethylenediamine-capped palladium nanoparticles of size 2.6 ± 0.2 nm and its size distribution 
(bottom right), synthesised from similar concentrations as in (a). 
 
Figure 3.33: (a) Bright-field TEM image of polydispersed small-sized ethylenediamine-capped 
palladium nanoparticles with an average diameter of 1.4 ± 0.4 nm, synthesised from the 
reduction of 10.15 µM palladium(II) salt with 2 mM sodium borohydride solution in the 
presence of 1 mM ethylenediamine capping agent, and (b) A plot of nanoparticle size (nm) 
against frequency (y-axis), highlighting a narrow size distribution.  
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Figure 3.34: (a) Bright-field TEM image of polydispersed medium-sized ethylenediamine-
capped palladium nanoparticles with an average diameter of 22 ± 6 nm, synthesised from the 
reduction of 10.38 µM palladium(II) salt with 800 µM sodium borohydride solution in the 
presence of 200 µM ethylenediamine capping agent, and (b) A plot of nanoparticle size (nm) 
against frequency (y-axis), highlighting a broad size distribution. (This image was acquired 
using a 120 kV TEM hence the low contrast between the background and the nanoparticles). 
 
Figure 3.35: (a) Bright-field TEM image of polydispersed medium-sized ethylenediamine-
capped palladium nanoparticles with an average diameter of 37 ± 6 nm, synthesised from the 
reduction of 10.15 µM palladium(II) salt with 800 µM sodium borohydride solution in the 
presence of 200 µM ethylenediamine capping agent, and (b) A plot of nanoparticle size (nm) 
against frequency (y-axis), highlighting a broad size distribution. (This image was acquired 
using a 120 kV TEM hence the low contrast between the background and the nanoparticles). 
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Figure 3.36: Bright-field TEM images of agglomerated large-sized ethylenediamine-capped 
palladium nanoparticles synthesised from; (a) the reduction of 10.38 µM palladium(II) salt 
with 800 µM sodium borohydride solution in the presence of 1.7 mM ethylenediamine 
capping agent, and (b) the reduction of 10.15 µM palladium(II) salt with 800 µM sodium 
borohydride solution in the presence of 1 mM ethylenediamine capping agent. From the 
measurable nanoparticles found on the grids, the size ranges were 95.19 ± 20.85 nm and 
204.37 ± 50.60 nm, respectively. 
3.5.3 Phthalocyanine capped nanoparticles 
Tetraaminophthalocyanine (referred as phthalocyanine) has free amine groups available to 
interact with metal orbitals. Phthalocyanine was used to stabilise palladium nanoparticles and 
the obtained results presented (Figure 3.37 – Figure 3.41).  
 
Figure 3.37: (a) Bright-field TEM image of dispersed small-sized phthalocyanine-capped 
palladium nanoparticles with an average diameter of 2.8 ± 0.4 nm synthesised from the 
reduction of 10.32 µM palladium(II) salt with 2 mM sodium borohydride solution in the 
presence of 1 mM phthalocyanine capping agent, and (b) A plot of nanoparticle size (nm) 
against frequency (y-axis), highlighting a narrow size distribution. The inset presents a 
magnified view (5X) of the encircled area showing phthalocyanine-capped palladium 
nanoparticles. 
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Figure 3.38: (a) Bright-field TEM image of monodispersed small-sized phthalocyanine-capped 
palladium nanoparticles with an average diameter of 3 ± 0.5 nm, synthesised from the 
reduction of 10.11 µM palladium(II) salt with 2 mM sodium borohydride solution in the 
presence of 1 mM phthalocyanine capping agent, and (b) A plot of nanoparticle size (nm) 
against frequency (y-axis), highlighting a narrow size distribution. 
 
Figure 3.39: (a) Bright-field TEM image of medium-sized phthalocyanine-capped palladium 
nanoparticles with an average diameter of 16 ± 2 nm, synthesised from the reduction of 10.11 
µM palladium(II) salt with 800 μM sodium borohydride solution in the presence of 100 µM 
phthalocyanine capping agent, and (b) A plot of nanoparticle size (nm) against frequency (y-
axis), highlighting a slightly broad size distribution.  
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Figure 3.40: (a) Bright-field TEM image of dispersed medium-sized phthalocyanine-capped 
palladium nanoparticles with an average diameter of 27 ± 6 nm, synthesised from the 
reduction of 10.32 µM palladium(II) salt with 800 μM sodium borohydride solution in the 
presence of 200 µM phthalocyanine capping agent, and (b) A plot of nanoparticle size (nm) 
against frequency (y-axis), highlighting a broad size distribution.  
 
Figure 3.41: Bright-field TEM images of agglomerated large-sized phthalocyanine-capped 
palladium nanoparticles synthesised from; (a) the reduction of 10.38 µM palladium(II) salt 
with 800 μM sodium borohydride solution in the presence of 1 mM phthalocyanine capping 
agent, and (b) the reduction of 10.11 μM palladium(II) salt with 800 μM sodium borohydride 
solution in the presence of 500 μM phthalocyanine capping agent. The estimated sizes from 
the measurable nanoparticles were 134 ± 6 nm and 252.06 ± 36 nm for (a) and (b), 
respectively. 
The nanoparticles were dispersed and could easily be measured exhibiting acceptable size 
distributions (Figure 3.37 – Figure 3.40). However, agglomerated nanoparticles are seen for 
large-sized nanoparticles (Figure 3.41) due to the tendency of the nanoparticles of large sizes 
to coagulate. The borohydride solution (800 μM) produced highly reactive nucleation centres 
which were possibly not fully stabilised by the phthalocyanines. 
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3.5.4 Folate-ethylenediamine capped nanoparticles 
The synthesised folate-phthalocyanine was used to stabilise the palladium(0) nanoparticles 
(Figure 3.42 – Figure 3.47). 
 
Figure 3.42: (a) Bright-field TEM image of polydispersed small-sized folate-ethylenediamine 
capped palladium nanoparticles with an average diameter of 2.1 nm ± 0.1 nm, synthesised 
from the reduction of 10.83 µM palladium(II) salt with 2 mM sodium borohydride solution in 
the presence of 1 mM folate-ethylenediamine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting a narrow size distribution.  
 
Figure 3.43: (a) Bright-field TEM image of polydispersed small-sized folate-ethylenediamine 
capped palladium nanoparticles with an average diameter of 4.9 ± 0.8 nm, synthesised from 
the reduction of 10.41 µM palladium(II) salt with 2 mM sodium borohydride solution in the 
presence of 500 µM folate-ethylenediamine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting a narrow size distribution. The inset shows folate-
ethylenediamine capped palladium nanoparticles with an average size of 1 ± 0.1 nm 
synthesised from 10.41 μM palladium salt with 1 mM sodium borohydride solution in the 
presence of 500 μM folate-ethylenediamine. 
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Figure 3.44: (a) Bright-field TEM image of dispersed medium-sized folate-ethylenediamine 
capped palladium nanoparticles with an average diameter of 28 ± 6 nm, synthesised from the 
reduction of 10.83 µM palladium(II) salt with 800 μM sodium borohydride solution in the 
presence of 200 µM folate-ethylenediamine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting a broad size distribution. The insets show magnified views (5X 
top, 2X bottom) of folate-ethylenediamine capped palladium nanoparticles clearly showing 
well defined shapes. 
 
Figure 3.45: (a) Bright-field TEM image of medium-sized folate-ethylenediamine capped 
palladium nanoparticles with an average diameter of 21 ± 3 nm, synthesised from the 
reduction of 10.41 µM palladium(II) salt with 800 μM sodium borohydride solution in the 
presence of 200 µM folate-ethylenediamine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting a broad size distribution. The inset presents a magnified view 
(2X) of (a) from the encircled region. 
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Figure 3.46: (a) Bright-field TEM image of large-sized folate-ethylenediamine capped 
palladium nanoparticles with an average diameter of 650 ± 164 nm, synthesised from the 
reduction of 10.41 µM palladium(II) salt with 800 μM sodium borohydride solution in the 
presence of 20 µM folate-ethylenediamine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting a broad size distribution. The inset shows partially 
agglomerated folate-ethylenediamine capped palladium nanoparticles. 
 
Figure 3.47: (a) Bright-field TEM image of large-sized folate-ethylenediamine capped 
palladium nanoparticles with an average diameter of 150 ± 30 nm, synthesised from the 
reduction of 10.83 µM palladium(II) salt with 800 μM sodium borohydride solution in the 
presence of 50 μM folate-ethylenediamine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting the palladium nanoparticles size distribution range. 
The folate-ethylenediamine stabilised palladium nanoparticles better than borohydride, 
ethylenediamine, and phthalocyanine. This can be attributed to its relatively larger size 
compared to borohydride, ethylenediamine, and phthalocyanine. However, folate-
phthalocyanine (larger conjugate) stabilised nanoparticles better than the other capping 
agents (Figure 3.48 – Figure 3.53). 
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3.5.5 Folate-phthalocyanine capped nanoparticles 
The synthesised folate-phthalocyanine was used to stabilise palladium(0) nanoparticles 
(Figure 3.48 – Figure 3.53). 
 
Figure 3.48: (a) Bright-field TEM image of monodispersed small-sized folate-phthalocyanine 
capped palladium nanoparticles with an average diameter of 3.5 ± 0.9 nm, synthesised from 
the reduction of 10.99 µM palladium(II) salt with 2 mM sodium borohydride solution in the 
presence of 1 mM folate-phthalocyanine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting a narrow size distribution.  
 
Figure 3.49: (a) Bright-field TEM image of polydisperse small-sized folate-phthalocyanine 
capped palladium nanoparticles with an average diameter of 1.2 ± 0.2 nm, synthesised from 
the reduction of 10.49 µM palladium(II) salt with 2 mM sodium borohydride solution in the 
presence of 800 µM folate-phthalocyanine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting a narrow size distribution. 
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Figure 3.50: (a) Bright-field TEM image of dispersed medium-sized folate-phthalocyanine 
capped palladium nanoparticles with an average diameter of 16 ± 3 nm, synthesised from the 
reduction of 10.49 µM palladium(II) salt with 800 μM sodium borohydride solution in the 
presence of 200 µM folate-phthalocyanine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting a broad size distribution. 
 
Figure 3.51: (a) Bright-field TEM image of medium-sized folate-phthalocyanine capped 
palladium nanoparticles with an average diameter of 23 ± 5 nm, synthesised from the 
reduction of 10.99 µM palladium(II) salt with 800 μM sodium borohydride solution in the 
presence of 200 µM folate-phthalocyanine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting a broad size distribution. The inset shows a magnified view 
(5X) of the folate-phthalocyanine capped palladium nanoparticles.  
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Figure 3.52: (a) Bright-field TEM image of large-sized folate-phthalocyanine capped palladium 
nanoparticles with an average diameter of 168 ± 28 nm, synthesised from the reduction of 
10.49 µM palladium(II) salt with 800 μM sodium borohydride solution in the presence of 1 
mM folate-phthalocyanine, and (b) A plot of nanoparticle size (nm) against frequency (y-axis), 
highlighting a broad size distribution. The inset shows well-defined monodispersed large-
sized folate-phthalocyanine capped palladium nanoparticles.  
 
Figure 3.53: (a) Bright-field TEM image of dispersed large-sized folate-phthalocyanine capped 
palladium nanoparticles with an average diameter of 190 ± 29 nm, synthesised from the 
reduction of 10.99 µM palladium(II) salt with 800 μM sodium borohydride solution in the 
presence of 1 mM folate-phthalocyanine, and (b) A plot of nanoparticle size (nm) against 
frequency (y-axis), highlighting a broad size distribution. The inset shows dispersed large-sized 
folate-phthalocyanine capped palladium nanoparticles.  
The folate conjugates provided the most well defined negatively charged nanoparticles. This 
finding is of great significance to the application of palladium nanoparticles in vitro and 
subsequent in vivo studies in the development of palladium nanoradiopharmaceuticals. 
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3.6 GENERAL DISCUSSION: OPTIMISED NANOPARTICLES SYNTHESES 
The synthesis of the optimised nanoparticles is reproducible. The small-sized borohydride 
capped nanoparticles were spherical and evenly dispersed. The dispersity was consistent for 
all the small-sized nanoparticles. The medium-sized borohydride-capped nanoparticles were 
agglomerated together forming a flower-like crump. The large-sized borohydride-capped 
nanoparticles agglomerated together. The average sizes of the agglomerates (obtained from 
the measurable nanoparticles) were slightly outside the discussed range (Table 2.3). 
However, it was challenging to obtain smaller and more dispersed desired nanoparticles.  
Ethylenediamine had spherical and elongated-like small-sized nanoparticles and slightly 
crumbed together large-sized nanoparticles forming elongates. The same trend was obtained 
for phthalocyanine capped nanoparticles. The small and medium-sized nanoparticles had 
dispersed nanoparticles and the large-sized palladium nanoparticles were agglomerated 
forming some branches. The size distributions were acceptable; there are no size overlaps, 
nullifying any results misinterpretation. 
The folate-ethylenediamine produced evenly distributed nanoparticles of defined shapes. 
They had non-overlapping narrow size distributions and small negative charges (Table 3.4). 
Folate-phthalocyanine nanoparticles gave dispersed nanoparticles for all the sizes. This 
agrees to the known trend that smaller capping agents prevent agglomeration less compared 
to their bigger or large-sized counterparts. Folate-phthalocyanine has a bulkier structure, and 
hence it could easily stabilise the nucleating centres preventing agglomeration, relative to the 
smaller capping agents.  
It can be concluded that different sized nanoparticles can be synthesised under controlled 
conditions and be reproduced (Figure 3.28 - Figure 3.53). As expected, it was confirmed that 
different shapes of palladium(0) nanoparticles exist and can be obtained from the reduction 
of palladium(II) by sodium borohydride and capped with amine-containing compounds.  
The optimised nanoparticles meet the required characteristics of nanoparticles for biological 
applications (Section 1.3.2). Despite the large-sized nanoparticles being in the micro- range 
(Table 3.4), they can be used in drug delivery applications [362]. 
This success led to the investigation of the cytotoxicity, cellular uptake, and internalisation 
using the optimised palladium nanoparticles (Chapter 4).  
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CHAPTER FOUR: BIOCHEMICAL EVALUATION OF PALLADIUM 
NANOPARTICLES 
4.1 GENERAL INTRODUCTION  
Nanoparticle applications have increasingly contributed towards the advancement of 
research development in several biomedical fields, e.g. the use of nanoradiopharmaceuticals 
[363]. Specific in vitro receptor delivery systems have been reported for protein toxins, such 
as anti-T-cell receptor antibodies, chemotherapy agents, and magnetic resonance imaging 
contrast agents [212], highlighting interest in the use of low molecular weight 
radiopharmaceuticals (RPs). 
Literature focuses on the ease of functionalisation and conjugation of nanoparticles with 
various biomolecules to enhance drug targeting and biodiagnostics. Metals and metal-derived 
compounds have been used in medicine for several thousands of years [364–366]. Metal 
nanoparticles are utilised in various diagnostic and therapeutic purposes [367], due to metal 
nanoparticles having the ability to translocate to tissues without having a detrimental effect 
on cell viability [364]. At higher concentrations, nanoparticles are usually toxic to biological 
systems because of their inherent ability to cross biomembranes and interference with basal 
metabolic reactions within the cell [128, 368]. 
Folic acid conjugated nanoparticles are reported to have less cytotoxicity, increased 
dispersibility, bio- and cytocompatibility, and increased specificity with other bioactive 
molecules [194, 218]. As foreign substances and with concerns around the safety of the 
application of nanomaterials in humans [126, 368], their cytotoxicity studies were conducted 
on four cell lines with varied alpha folate receptor (FR) expression (Table 1.8), namely; MDA-
MB-468 (α-FR negative), MCF-7 (overexpressed α-FR), MDA-MB-231 (overexpressed α-FR), 
and MCF-10A (normal α-FR expression).  
One of the primary aims of this study was to preferentially target cancer cells by exploiting 
the overexpressed levels alpha folate receptor (α-FR) levels in cancer cell lines using non-toxic 
concentrations of palladium nanoparticles. The FR is generally not overexpressed in most 
normal tissues [369], thus the α-FR overexpression in cancer cells was targeted as a potential 
target for folate conjugated palladium nanoparticles. 
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4.2 CYTOTOXIC STUDIES 
Recent studies showed successful folate receptor targeting [370], however, the potential 
toxicity of nanoparticles remains a major concern [126, 371]. The cytotoxicity of the different 
nanoparticles and their precursors (Table 4.1) for in vitro studies was conducted using the 
four cell lines (Table 1.8). Treatment screening concentrations were 10 and 100 µM 
palladium(0) content (Table 2.5 and Table 4.2). The main focus of this section was to 
determine the relevant concentrations that did not result in low cell viability (i.e. non-
cytotoxic concentrations) since the hot isotopes would have an effect on the theranostic 
aspects for the in vivo studies.  
Table 4.1: The important abbreviations and colours for interpreting the cytotoxic results. 
 Colour used to denote small-sized (sz) nanoparticles (NPs) of less than 10 nm 
 Colour used to denote medium-sized (mz) nanoparticles (NPs) with sizes 
between 10 and 80 nm 
 Colour used to denote large-sized (lz) nanoparticles (NPs) with sizes between 
80 and 300 nm 
 Colour used to denote an untreated cell line (UT) 
 Colour used to denote a control treatment  
UT Untreated cells  
FA Folic acid  
MTX Methotrexate  
EDA Ethylenediamine  
Pc Phthalocyanine  
FA-EDA Folate-ethylenediamine 
FA-Pc Folate-phthalocyanine 
Bĥ-NPs Small-sized borohydride capped nanoparticles (sz-Bĥ-NPs) 
Bĥ-NPs Medium- sized borohydride capped nanoparticles (mz-Bĥ-NPs) 
Bĥ-NPs Large-sized borohydride capped nanoparticles (lz-Bĥ-NPs) 
EDÂ-NPs Small sized ethylenediamine capped nanoparticles (sz-EDÂ-NPs) 
EDÂ-NPs Medium-sized ethylenediamine capped nanoparticles (mz-EDÂ-NPs) 
EDÂ-NPs Large-sized ethylenediamine capped nanoparticles (lz-EDÂ-NPs) 
Pĉ-NP Small-sized phthalocyanine capped nanoparticles (sz-Pĉ-NPs) 
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Table 4.1: Continued. 
Pĉ-NP Medium-sized phthalocyanine capped nanoparticles (mz-Pĉ-NPs) 
Pĉ-NP Large-sized phthalocyanine capped nanoparticles (lz-Pĉ-NPs) 
FA-EDÂ-NP Small-sized folate-ethylenediamine capped nanoparticles 
FA-EDÂ-NP Medium-sized folate-ethylenediamine capped nanoparticles 
FA-EDÂ-NP Large-sized folate-ethylenediamine capped nanoparticles  
FA-Pĉ-NP Small-sized folate-phthalocyanine capped nanoparticles 
FA-Pĉ-NP Medium-sized folate-phthalocyanine capped nanoparticles 
FA-Pĉ-NP Large-sized folate-phthalocyanine capped nanoparticles 
 Colour used to denote the MCF-10A cell line  
 Colour used to denote the MDA-MB-231 cell line  
 Colour used to denote the MCF-7 cell line 
 Colour used to denote the MDA-MB-231 cell line 
Palladium has no known negative therapeutic effects [372] and is non-toxic to the skin [373]. 
Its ability to possibly coordinate with amino acids, proteins, DNA, and other macromolecules 
(e.g. vitamin B6), makes it capable of inhibiting some cellular functions [374]. Palladium’s 
toxicity is dependent on its covalent state [375]. At 500 µM, palladium(II) inactivates trypsin 
[376] and is known to competitively inhibit creative kinase and non-competitively inhibit 
aldolase, succinate dehydrogenase, and alkaline phosphatase [372]. Higher concentrations 
(>100 µM) of palladium nanoparticles are reported to induce mitochondrial dysfunction [377, 
378] in some cell lines, however, at the lower concentrations, there are no reported cytotoxic 
effects. As a result, the cytotoxicity effects of the palladium nanoparticles in this study were 
initially screened at 100 µM (palladium content) using the MDA-MB-468 cell line, and 
subsequently at 10 µM (palladium content) using MDA-MB-468, MCF-7, MDA-MB-231, and 
MCF-10A cell lines. 
4.2.1 MDA-MB-468 cell viability screen 
The MDA-MB-468 cell line has no folate receptors (Table 1.8). The cytotoxic effects of the 100 
µM palladium nanoparticles (palladium content), and control treatments at the higher 
concentrations than the amounts used to cap the nanoparticles were investigated (Figure 
4.1). 
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Figure 4.1: The MDA-MB-468 cell line’s cytotoxic profiles for the different treatments; 100 
µM (palladium content) palladium nanoparticles, 13.6 mM folic acid (FA), 13.2 mM 
methotrexate (MTX), 13.5 mM ethylenediamine (EDA), 13.6 mM phthalocyanine (Pc), 12.5 
mM folate-ethylenediamine (FA-EDA), 12.9 mM folate-phthalocyanine (FA-Pc), and untreated 
(UT) MDA-MB-468 cell line. The experiments were completed in triplicate (N=3), and the 
significance was marked with asterisks *; for a p-value <0.05 (significant), ** for a p-value 
<0.01 (significant), and *** for a p-value <0.001 (highly significant) was determined using one-
way analysis of variance (ANOVA) relative to the control (untreated cells). 
Treatments that resulted in cell viability values higher than 80% were considered non-toxic 
[379]. The treatments that resulted in cell viability values below 80% relative to the untreated 
(UT) cells (Figure 4.1) were folic acid (control), small-sized borohydride capped, large-sized 
phthalocyanine capped, small-sized folate-ethylenediamine capped, large-sized folate-
ethylenediamine capped, and the small-sized folate-phthalocyanine capped palladium 
nanoparticles treated cells exhibited cell viability values above 60%. 
The small-sized and large-sized folate-phthalocyanine capped nanoparticles exhibited a highly 
significant (p<0.001) decrease in cell viability relative to the untreated cell line, a significant 
(p<0.01) increase in cell viability for the folate-phthalocyanine treatment (control). The small-
sized folate-phthalocyanine capped nanoparticles treatment displayed a higher cell viability 
relative to the large-sized folate-phthalocyanine capped nanoparticles treatment. The small-
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sized and large-sized folate-ethylenediamine capped nanoparticles treatments had a highly 
significant (p<0.001) decrease in cell viability relative to the untreated cell line, and a 
significant increase in viability relative to the folate-ethylenediamine (control). The small-
sized folate-ethylenediamine capped nanoparticles treatments displayed a significant 
(p<0.01) increase in cell viability relative to the large-sized folate-ethylenediamine capped 
nanoparticles. The small-sized and large-sized phthalocyanine capped nanoparticles 
treatments exhibited highly significant (p<0.01) decrease in cell viability relative to the 
untreated cell line, and a significant (p<0.05) increase in viability relative to the folate-
ethylenediamine (control). The small-sized and large-sized ethylenediamine capped 
nanoparticles treatments exhibited a highly significant (p<0.001) decrease in cell viability 
relative to the untreated cell line, and significant (p<0.01) increase in cell viability relative to 
free ethylenediamine (control). The large-sized ethylenediamine capped nanoparticles 
treatments displayed a lower cell viability relative to the small-sized ethylenediamine capped. 
The small-sized borohydride capped nanoparticles treatments showed significant (p<0.01) 
decrease in cell viability relative to the untreated cells, with the large-sized borohydride 
capped nanoparticles displaying a highly significant (p<0.001) decrease in cell viability relative 
to the untreated cells and a lower cell viability relative to the small-sized borohydride capped 
nanoparticles.  
Folic acid unexpectedly showed low cell viability; however, it has previously been shown to 
possibly be toxic at 13.6 mM [380]. In this case, the folate may not be taken up via the folate 
receptor [230], but potentially via the low affinity (micromolar range) reduced folate carrier 
(RFC) [381]. MDA-MB-468 cell line is folate receptor negative, methotrexate (MTX), a folate-
analogue cancer drug, gave a decrease in cell viability as expected [381–383], and is attributed 
to the uptake of MTX via non-folate receptor-mediated processes. Ethylenediamine (EDA) 
exhibited the highest toxicity; this may be attributed to the selective ability of diamines to 
interact with cellular components triggering apoptosis [384]. It is possible that the cell line 
MDA-MB-468 is poorly resistant to ethylenediamine, possibly due to its chelating nature to 
metal ions. Ethylenediamine containing palladium nanoparticles were cytotoxic at 100 µM. 
This can be attributed to possible DNA denaturation since palladium(II) ethylenediamine 
containing complexes are cytotoxic [385] at 100 µM [386] and this finding should be discussed 
further. The low cell viability for the phthalocyanine control treatment was unexpected since 
phthalocyanines are known to be non-cytotoxic [387–390], and have no reported cytotoxicity 
at this concentration [391] and as we are aware no available literature exists reporting Pc 
effects on the MDA-MB-468 cell line. The MDA-MB-468 cell line’s response to amine-
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containing compounds (EDA and Pc) at 13 mM will be further deconvoluted in future studies 
to provide an experiment-based explanation. It is possible, therefore, that the absence of 
oestrogen, progesterone, HER2, and adenosine receptors, play an unknown and unpublished 
role in the MDA-MB-468 cell line being more reactive to the amine functional group at the 
reported concentrations. Nanoparticles have peculiar physical properties, and their potential 
toxic effects cannot be assumed or predicted from the metal ion properties; however, at 100 
µM the palladium(0) nanoparticles showed cytotoxicity similar to palladium(II) [392]. The 
absence of literature on palladium’s role in cancer development [392], the toxicity of 
palladium(0) nanoparticles, and the pending mechanistic assays studies on palladium 
compounds [393], limit explanations for unexpected findings. 
For this study, a non-toxic concentration was required. The preferred results in this study are 
those that have no significant cytotoxicity (Figure 4.2 - Figure 4.5), since this is a preliminary 
study for radiation-induced apoptosis (cell death). Treatments at 100 M studies displayed 
cytotoxic effects over the palladium nanoparticles on MDA-MB-468, as such the experiment 
was repeated at 10 µM palladium nanoparticles (Figure 4.2), with the addition of medium-
sized nanoparticles treatments. 
 
Figure 4.2: The MDA-MB-468 cell line’s cytotoxic profiles for the different treatments; 10 µM 
(palladium content) palladium nanoparticles, 1.36 mM folic acid (FA), 1.32 mM methotrexate 
(MTX), 1.35 mM ethylenediamine (EDA), 1.36 mM phthalocyanine (Pc), 1.25 mM folate-
ethylenediamine (FA-EDA), 1.29 mM folate-phthalocyanine (FA-Pc), and untreated (UT) MDA-
MB-468 cells. The experiments were completed in triplicate (N=3), and the significance was 
marked with asterisks *; for a p-value <0.05 (significant), ** for a p-value <0.01 (significant), 
and *** for a p-value <0.001 (highly significant) was determined using one-way analysis of 
variance (ANOVA) relative to the control (untreated cells). 
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Reducing the nanoparticles treatment concentration to 10 M did significantly (p<0.05) 
increase in cell viability as reported in literature [379]. Only ethylenediamine exhibited 
cytotoxicity of greater than 80% (Figure 4.2). Ethylenediamine and its derivatives are known 
to be toxic at amounts (>100 µM) [394]. However, this could be attributed to the sensitivity 
of the MDA-MB-468 cell line to free ethylenediamine. The ethylenediamine capped 
nanoparticles treatment exhibited an increased cell viability relative to the free 
ethylenediamine (control), this may be due to known unavailability of lone pairs on capping 
agents as they electronically stabilise the metal nanoparticles [395]. 
At 1.32 mM, FA was not cytotoxic as previously reported [380]. MTX uptake is non-folate 
receptor-dependent; however, it is time- and concentration-dependent. At this concentration 
(1.32 mM), it can be concluded that the cellular uptake was not significant at decreasing cell 
viability. A similar trend has been previously documented using a similar concentration (2.2 
mM) and exposure time (24 h) [396], and may be attributed to the affinity of reduced folate 
carrier (RFC) affinity’s for MTX [397]. At lower concentrations, phthalocyanine and folate 
conjugates showed increased cell viability as expected [398, 399]. There is no significant cell 
viability difference or notable trend in cell viability across the different sizes and capping 
agents used. With MDA-MB-468 cell line being folate receptor negative and the nanoparticles 
optimised for differential uptake based on capping agent, any possible uptake and 
internalisation was expected to be a similar rate and independent of size and capping agents 
(Section 4.5). As a result, since palladium nanoparticles at 10 µM are non-toxic [392], the 
difference in the cell viability was not significant across all the investigated treatments. 
4.2.2 MCF-7 cell viability screen  
No significant difference in cell viability was reported for MDA-MB-468 (folate receptor 
negative) cell line; the cytotoxic effects were investigated (Figure 4.3) using the MCF-7, which 
is considered a low folate receptor expression cell line. 
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Figure 4.3: The MCF-7 cell line’s cytotoxic profiles for the different treatments; 10 µM 
(palladium content) palladium nanoparticles, 1.36 mM folic acid (FA), 1.32 mM methotrexate 
(MTX), 1.35 mM ethylenediamine (EDA), 1.36 mM phthalocyanine (Pc), 1.25 mM folate-
ethylenediamine (FA-EDA), 1.29 mM folate-phthalocyanine (FA-Pc), and untreated (UT) MCF-
7 cell line. The experiments were completed in triplicate (N=3), and the significance was 
marked with asterisks *; for a p-value <0.05 (significant), ** for a p-value <0.01 (significant), 
and *** for a p-value <0.001 (highly significant) was determined using one-way analysis of 
variance (ANOVA) relative to the control (untreated cells). 
Folic acid (FA) treatment had no significant change (Figure 4.3) in cell viability compared to 
the untreated cell line (control), potentially indicating that at the investigated folic acid 
concentration no up-regulation of the folate receptors did not lead to increased folate uptake 
to trigger proliferation as reported in literature [210]. As expected, methotrexate (MTX) 
treatment had the lowest cell viability (compared to other treatments), due to the reported 
decrease in the antiproliferative action on MCF-7 cells [400]. Literature reported that to a 
lesser extent MCF-7 cell line is resistant to low levels of MTX [396, 401, 402]. Unlike for the 
MDA-MB-468 cells, the MCF-7 cells displayed a cell viability of about 86% for the 
ethylenediamine (EDA) treatment. Phthalocyanine (Pc) treatment was non-toxic confirming 
previous findings documented in literature [389, 398, 403]. The folate conjugates (FA-EDA 
and FA-Pc) treatments demonstrated similar cytotoxicity levels (between 105 and 122%). All 
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the palladium nanoparticle treatments exhibited the preferred and expected increase in cell 
viability [378] between 90 and 100%. The large-sized nanoparticle treatments gave a higher 
cell viability compared to the small and medium-sized nanoparticles, with the large-sized 
ethylenediamine capped nanoparticles showing the most mitochondrial activity relative to all 
other treatments. The small-sized borohydride capped nanoparticles showed the lowest cell 
viability compared to other capping agents of similar sizes. This contradicts the notable 
observation for the MDA-MB-231 cell line, which also overexpresses folate receptors. 
4.2.3 MDA-MB-231 cell viability screen 
Compared to the MCF-7 cells, the MDA-MB-231 cells have a high folate receptor expression 
(Table 1.8). The cytotoxicity of the 10 µM palladium nanoparticles and control treatments 
(Table 2.5) were investigated (Figure 4.4). 
 
Figure 4.4: The MDA-MB-231 cell line’s cytotoxic profiles for the different treatments; 10 µM 
(palladium content) palladium nanoparticles, 1.36 mM folic acid (FA), 1.32 mM methotrexate 
(MTX), 1.35 mM ethylenediamine (EDA), 1.36 mM phthalocyanine (Pc), 1.25 mM folate-
ethylenediamine (FA-EDA), 1.29 mM folate-phthalocyanine (FA-Pc), and untreated (UT) MDA-
MB-231 cell line. The experiments were completed in triplicate (N=3), and the significance 
was marked with asterisks *; for a p-value <0.05 (significant), ** for a p-value <0.01 
(significant), and *** for a p-value <0.001 (highly significant) was determined using one-way 
analysis of variance (ANOVA) relative to the control (untreated cells). 
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All treatments had between 80 and 100% cell viability (Figure 4.4), with folate-
ethylenediamine recording the highest cell viability (96%) relative to other control 
treatments. MTX, EDA, Pc, FA-Pc, and FA-EDA showed cell viability values lower than the 
untreated cells. However, the MDA-MB-231 cell line was found to be resistant to MTX [223], 
and had very low toxicity for N-containing compounds [394]. Therefore, low cell viability 
values were unexpected. Furthermore, the cell viability of the controls was insignificantly 
different to the nanoparticles as expected, but lower than the untreated cell line. Thus, 
pending further investigations, it can be accepted that the cell line exhibited decreased 
viability for palladium nanoparticles treatments relative to the untreated cell line (control). 
4.2.4 MCF-10A cell viability screen 
MCF-10A cell line was a non-tumorigenic control and for the purpose of this study was considered the 
normal cell line with extremely low expression of α-folate receptor expression [404]. The cytotoxic 
effects of 10 µM palladium nanoparticles and control treatments (Table 2.5) on the MCF-10A cell line 
were investigated (Figure 4.5). 
 
 
Figure 4.5: The MCF-10A cell line’s cytotoxic profiles for the different treatments; 10 µM 
(palladium content) palladium nanoparticles, 1.36 mM folic acid (FA), 1.32 mM methotrexate 
(MTX), 1.35 mM ethylenediamine (EDA), 1.36 mM phthalocyanine (Pc), 1.25 mM folate-
ethylenediamine (FA-EDA), 1.29 mM folate-phthalocyanine (FA-Pc), and untreated (UT) MCF-
10A cell line. The experiments were completed in triplicate (N=3), and the significance was 
marked with asterisks *; for a p-value <0.05 (significant), ** for a p-value <0.01 (significant), 
and *** for a p-value <0.001 (highly significant) was determined using one-way analysis of 
variance (ANOVA) relative to the control (untreated cells). 
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All treatments had cell viability between 84 and 122% at the investigated concentrations 
(Figure 4.5). At 1.36 mM, folic acid has been documented to be nontoxic [380] and promote 
cell proliferation [197]. Therefore, it was expected that the folate-containing controls have 
increased proliferation relative to the untreated cell line (control). Methotrexate (MTX) 
treatment had no significant change in cell viability and is reportedly non-toxic to non-
tumorigenic cell lines [383]. The ethylenediamine-capped and phthalocyanine-capped 
palladium nanoparticles treatments showed decreased viability relative to ethylenediamine 
and phthalocyanine control treatments. Despite the amine lone pair of electrons being 
unavailable, it can further be suggested that the amine functional group is attributed to the 
notable decrease in cell viability, since other palladium nanoparticles exhibited no significant 
cell viability changes relative to the control treatments. The folate-ethylenediamine and 
folate-phthalocyanine capped nanoparticles treatments showed higher cell viability relative 
to the untreated cell line (control). The small-sized nanoparticles treatment showed a slightly 
higher cell viability compared to their counterparts, with the exception being the small-sized 
ethylenediamine capped nanoparticles. 
4.3 GENERAL DISCUSSION AND CONCLUSION: CYTOTOXICITY STUDIES 
Biomolecule conjugation method and capping agent used can have cytotoxicity effects [355–
357]. In this study, no significant toxic effect or consistent trend across the four cell lines was 
observed for the capping agent, because a non-toxic nanoparticle concentration 
(independent of capping agent and size) was used. Free ethylenediamine (EDA), free 
phthalocyanine (Pc), folate-ethylenediamines (FA-EDA), and folate-phthalocyanines (FA-Pc), 
and conjugated nanoparticles (FA-EDÂ-NPs and FA-Pĉ-NPs) showed similar trends for the 
large-sized nanoparticles. However, small- and medium-sized phthalocyanine-capped (Pĉ) 
indicated that at 10 µM palladium content, the used capping agents did not affect cell 
viability. For the MCF-7, MCF-10A, and MDA-MB-468 cell lines, most of the folate-conjugated 
nanoparticles showed a significant increase in cell viability relative to the untreated cells, 
independent of their sizes, except for MDA-MB-231 cell line, which generally showed lower 
cell viability results compared to the other cell lines. This may be attributed to folate-
conjugated nanoparticles being non-cytotoxic at the investigated concentration as previously 
reported [225, 408, 409]. 
Except ethylenediamine (EDA) demonstrating a decreased cytotoxic effect on the MDA-MB-
468 cells (Figure 4.2), the cell viability differences between the free capping agents and their 
complimentary capped nanoparticles (for instance, Pc and Pĉ-NPs) was not significant (<20%). 
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Thus, it can be concluded that the capping agents and palladium nanoparticles were non-
cytotoxic at a 10 µM concentration palladium content. For small-sized nanoparticles, only EDÂ 
and Pĉ nanoparticles showed a decrease in cell viability of approximately 18% for more than 
one cell line (MDA-MB-231, MCF-7, and MCF-10A compared to the untreated cells), with the 
MDA-MB-468 showing an increase in cell viability in comparison to untreated cells for the 
MCF-7 and MDA-MB-231 cell lines. For the medium-sized nanoparticles, only the MDA-MB-
468 cell line showed increased cell viability when treated with EDÂ-NPs. However, the other 
cell lines showed their lowest cell viability for the EDÂ-NPs. A possible explanation for this 
observation is that MDA-MB-468 cells were more susceptible to the toxic effects of free EDA 
than EDA bound to NPs, while EDÂ-NPs are known to decrease mitochondrial mitosis in the 
other cell line [410], in comparison to the free EDA. Despite having free amine groups, Pc 
showed low cytotoxicity compared to EDA treated cells, because of Pc structure [260] 
resulting in the lone pair of electrons being localised within the ring and not readily available, 
unlike EDA with a readily available lone pair of electrons in comparison to the aromatic amines 
[411]. EDA also has better chelating abilities in comparison to Pc, and possibly chelate some 
key metals for mitochondrial mitosis.  
For all cell lines, folate conjugates (FA-EDA and FA-Pc) control treatments showed no 
significant difference in cell viability compared to the folate-conjugated capped NPs. 
Borohydride capped nanoparticles had a lower cell viability compared to the folate-
conjugated nanoparticles as expected which can be attributed due to the corrosive nature 
and toxicity of borohydride. Folate-conjugated nanoparticles showed increased cell viability 
to their non-folate counterparts as reported by other researchers [225, 412]. 
The exhibited cell viability trend across the four cell lines can be attributed to their different 
proliferative indexes (Table 1.8), which corresponded to the observed trends. MDA-MB-231 
and MDA-MB-468 showed the lowest and highest cell viability, respectively, across most of 
the treatments, and MCF-10A and MCF-7 cell lines showed similar cell viability as previously 
reported [243]. In some cell lines, folate receptor expression is inversely proportional to cell 
proliferation [413], and no conclusive FRs-cell viability trend was observed. The MDA-MB-468 
cell line was expected to have better proliferation, angiogenesis, invasion, and metastasis 
[414, 415] compared to the other three cell lines because of the high effects of EGFR on cancer 
cell lines [416]. This was kept at a minimum as the focus was to investigate uptake. 
Folic acid (FA) is essential for cell survival due to its association in various biochemical 
processes including DNA and RNA synthesis and transmethylation reactions. It is possible that 
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elevated levels of α-FR induce proliferation, by mediating folate uptake [205]. Physiological 
concentrations of FA can induce cell type-specific changes in gene regulation consistent with 
proliferative phenotype. However, a sub-optimal FA content has been demonstrated to 
suppress tumorigenesis [417]. The difference in FA internalisation between the cell lines is a 
crucial factor that determines the effect of FA on cancer-related processes [417]. At similar 
FA concentrations, different breast cancer cell line’s unique gene transcript alterations are 
either up or down-regulated [417]. For example, TAGLN, an associate gene encoding 
transgelin, is altered by FA in all breast cancer cell lines, for example, TAGLN is down-
regulated in MCF-10A and up-regulated in MCF-7 cell line [417]. TAGLN has been associated 
with suppression of cell proliferation and invasion, promoting apoptosis in colorectal 
carcinoma [418], this could have been why the FA (13.6 mM) resulted in low cell viability for 
the MDA-MB-468 (Figure 4.1). It can be concluded that the effect of folate in folate-
conjugated nanoparticles may have up-regulated pathways associated with tumorigenesis 
(migration, proliferation, vascularisation), while pathways associated with apoptosis and cell 
differentiation were down-regulated as previously reported [418, 419] for the MCF-7 and 
MCF-10A, resulting in the increased cell viability (>100%). 
Methotrexate (MTX) is not taken up via the folate receptor, and the observed (Figure 4.2 – 
Figure 4.5) cell viability corresponds with available literature [381–383]. The MDA-MB-468 
cell line has a high proliferative index and showed increased cell viability since it is not affected 
by MTX due to the absence of folate-receptors. MDA-MB-231 and MCF-7 cells are resistant 
to MTX [413], and displayed a similar cell viability to that found in the MCF-10A cells. It can 
be concluded that the overexpression of FR did not invariably render cells more sensitive to 
MTX as reported in literature [413]. 
At low concentrations, phthalocyanines are non-toxic [420, 421] theranostic agents [422]. 
Positive cell viability was noted for folate-phthalocyanines and other controls (except for EDA 
on MDA-MB-468 cell line). The capped nanoparticles showed less cytotoxicity, potentially 
indicating increased dispersibility, bio- and cytocompatibility and better conjugation with 
other bioactive molecules which has previously been documented in literature [363]. The 
nanoparticles were designed to be internalised via folate-receptor-mediated endocytosis; 
however, the reported cell viability results were inconclusive in correlating folate-receptor 
expression and cell viability. Since cytotoxicity can be due to nanoparticle cell-membrane 
interactions [423] or nanoparticle intracellular interactions [375, 424] and the inverse 
regulation of FR expression by the extracellular folate concentration further suggest 
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heterogenicity in underlying mechanisms as reported [413]. Similarly, cell viability was 
independent of surface coating as expected [96, 353]. The surface charge was kept within the 
preferred range (-30 mV to +30 mV) for folate-targeted receptor-mediated endocytosis by 
ensuring that the synthesised nanoparticles’ surface charge would be stable in a physiological 
environment such as cellular media, and with the surface composition containing a similar 
functional group (amine), no significant difference was expected [425] and corresponds with 
was observed. The hydrophilicity of the nanoparticles and conjugates was particularly 
important to disperse them in biological systems and also increases ease of synthesis and 
residence time thereby enhancing cell viability [426–428]. The difference in cell viability 
between 10 and 100 µm palladium nanoparticles suggest that palladium nanoparticles 
toxicity is dose and concentration-dependent as previously reported [77, 429]. 
4.4 CELL UPTAKE STUDIES 
As previously discussed (Section 1.3.2), the nanoparticles were optimised for folate-receptor 
targeted endocytosis. During folate-receptor targeted endocytosis, the folate-conjugated 
nanoparticles bind specifically to folate receptor (FR) creating a folate receptor-folate-
conjugated nanoparticle complex; then through invagination and budding off, forms 
intracellular early endosomes, which undergo acidification and subsequent fusion with 
lysosomes to release the FR and folate-nanoparticle complex [204, 430] into the cytoplasm. 
The FR is then translocated to the nucleus, where it binds to cis-regulatory elements at 
promoter regions to self-regulate their expression and nuclear localisation, acting directly as 
transcription factors [431]. The FR undergoes exocytosis as endosomes [432]. Some 
endosomes evade cytosol release, mature, and get exocytosed [406, 433]. The cell uptake and 
internalisation were qualitatively investigated using transmission electron microscopy (TEM). 
4.4.1 Cell internalisation studies: Transmission electron microscopy (TEM) 
TEM is an essential tool to obtain the information on the cellular structure, confirm uptake, 
and identify the localisation of the nanoparticles. The preparation of cellular material for TEM 
considered the resolution of cellular ultrastructure while avoiding significant alteration or loss 
of target nanoparticles [434, 435]. Sample preparation that does not detrimentally alter the 
cells or NPs, or obscure NP location, work constraints enhancing heavy metal stains and 
suitable control of the electron influence during imaging are critical. More importantly, 
spectroscopic analysis such that the particle structure (and ideally the cellular material) 
remains unaltered under investigation [436] is key. To improve the visibility of NPs in thin cell 
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sections of TEM, osmication or bulk and post-embedding and staining steps were originally 
omitted (Figure 4.6) [437]. 
 
Figure 4.6: Bright-field transmission electron microscope (TEM) images of unstained MCF-10A 
cells after 24 h treatment with 10 µM (palladium content) small-sized folate-ethylenediamine 
capped palladium(0) nanoparticles (sz-FA-Pĉ-NPs). Higher magnifications were used, from (a) 
to (d) to acquire the images, with the encircled regions indicating the area where the following 
image was acquired. The nanoparticles were clearly visualised with no cell ultrastructure. 
The small-sized folate-ethylenediamine capped nanoparticles were easily visualised (Figure 
4.6) and scanning transmission electron microscopy-energy dispersive X-ray spectroscopy 
(STEM-EDS) confirmed the composition of the palladium nanoparticles (Figure 4.7).  
(a)
(c)(d)
(b)
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Figure 4.7: The STEM-EDS spectrum of the nanoparticles on the unstained sample. Palladium 
presence was observed. The presence of carbon (C), nitrogen (N), and oxygen (O) can be 
attributed to the presence of folate-phthalocyanine or cellular organelles. The presence of 
potassium (K) and chlorine (Cl) can be attributed to incomplete washing of PBSA with the 
cobalt (Co) and iron (Fe) attributed to system artefacts from the TEM chamber, while the 
presence of copper is attributed to the use of a copper TEM grid for the sample. 
For the unstained specimen, the presence of palladium nanoparticle was confirmed (Figure 
4.7). However, the absence of stains did not clearly resolve the various cellular ultrastructure, 
but additional unwanted stain chemical effects were avoided. With localisation being of great 
interest to our study, an attempt to obtain optimal results without compromising sample 
preservation and clear visualisation of the structure was attempted as recommended in 
literature [438]. Unstained specimens’ sensitivity to radiation damage is reportedly high 
[439], and viewing of unstained biological molecules [440, 441] was difficult. The same 
specimen (Figure 4.6) was osmicated and analysed (Figure 4.8). Having a stained and 
unstained sample allowed the identification of artefacts introduced by the osmium stains. 
The intact cell membranes (Figure 4.8) confirmed the expected non-invasive nanoparticle-
membrane interactions for the optimised nanoparticles [423, 442–446]. 
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Figure 4.8: Bright-field TEM images of osmicated MCF-10A cells (from Figure 4.6) after 24 h 
treatment with small-sized folate-phthalocyanine capped palladium(0) nanoparticles (sz-FA-
Pĉ-NPs); (a) TEM image showing a well- defined cell ultrastructure; intact cell membranes 
(CM), protruding cell membranes (encircled CM), mitochondrion (M), endoplasmic reticulum 
(ER), and possible metal stains, artefacts, or nanoparticles (encircled), (b) A magnified cellular 
area showing well-defined ultrastructure; nuclear membrane (NM), mitochondrion (M), cell 
membrane (CM), and unclear possible nanoparticles or metal stains or artefacts (encircled), 
(c) Clear ultrastructure of magnified specimen area showing intact cell membranes (CM) and 
possible nanoparticles or metal stains or artefacts (encircled), (d) TEM image displaying the 
visualised zoomed cytoplasm area with endoplasmic reticulum (ER), and (e) Inset showing a 
highly magnified section of the cells showing notable metal precipitate or artefacts 
(encircled). 
The crystalline nanoparticles could not be clearly visualised in the prepared samples. This can 
be attributed to the introduction of artefacts during sample preparation [127, 447], thereby 
obscuring the nanoparticles. It can also be suggested that palladium nanoparticles can be 
oxidised to palladium(II) by the staining and post-embedding chemicals, for example, osmium 
tetroxide is a strong oxidising agent [448–450]. Similarly, staining liver tissues sections with 
(a)
(e)
(b)
(c)(d)
M
ER CM NM
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M
CM
M
CM
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uranyl acetate and lead citrate to generate image contrast in the TEM oxidised iron in the 
nanoparticulate core of ferritin molecules [437]. It is also reported that nanoparticles can 
dissociate or change their oxidation state or ionic state, for example, ZnO nanoparticles are 
known to dissociate and produce Zn2+ which can cause toxicity [451], and similarly, iron 
undergoes a redox state change [452]. This poses a challenge as it is difficult to determine the 
composition of the metal particles once taken up into the cell using microscopy (Figure 4.8 
inset) found on the specimen. This challenge was encountered, and the STEM-EDS could not 
be done as the specimen was highly unstable under the electronic beam, resulting in the resin 
disintegrating. Challenges of the beam damaging the specimen and resin [439], unstained 
specimens sensitivity to radiation damage [441] and viewing of unstained biological 
molecules have been previously reported [440, 453]. Some nanoparticles are known to be 
located in mitochondria and nucleus [454]; however, no palladium crystalline nanoparticles 
were observed in these organelles. 
For a different specimen, chemical fixation and staining (with the inclusion of osmium 
tetroxide) was employed (Figure 4.9). It enabled visualisation of some of the main cellular 
structure because osmium binds to lipid-rich structures such as membranes [455]. This 
approach did not enable the localisation of NPs within a cell to be clearly visualised, without 
a contrast from the NPs themselves being obscured by the heavy metal stains as expected 
[456, 457]. 
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Figure 4.9: Bright-field TEM images of osmicated MDA‐MB‐231 cells after 24 h treatment with 
large‐sized folate‐ethylenediamine capped palladium(0) nanoparticles (lz‐FA‐EDÂ‐NPs); (a) 
Visible cell membrane (CM), endoplasmic reticulum (ER), nuclear membrane (NM), and 
nucleus (N) and possible metal nanoparticles or stains (encircled), (b) Visible cell membrane 
(CM) and mitochondrion (M) with possible nanoparticle or osmium stains (encircled), (c) 
Zoomed ultrastructure showing mitochondria (M), and possible nanoparticles or osmium 
stains (encircled), (d) Ultrastructure showing endoplasmic reticulum (ER) and possible 
nanoparticles or osmium stains (encircled). The ultrastructure was seen, with no confirmed 
crystalline palladium nanoparticles.  
Other specimens were not stained with osmium tetroxide and stained with uranyl nitrate and 
lead citrate (Figure 4.10). The contrast was achieved; however, locating the nanoparticles was 
not achieved, and this could be due to the possible resin instability under the electron beam, 
possible oxidation of the nanoparticles or no internalisation having taken place (or 
preparation technique). However, with inductively coupled plasma-optical emission 
spectroscopy (ICP-OES) having proved that internalisation or attachment to the cell 
membrane occurred (Table 4.3), it can be suggested that this could be an analytical challenge 
and this finding was further investigated. 
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Figure 4.10: Bright-field TEM images of non-osmicated, lead citrate and uranyl acetate stained 
MCF-7 cells treated with medium-sized phthalocyanine capped palladium(0) nanoparticles 
(mz-Pĉ-NPs) for 24 h; (a) Cell membrane (CM) is visible and no clear ultrastructure (b) unclear 
ultrastructure showing possible nanoparticle, artefacts or metal stains (encircled) and cell 
membrane (CM). 
Possible artefacts can be seen (Figure 4.10). Additionally, biological systems have the 
capabilities of converting metal ions into metal NPs [458, 459], effect partial oxidation of 
nanoparticles [460], and the palladium nanoparticle stability in all cell lines cannot be ruled 
out [461]. Cells have an unclearly understood ability to change the oxidation state of 
nanoparticles [462]. Some metal NPs can be oxidised by cells under certain conditions and 
this could be a possibility for PdNPs [463] in MDA-MB-231 and MCF-7 cell lines. To examine 
the effects of sample preparation, untreated MCF-7 cells were stained and analysed (Figure 
4.11).  
(a) (b)
CMCM
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Figure 4.11: Bright‐field TEM images showing osmicated, lead citrate, and uranyl acetate 
stained MCF‐7 untreated cells (no nanoparticle treatments); (a) Mitochondrion (M) is visible 
and artefacts are shown by arrows, (b) Cell membrane (CM), mitochondrion (M), and possible 
artefacts (A) are highlighted, (c) and (d) presents untreated MCF‐7 cells showing possible 
artefacts or unidentifiable organelles. 
This proved that possible contamination or presence of artefacts, sample preparation 
problem, is among the reasons for the unseen or unlocated nanoparticles. No dark spots were 
expected to be seen. Further analysis was completed (Figure 4.12) on the MCF-7 cell line 
treated with large-sized folate-phthalocyanine capped palladium(0) capped nanoparticles. 
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Figure 4.12: Bright‐field TEM images of osmicated, lead citrate and uranyl acetate stained 
MCF‐7 cells treated with 10 µM large‐sized folate‐phthalocyanine capped palladium(0) 
nanoparticles (lz‐FA‐Pĉ‐NPs); (a) shows an MCF‐7 with an unclearly defined ultrastructure and 
some dark spots (encircled), (b) a magnified area on the specimen showing possible 
nanoparticles (encircled) and the dark spot area (arrowed) that gave image (c), (c) a crystalline 
palladium nanoparticle, and (d) a magnification of the encircled area (on (c)). 
Despite inductively coupled plasma-optical emission spectroscopy (ICP-OES) having 
confirmed the uptake (Table 4.3) and or internalisation, very few nanoparticles were 
visualised and the palladium nanoparticle stability in all cell lines used remained unclear. 
Nanoparticles stable in cell media can become unstable through chemical modification or loss 
of surface functionality, or altering change distribution, thereby affecting their stability in 
biological systems [90, 464]. STEM-EDS could not be employed to obtain the nanoparticle 
composition. This was due to the specimen being highly unstable under the electronic beam, 
resulting in the resin’s disintegration. This challenge of the beam damaging the specimen and 
resin has been previously reported [439]. 
Considering TEM’s limitations [465] and complexity for quantifying uptake, requiring 
extensive, time-consuming sample preparation, and typically providing qualitative 
(b)(a)
(d) (c)
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information, inductively coupled-optical emission spectroscopy (ICP-OES) was employed to 
quantify the uptake and or the internalisation as a preferred previously recommended 
method [466]. 
4.4.2 Cell internalisation studies: Inductively coupled plasma-optical emmision 
spectroscopy (ICP-OES) 
ICP-OES is a common technique for absolute quantification of the cellular uptake of NPs. It 
offers high selectivity for elemental analysis; however, it does not allow for differentiation 
between single, agglomerates, or ionic species [270]. The quantified cellular uptake were 
reported (Table 4.3). 
Table 4.2: The inductively coupled plasma-optical emission spectroscopy (ICP-OES) results 
obtained for the various treatments from the cell lysate (N=6). 
 [Pd] content found in each cell line (ppm) 
Treatment [Pd] ppm in 
media 
MDA-MB-468 MCF-7 MDA-MB-231 MCF-10A 
UT 0.000 0.000 0.000 0.000 0.000 
sz-Bĥ-NPs 0.870 0.184 0.462 0.463 0.248 
lz-Bĥ-NPs 0.880 0.251 0.512 0.648 0.190 
sz-FA-EDÂ-NPs 0.893 0.294 0.595 0.729 0.297 
lz-FA-EDÂ-NPs 0.859 0.299 0.656 0.804 0.279 
sz-FA-Pĉ-NPs 0.870 0.341 0.417 0.393 0.337 
lz-FA-Pĉ-NPs 0.873 0.346 0.496 0.720 0.329 
The small-sized borohydride capped nanoparticles showed the MDA-MB-468 had the least 
palladium content (0.184 ppm). MCF-7 (0.462 ppm) and the MDA-MB-468 (0.463 ppm) had 
relatively similar uptake of the small negatively charged nanoparticles (-2.86 mV), with MCF-
10A (0.248 ppm) showing more uptake compared to the breast cancer folate positive cell lines 
(MCF-7 and MDA-MB-231). With the exception in MCF-10A cell line, large-sized borohydride-
capped nanoparticles had a higher nanoparticle uptake compared to their smaller-sized 
borohydride capped nanoparticles. This was unexpected and is attributed to the tumourigenic 
cell lines having a higher affinity for borohydride-capped nanoparticles, since the MCF-10A 
cell line showed a relatively lower palladium uptake. This could also be linked to metabolism 
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or growth rate since the MCF-10A represents a cell line which is a representative of a “normal 
cell population” and grow substantially slower.  
Small-sized folate-ethylenediamine capped nanoparticles showed a higher palladium content 
compared to borohydride capped nanoparticles, but lower palladium content compared to 
the large sized folate-ethylenediamine capped nanoparticles as expected when 
internalisation is folate receptor-dependent. This can be attributed to their near-neutral 
charge (-0.05 mV), that favoured the nanoparticle uptake via folate receptor-targeted 
endocytosis [353]. The large-sized nanoparticles have a larger surface area, therefore, the 
availability of the capping agents’ folate receptor binding moiety is readily available compared 
to the smaller nanoparticles [427]. The nanoparticles were optimised to minimise other 
uptake mechanisms [159] and promote folate receptor-mediated endocytosis, it can be 
concluded that the folate-conjugated and large-sized nanoparticles were internalised via 
folate-receptor mediated endocytosis and not phagocytosis, clathrin-mediated endocytosis, 
caveolae-dependent endocytosis, micropinocytosis or any other mechanism [467].  
The MCF-10A and MDA-MB-231 cells low palladium content can be attributed to folate-
conjugated nanoparticle uptake via the reduced folate carrier (RFC) or proton coupled-folate 
transporter (PCFT) [227, 228], since the expression of folate-receptors is very low, almost 
undetectable in normal cells [468] and absent in the MDA-MB-468 cell line.  
The small and large-sized folate-phthalocyanine capped nanoparticles showed a higher 
palladium uptake for the MDA-MB-468 and MCF-10A cell lines compared to the folate-
ethylenediamine and borohydride capped nanoparticles. However, the uptake is about 40% 
of the available palladium. The MCF-7 cell line also showed reduced palladium nanoparticle 
uptake for the FA-Pĉ-NPs compared to the FA-EDÂ-NPs internalisation. In a similar study, 
MCF-7 cells have been shown to take up folate-functionalised nanoparticles was at around 8 
µg/mL from the available 100 µg/mL, and 50 µg/mL when treated with 500 µg/mL 
concentrations [249]. Folate-conjugated nanoparticles was cell-type specific, time, and 
concentration dependent until a certain maximum concentration (saturated uptake 
phenomenon) [101]. There was also a reported increase in cellular uptake of folate within the 
MCF-7 cell line for preincubation without folic acid [249]. 
Generally, functionalised nanoparticles have improved uptake and cytotoxicity [250, 469, 
470]. However, another possible explanation for folate receptor-targeting nanoparticles not 
showing much higher palladium uptake compared to non-folate receptor targeting 
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nanoparticles can be ascribed to the folate receptor-mediated endocytosis mechanism that 
requires the recycling of the receptor back to the cell surface, a response that has been 
reported to take between 30 min and 5 h [471–473], highlighting a possible increased uptake 
if exposure time was increased. There is an optimal size for efficient folate-receptor targeted 
endocytosis of nanoparticles independent of particle composition [103]. This critical size 
varies with cell type and surface properties of the nanoparticles [225]. Due to the complexity 
of biological probes, it was slightly difficult to draw a conclusion of a trend followed by the 
nanoparticles used. However, from their properties, it can be concluded that the folate-
functionalised nanoparticles were taken up via the folate-receptor mediated endocytosis.  
4.5 GENERAL DISCUSSION AND CONCLUSION: CELL UPTAKE STUDIES 
Despite the challenges and limitations for nanomedicine [474], folate receptor-targeted 
nanoparticles offer great prospects in targeted therapy. Nanoparticle visualisation can be 
seen (Figure 4.11) and the uptake was further confirmed (Table 4.3). It can be concluded that 
it is possible to target cancer cells selectively without damaging healthy tissues. Increased 
exposure time with reduced concentration can yield higher and selective nanoparticle 
content in cancer cells. Folate functionalised nanoparticles were internalised in higher 
amounts in tumorigenic cancer lines compared to non-tumorigenic (Table 4.3), corresponding 
to previously published literature [475]. 
All the challenges encountered with TEM studies can be circumvented. Instead of using heavy 
metal stains [465], chemical stains can be used to enhance NP identification, for example, 
alkaline bismuth has been used to stain iron oxide NPs and biological membranes [476]. 
Alternative stains have been reported to prevent elemental signals from NPs being obscured, 
for example, ruthenium tetroxide can be used to replace osmium tetroxide, because osmium 
irradiated by an electron beam produces X-rays of the same energy as phosphorous, whereas 
ruthenium does not [477]. 
Possible artefacts induced by the thin sectioning process itself can be limited when 
embedding and sectioning [478], for example, by matching the hardness of the epoxy to that 
of that nanomaterial, limiting the size of the cutting face, and or careful selection of the angle 
of the cutting knife [479] minimises artefacts. The use of an oscillating knife can further 
reduce or eliminate section compression [480]. The ultra-microtome sectioning of 
nanocrystalline materials has also been shown to result in pull out of sample from the 
embedding resin during cutting [481]. 
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Precise NPs localisation, requiring excellent resolution of cellular ultrastructure, can still be 
developed further and quantification of NPs alteration or degradation when in cellular 
environment is possible. Rapid freezing to preserve cellular material closer to its native state 
can also be explored [434]. The possible change of oxidation state can be investigated by 
quantifying the oxidation states in and outside the cells, and organelles using correlated 
scanning transmission spectroscopy [462]. 
The cytotoxic findings did not corroborate that nanoparticles cellular uptake depends on the 
particle size distribution, and capping agent [425]. Thus, it can be concluded that at 10 µm 
palladium content, palladium nanoparticles and the designed nanoradiopharmaceuticals 
have low or minimal toxicity and are biocompatible. To conclude, this work offers valuable 
insights into further investigating and understanding the cell uptake and internalisation in 
vitro studies and subsequently paving way for in vivo studies. It is possible to use folate-
functionalised palladium nanoparticles to target cancer cells selectively, to normal cells.  
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CHAPTER FIVE: CONCLUSIONS AND FUTURE WORK  
5.1 CONCLUSIONS 
Despite the challenges and limitations for nanomedicine [474] and the complexity of 
nanoradiopharmaceutical design, it can be concluded that the study was successful.  
(i) The determination of optimal diamine used as capping agent, optimisation of reducing 
agent, optimisation of concentrations, stoichiometric ratios and reaction parameters, 
and the aqueous synthesis of stable (in aqueous solution and cell media) palladium 
nanoparticles (PdNPs) at room temperature was successfully achieved.  
(ii)  The synthesis of tetraaminophthalocyanine (referred to as phthalocyanine, Pc, after 
its synthesis), and the conjugation of phthalocyanine and ethylenediamine with folate 
was successfully reported. The nanoparticles capped with the various capping agents 
were also successfully synthesised.  
(iii) The investigation of a non-cytotoxic concentration for all control and nanoparticle 
treatments provided an acceptable pre-screening method requiring further 
confirmatory studies prior to in vivo rat model studies and employing the hot (109Pd) 
isotope. In vitro, at 10 μM palladium nanoparticles were found to be non-cytotoxic. 
(iv) The selective uptake of folate functionalised nanoparticles via folate receptor-
targeted endocytosis was achieved. Folate receptor positive cells (MCF-7 and MDA-
MB-231) internalised more palladium nanoparticles than folate receptor negative 
(MDA-MB-468) or control non-tumourigenic (MCF-7A). 
While the in vitro experiments may never replace in vivo studies [482], the cytotoxic tests and 
cell internalisation results offered great prospects in the use of palladium nanoparticles in 
folate receptor-targeted therapy. It can be concluded that folate-functionalised palladium 
nanoparticles can be employed as theranostic nanoradiopharmaceuticals for selective 
targeting of cancer cells in the near future. The findings provide a foundation towards an 
improved experimental design that minimises and circumvents possible shortcomings.  
5.2 FUTURE WORK 
Our future synthesis of palladium nanoparticles (PdNPs) aims to understand and close the 
knowledge gap in biological NP synthesis, investigating the possible oxidation of NPs to metal 
ions in biological systems [483], and understanding the retention and clearance of the 
nanoparticles. In summary, bettering the palladium-based folate receptor-targeted 
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nanoradiopharmaceutical design reported in this study, addressing all concerns prior to in 
vivo studies.  
(i) Thiol groups are known to stabilise metal nanoparticles better than amine groups [484–
487]. Capping agents containing both the amine and thiol groups will be explored (Scheme 
5.1), from simple molecules [488, 489] to thiol group-containing polymers [490–493], and 
copolymers conjugated to biomolecules [494–496]. 
 
Scheme 5.1: The proposed new thiol-amine stabilised palladium(0) nanoparticles; (a) 4-
aminophenol-, (b) 2-aminoethanethiol- (cysteamine), and (a) polyethyleneimine (PEI)-capped 
nanoparticles. For simplicity, one capping agent unit is shown, however, m, n, and y are 
unknown. 
(ii) The conjugation and functionalisation of Pcs with poly(ethylene glycol) (PEG) improves 
the chemical inertness, biocompatibility [449], improved serum life, and tumour 
accumulation of PEG and PEGylated Pcs [498, 499] and will also be considered. 
(iii) During folate conjugation, the separation of low molecular weight folate conjugates (α-
conjugates, bioconjugates, or unreacted folic acid) by precipitation, and separation of the 
α and γ isomers by preparative reverse phase chromatography was not conducted and 
could also be investigated [258]. 
(iv) The investigation of the palladium metal oxidation state in cells could be investigated 
using correlated scanning transmission spectroscopy to quantify the oxidation states in 
and outside the cells, and organelles [462, 500], single particle inductively coupled-mass 
spectroscopy will also be employed to distinguish between ionic Pd(II) and Pd(0) [501, 
502] or single cell mass inductively coupled plasma mass spectrometry [503]. 
(a)
(c)
(b)
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(v) With the reported uptake being receptor recycling-, time- and concentration-dependent, 
the amount of folate receptors on the cell surface needs investigation. Increased folate 
receptors levels on the cell surface will be achieved by culturing cells in folate-depleted 
medium, thereby inducing the overexpression of FRs on the cell-membrane membrane 
[504]. To fully investigate and understand the effect of folate receptor-mediated 
endocytosis, cells cultured in media with and without folic acid could be compared [249], 
and folate receptor expression could also be examined by Western blotting [302]. Surface 
plasmon resonance (SPR) studies could also provide information on the folate-binding 
protein in the presence of free folic acid, for instance, despite dietary folate not having 
been of significant effect in clinical studies, folic acid has been given to the patient in 
clinical trials to reduce normal tissue uptake of etarfolatide in a clinical trial, suggesting 
that low concentrations of circulating folate may be helpful for targeting tumour cells in 
vivo [235]. 
(vi) Similarly, the cytotoxicity is time- and concentration-dependent, the effects of different 
concentrations and exposure time will be investigated [482]. Specified time interval 
imaging after exposure to nanoparticles, will aid in elucidating the underlying mechanisms 
and possible morphological changes, providing a better understanding and visual 
confirmation and details of the internalisation routes. The understanding of in-depth 
effects of nanoparticles is a perquisite [505–507]. The inability of the cell viability assay to 
provide possible mechanisms of action prompts the need for additional cell viability 
assays, for instance, assays to investigate necrosis, DNA synthesis, myology formation, 
apoptosis (membrane structure) and LIVE-DEAD (esterase activity/membrane integrity) 
and mechanistic assays to examine DNA damage and oxidative stress, and time- and dose-
dependent genotoxicity will also be explored [454]. Qualitative methods could also be 
considered to and characterise the effects of nanoparticles on cells, and are equally 
elusive [508]. 
(vii) Palladium nanoparticles are known to have anti-microbial effects [83, 252]. A 
knowledge gap exists on the anti-inflammatory properties of palladium nanoparticles. The 
in vivo effects are key to the success of rat model studies and serum protein opsonisation 
properties of the nanoparticles could also be investigated prior to the in vivo studies and 
so as the cellular fate of the conjugates and nanoparticles in cells. The imaging of 
radiolabelled derivatives of folic acid offer greater tissue selectivity [204], and additional 
visual detection is achieved by attaching a fluorescent probe [509–511] bound to 
nanoparticles or capping agents, or a colorimetric probe specific for palladium detection 
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[512], or the use of both radioactive and fluorescent conjugates [513], or radiolabelled 
folic acid [514], could contribute greatly to the understanding and quantification of the 
internalisation studies. 
(viii) Computational studies on the interaction of nanoparticles with membranes [515], 
folate conjugates interaction with the folate binding protein [191], and the investigation 
of molecular docking and molecular dynamics simulations [510, 516]. 
(ix) Evaluating the interaction between the conjugated folate nanoparticles and the folate 
binding protein using isothermal calorimetry could be considered for an in-depth 
understanding of the binding studies, and the determination of binding affinity (KD) of the 
folate conjugates [517, 518]. 
(x) The tumour and organ biodistribution studies of the nanoparticles could be completed 
using micro-SPECT kits and model mice/rat studies (using the “hot” isotopes of 109Pd in a 
radiopharmacy laboratory) as published in literature [109]. The effects of the 109Ag 
(radioactive product of 109Pd) could also be extensively studied. 
The success of the above findings would give rise to a new set of palladium theranostic 
nanoradiopharmaceutical being recommended for clinical trials. Therefore, it can be 
concluded that palladium nanoparticles and the designed nanoradiopharmaceuticals have 
great prospects to ensure improved drug delivery: retention, evasion, targeting recognition, 
and release, by considering various key aspects in drug development [139, 519]. 
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